<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="review-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Vaccines (Basel)</journal-id><journal-id journal-id-type="iso-abbrev">Vaccines (Basel)</journal-id><journal-id journal-id-type="publisher-id">vaccines</journal-id><journal-title-group><journal-title>Vaccines</journal-title></journal-title-group><issn pub-type="epub">2076-393X</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40006673</article-id><article-id pub-id-type="pmc">PMC11860605</article-id><article-id pub-id-type="doi">10.3390/vaccines13020126</article-id><article-id pub-id-type="publisher-id">vaccines-13-00126</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Revolutionizing Nanovaccines: A New Era of Immunization</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Saleh</surname><given-names>Mohammed</given-names></name><xref rid="af1-vaccines-13-00126" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>El-Moghazy</surname><given-names>Ahmed</given-names></name><xref rid="af2-vaccines-13-00126" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-7481-1602</contrib-id><name><surname>Elgohary</surname><given-names>Adel H.</given-names></name><xref rid="af3-vaccines-13-00126" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-0631-4089</contrib-id><name><surname>Saber</surname><given-names>WesamEldin I. A.</given-names></name><xref rid="af4-vaccines-13-00126" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-1470-5418</contrib-id><name><surname>Helmy</surname><given-names>Yosra A.</given-names></name><xref rid="af1-vaccines-13-00126" ref-type="aff">1</xref><xref rid="c1-vaccines-13-00126" ref-type="corresp">*</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>Gomez-Casado</surname><given-names>Eduardo</given-names></name><role>Academic Editor</role></contrib><contrib contrib-type="editor"><name><surname>Ahmadivand</surname><given-names>Sohrab</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-vaccines-13-00126"><label>1</label>Department of Veterinary Science, Martin-Gatton College of Agriculture, Food, and Environment, University of Kentucky, Lexington, KY 40546, USA</aff><aff id="af2-vaccines-13-00126"><label>2</label>Department of Microbiology and Plant Pathology, University of California, Riverside, CA 92521, USA</aff><aff id="af3-vaccines-13-00126"><label>3</label>Department of Hygiene and Zoonoses, Faculty of Veterinary Medicine, Mansoura University, Mansoura 35516, Egypt</aff><aff id="af4-vaccines-13-00126"><label>4</label>Microbial Activity Unit, Department of Microbiology, Soils, Water and Environment Research Institute, Agricultural Research Center, Giza 12619, Egypt</aff><author-notes><corresp id="c1-vaccines-13-00126"><label>*</label>Correspondence: <email>yosra.helmy@uky.edu</email></corresp></author-notes><pub-date pub-type="epub"><day>27</day><month>1</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>2</month><year>2025</year></pub-date><volume>13</volume><issue>2</issue><elocation-id>126</elocation-id><history><date date-type="received"><day>16</day><month>11</month><year>2024</year></date><date date-type="rev-recd"><day>13</day><month>1</month><year>2025</year></date><date date-type="accepted"><day>17</day><month>1</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; 2025 by the authors.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p>Infectious diseases continue to pose a significant global health threat. To combat these challenges, innovative vaccine technologies are urgently needed. Nanoparticles (NPs) have unique properties and have emerged as a promising platform for developing next-generation vaccines. Nanoparticles are revolutionizing the field of vaccine development, offering a new era of immunization. They allow the creation of more effective, stable, and easily deliverable vaccines. Various types of NPs, including lipid, polymeric, metal, and virus-like particles, can be employed to encapsulate and deliver vaccine components, such as mRNA or protein antigens. These NPs protect antigens from degradation, target them to specific immune cells, and enhance antigen presentation, leading to robust and durable immune responses. Additionally, NPs can simultaneously deliver multiple vaccine components, including antigens, and adjuvants, in a single formulation, simplifying vaccine production and administration. Nanovaccines offer a promising approach to combat food- and water-borne bacterial diseases, surpassing traditional formulations. Further research is needed to address the global burden of these infections. This review highlights the potential of NPs to revolutionize vaccine platforms. We explore their mechanisms of action, current applications, and emerging trends. The review discusses the limitations of nanovaccines, innovative solutions and the potential role of artificial intelligence in developing more effective and accessible nanovaccines to combat infectious diseases.</p></abstract><kwd-group><kwd>nanoparticles (NPs)</kwd><kwd>nanoparticle-based vaccines</kwd><kwd>preclinical and clinical trials</kwd><kwd>regulatory challenges</kwd><kwd>future innovations</kwd><kwd>food safety</kwd></kwd-group><funding-group><award-group><funding-source>Center of Biomedical Research Excellence (COBRE)</funding-source><award-id>NIH P20 GM130456</award-id></award-group><award-group><funding-source>National Center for Advancing Translational Sciences, National Institutes of Health</funding-source><award-id>KL2TR001996</award-id></award-group><funding-statement>This research was supported by the Center of Biomedical Research Excellence (COBRE) for Translational Chemical Biology (CTCB, NIH P20 GM130456), and the National Center for Advancing Translational Sciences, National Institutes of Health (Grant number KL2TR001996).</funding-statement></funding-group></article-meta></front><body><sec sec-type="intro" id="sec1-vaccines-13-00126"><title>1. Introduction</title><p>The world is currently grappling with a series of critical public health challenges, including the emergence of multidrug-resistant bacteria, rapidly mutating viruses, increasing populations of superbugs, anthelmintic-resistant parasites, zoonotic pathogens, and secondary tumors. These challenges, compounded by the recent COVID-19 pandemic, pose significant threats to human health and livestock [<xref rid="B1-vaccines-13-00126" ref-type="bibr">1</xref>]. These epidemic and pandemic outbreaks have far-reaching consequences, contributing to global mortality rates and hindering socioeconomic development. Additionally, they necessitate robust biodefense strategies to protect populations from future health crises [<xref rid="B2-vaccines-13-00126" ref-type="bibr">2</xref>,<xref rid="B3-vaccines-13-00126" ref-type="bibr">3</xref>,<xref rid="B4-vaccines-13-00126" ref-type="bibr">4</xref>,<xref rid="B5-vaccines-13-00126" ref-type="bibr">5</xref>]. The overuse and misuse of antibiotics and other drugs have significantly contributed to the rise of antimicrobial resistance, a major global health crisis [<xref rid="B6-vaccines-13-00126" ref-type="bibr">6</xref>,<xref rid="B7-vaccines-13-00126" ref-type="bibr">7</xref>]. Additionally, climate change and environmental pollution have accelerated the emergence, transmission, and spread of infectious diseases, further exacerbating the challenges faced by public health systems worldwide [<xref rid="B8-vaccines-13-00126" ref-type="bibr">8</xref>,<xref rid="B9-vaccines-13-00126" ref-type="bibr">9</xref>]. Global cooperation has highlighted the need to tackle these rising resistance and infection levels. The One Health Trust has declared that vaccination is considered an integral strategy to combat antimicrobial resistance, slow the spread of superbugs, and lower the overall burden of infection [<xref rid="B10-vaccines-13-00126" ref-type="bibr">10</xref>,<xref rid="B11-vaccines-13-00126" ref-type="bibr">11</xref>,<xref rid="B12-vaccines-13-00126" ref-type="bibr">12</xref>].</p><p>The immune system is highly sophisticated and is considered the first line of defense against foreign infectious and non-infectious signals. The innate immune cells are composed of a variety of circulating cells, such as natural killer cells, granulocytes (neutrophils, basophils, eosinophils, and mast cells), and antigen-presenting cells (macrophages and dendritic cells). The immune system is responsible for the processes driving the uptake and ingestion of phagocytosed particles as well as the process associated with breaking them down [<xref rid="B13-vaccines-13-00126" ref-type="bibr">13</xref>]. The five pattern-recognition receptors that can recognize pathogens play important roles in the initiation and activation of the immune response [<xref rid="B13-vaccines-13-00126" ref-type="bibr">13</xref>,<xref rid="B14-vaccines-13-00126" ref-type="bibr">14</xref>]. The intended output of vaccination is to stimulate the innate and adaptive immune systems to induce B- or T-cell responses and provide prolonged protection [<xref rid="B15-vaccines-13-00126" ref-type="bibr">15</xref>]. When a vaccine introduces an antigen into the body, B-lymphocytes produce antibodies that fight infection, while T-cells recognize and kill cells infected with a virus or other foreign cells, thus controlling the infection transmission and spread [<xref rid="B16-vaccines-13-00126" ref-type="bibr">16</xref>].</p><p>Recently, nanotechnology has provided significant advancements in the medical sector, including the production of nanovaccines, nanotherapeutics, diagnostics, and the improvement of drug screening and gene delivery approaches [<xref rid="B17-vaccines-13-00126" ref-type="bibr">17</xref>,<xref rid="B18-vaccines-13-00126" ref-type="bibr">18</xref>,<xref rid="B19-vaccines-13-00126" ref-type="bibr">19</xref>]. Nanovaccine platforms represent a transformative avenue for vaccine delivery, offering potential solutions to challenges in traditional vaccine development [<xref rid="B20-vaccines-13-00126" ref-type="bibr">20</xref>]. These platforms use nanoparticles (NPs), such as lipids, polymers, proteins, etc. to improve the delivery of antigens to target cells, resulting in broader and more specific protection against cancers, infectious diseases, inflammatory diseases, atopic diseases, autoimmune diseases, and others [<xref rid="B20-vaccines-13-00126" ref-type="bibr">20</xref>]. Nanoparticles can be designed to increase the stability and immunogenicity of antigens. They not only serve as antigens carriers but can also function as antigens themselves [<xref rid="B21-vaccines-13-00126" ref-type="bibr">21</xref>]. NPs can efficiently target vaccine molecules to the desired cell and its receptors, thereby minimizing side effects [<xref rid="B22-vaccines-13-00126" ref-type="bibr">22</xref>]. Additionally, they have been found to facilitate antigen distribution to APCs and protect antigens and adjuvants from proteolytic and enzymatic degradation [<xref rid="B23-vaccines-13-00126" ref-type="bibr">23</xref>]. Nanovaccines can evoke both humoral and cell-mediated immune responses [<xref rid="B22-vaccines-13-00126" ref-type="bibr">22</xref>]. Nanovaccines can persist for a longer time without degradation or alteration, thereby providing enough opportunity for antigen presentation and dendritic cell (DC)-mediated antigen uptake, resulting in mature DC&#x02013;T-cell interaction, which is necessary to influence the release of pro- and anti-inflammatory cytokines that promote cell-mediated immunity [<xref rid="B24-vaccines-13-00126" ref-type="bibr">24</xref>]. The NP-mediated vaccine can enhance B-cell antibody production by activating lymphocytes and monocytes. Furthermore, they can enable a targeted release of cargo into draining lymph nodes after passing through the lymphatic drainage system, generating a potent, long-lasting, and antigen-specific immune response [<xref rid="B25-vaccines-13-00126" ref-type="bibr">25</xref>,<xref rid="B26-vaccines-13-00126" ref-type="bibr">26</xref>]. These characteristics suggest that NPs might be crucial to vaccines as immune cell stimulators.</p><p>In this review, we highlight the transformative impact of NPs on vaccine platforms, focusing on their ability to enhance antigen delivery, improve immune system activation, and address the limitations of traditional vaccines. Specifically, we explore the types of NPs utilized, their mechanisms of action, current applications in vaccine development, and the potential they hold for creating more effective, stable, and accessible immunization strategies in the future. Additionally, we discuss the challenges and opportunities that lie ahead in the development and deployment of nanoparticle-based vaccines.</p></sec><sec id="sec2-vaccines-13-00126"><title>2. Conventional vs. Nanoparticle-Based Vaccines</title><sec id="sec2dot1-vaccines-13-00126"><title>2.1. Conventional Vaccines</title><p>Conventional vaccines are considered one of the greatest advances in medical history against various diseases. They were discovered in the 1700s when Edward Jenner, a British physician, demonstrated that infection with mild cowpox virus can confer immunity against smallpox virus. This discovery led to the development of the smallpox vaccine, which was the first vaccine to be developed against a contagious disease. Consequently, scientists and vaccinologists began occasional and inconclusive experiments for immunization against specific pathogens, as illustrated in <xref rid="vaccines-13-00126-f001" ref-type="fig">Figure 1</xref> [<xref rid="B27-vaccines-13-00126" ref-type="bibr">27</xref>,<xref rid="B28-vaccines-13-00126" ref-type="bibr">28</xref>,<xref rid="B29-vaccines-13-00126" ref-type="bibr">29</xref>,<xref rid="B30-vaccines-13-00126" ref-type="bibr">30</xref>,<xref rid="B31-vaccines-13-00126" ref-type="bibr">31</xref>]. The traditional vaccine development pipeline consists of exploratory research, pre-clinical studies, and clinical trials (Phases I, II, and III), followed by regulatory evaluation and approval. However, there are many types of conventional vaccines, which are classified based on their mechanisms of action.</p><sec id="sec2dot1dot1-vaccines-13-00126"><title>2.1.1. Inactivated Vaccines</title><p>This type contains killed pathogens such as influenza, coryza, typhoid, cholera, mycoplasma, hepatitis A, rabies, <italic toggle="yes">Brucella abortus</italic>, <italic toggle="yes">Mannheimia haemolytica</italic>, and <italic toggle="yes">Erysipelothrix rhusipathiae</italic> vaccines [<xref rid="B19-vaccines-13-00126" ref-type="bibr">19</xref>,<xref rid="B32-vaccines-13-00126" ref-type="bibr">32</xref>,<xref rid="B33-vaccines-13-00126" ref-type="bibr">33</xref>]. These vaccines do not offer as much protection as live vaccines do, so booster shots are often required to maintain immunity.</p></sec><sec id="sec2dot1dot2-vaccines-13-00126"><title>2.1.2. Live Vaccines</title><p>Live vaccines contain attenuated forms of pathogens such as measles, rotavirus, avian infectious bronchitis, Newcastle disease, bovine viral diarrhea, canine distemper, and fowl pox [<xref rid="B34-vaccines-13-00126" ref-type="bibr">34</xref>]. The immune system responds to this type of vaccine by producing strong and long-lasting protection. However, they may not be suitable for hosts with weakened immune systems, due to the possibility of reversion to virulence, interference with maternal immunity, and tissue damage, which may result in pathological disorders or secondary bacterial infection.</p></sec><sec id="sec2dot1dot3-vaccines-13-00126"><title>2.1.3. Subunit Vaccines</title><p>Subunit, recombinant, polysaccharide, and conjugate vaccines utilize specific microbial components, such as proteins, sugars, or capsules, to induce a targeted immune response. Examples include vaccines for hepatitis B, human papillomavirus, and shingles. While these vaccines offer several advantages, including suitability for immunocompromised individuals, they may require booster doses to maintain long-lasting immunity. Additionally, the absence of pathogen-associated molecular patterns in subunit vaccines can limit their ability to stimulate a robust immune response [<xref rid="B35-vaccines-13-00126" ref-type="bibr">35</xref>,<xref rid="B36-vaccines-13-00126" ref-type="bibr">36</xref>].</p></sec><sec id="sec2dot1dot4-vaccines-13-00126"><title>2.1.4. Toxoid Vaccines</title><p>Toxoid vaccines, such as tetanus and diphtheria vaccines [<xref rid="B37-vaccines-13-00126" ref-type="bibr">37</xref>], contain attenuated bacterial toxins, and have a more effective anti-toxin immune response [<xref rid="B38-vaccines-13-00126" ref-type="bibr">38</xref>,<xref rid="B39-vaccines-13-00126" ref-type="bibr">39</xref>]. These conventional vaccines have different administration routes, including intramuscular, subcutaneous, ocular, oral, and intranasal routes [<xref rid="B13-vaccines-13-00126" ref-type="bibr">13</xref>].</p><p>Traditional vaccines offer several advantages, including safety, proven efficacy in disease prevention, and the establishment of strong and long-lasting immunity [<xref rid="B40-vaccines-13-00126" ref-type="bibr">40</xref>,<xref rid="B41-vaccines-13-00126" ref-type="bibr">41</xref>]. However, their main limitations include a lack of genetic stability, the potential of mutations in live vaccines, and a limited ability to induce a robust immune response for long-lasting immunity for inactivated vaccines [<xref rid="B42-vaccines-13-00126" ref-type="bibr">42</xref>,<xref rid="B43-vaccines-13-00126" ref-type="bibr">43</xref>,<xref rid="B44-vaccines-13-00126" ref-type="bibr">44</xref>]. This has led to the emergence of nanovaccines as a next-generation approach.</p></sec></sec><sec id="sec2dot2-vaccines-13-00126"><title>2.2. Nanoparticle-Based Vaccines</title><p>NPs can be defined as ultrafine particles with definite dimensions that exhibit unique physicochemical characteristics, supporting their application in various biomedical and food quality fields [<xref rid="B45-vaccines-13-00126" ref-type="bibr">45</xref>,<xref rid="B46-vaccines-13-00126" ref-type="bibr">46</xref>,<xref rid="B47-vaccines-13-00126" ref-type="bibr">47</xref>]. They have emerged as promising vectors in vaccine technology development and are considered a promising alternative to conventional vaccines (<xref rid="vaccines-13-00126-t001" ref-type="table">Table 1</xref>) [<xref rid="B48-vaccines-13-00126" ref-type="bibr">48</xref>,<xref rid="B49-vaccines-13-00126" ref-type="bibr">49</xref>]. Studies have revealed that the physicochemical properties of NPs can influence the immune response in terms of factors such as particle size, hydrophilicity/hydrophobicity ratio, the number of antigens associated with each particle, and the ability of an antigen to raise a B- or T-cell response. Smaller-sized particles can pass biological barriers and epithelia more easily when compared with particles ranging from 20 to 50 nm in diameter [<xref rid="B46-vaccines-13-00126" ref-type="bibr">46</xref>]. The size of nanoparticle-based vaccines is similar, to some extent, to the size of intracellular components, making it easy for them to enter cells and induce robust and long-lasting immune responses against intracellular pathogens [<xref rid="B50-vaccines-13-00126" ref-type="bibr">50</xref>]. Spherical NPs induce the most effective immune responses when compared to other nanoparticle shapes [<xref rid="B51-vaccines-13-00126" ref-type="bibr">51</xref>]. Hydrophobic NPs are more efficiently taken up by specific immune cells and potentially enhance the immune response when compared with hydrophilic NPs that produce a weakened immune response [<xref rid="B52-vaccines-13-00126" ref-type="bibr">52</xref>,<xref rid="B53-vaccines-13-00126" ref-type="bibr">53</xref>]. Negatively charged NPs interact more efficiently with macrophages, while positively charged NPs interact more efficiently with dendritic cells [<xref rid="B54-vaccines-13-00126" ref-type="bibr">54</xref>]. NPs can be composed of polymers, lipids, proteins, emulsions, nano-beads, inorganic nanomaterials, and virus-like particles and have been approved for both animal and human use to prevent infectious and non-infectious diseases [<xref rid="B55-vaccines-13-00126" ref-type="bibr">55</xref>].</p><p>The major types of NPs used for vaccinology against infectious and non-infectious diseases are illustrated in <xref rid="vaccines-13-00126-t002" ref-type="table">Table 2</xref>. They exhibit a wide range of properties that make them valuable humoral and cellular immune stimulators [<xref rid="B13-vaccines-13-00126" ref-type="bibr">13</xref>]. They can enhance immune responses by effectively presenting or transporting antigens and allowing precise targeting of immune cells [<xref rid="B56-vaccines-13-00126" ref-type="bibr">56</xref>,<xref rid="B57-vaccines-13-00126" ref-type="bibr">57</xref>]. They protect antigens from degradation before reaching their target, thus improving vaccine efficacy and shelf life [<xref rid="B58-vaccines-13-00126" ref-type="bibr">58</xref>]. Some NPs can act as adjuvants themselves, thus stimulating the immune response without the need for additional substances to the vaccine formula [<xref rid="B59-vaccines-13-00126" ref-type="bibr">59</xref>]. NPs can be designed to control antigen release, extending immune response duration [<xref rid="B60-vaccines-13-00126" ref-type="bibr">60</xref>]. Additionally, NPs can be tailored for specific pathogens, making them versatile tools for preventing and controlling infectious diseases [<xref rid="B49-vaccines-13-00126" ref-type="bibr">49</xref>,<xref rid="B61-vaccines-13-00126" ref-type="bibr">61</xref>,<xref rid="B62-vaccines-13-00126" ref-type="bibr">62</xref>,<xref rid="B63-vaccines-13-00126" ref-type="bibr">63</xref>,<xref rid="B64-vaccines-13-00126" ref-type="bibr">64</xref>]. The nanoparticle-based vaccines have different administration routes, including ocular, oral, nasal, sublingual, topical, intradermal, intramuscular, and subcutaneous routes. The subcutaneous route is considered the most advantageous route in stimulating the immune response, as vaccines are injected directly into a site that is rich in immune cells, resulting in the production of antibodies at high concentrations [<xref rid="B65-vaccines-13-00126" ref-type="bibr">65</xref>].</p><p>The increasing diversity of nanoparticle-based vaccines has prompted ongoing research toward the optimization of delivery methods and the maximization of immune responses against specific antigens. As depicted in <xref rid="vaccines-13-00126-f002" ref-type="fig">Figure 2</xref>, nanoparticle-based vaccines have gained significant prominence in the pharmaceutical and biological industries over the past century. The continued development and implementation of nanoparticle-based vaccines hold immense potential to address a wide range of infectious diseases (viral, bacterial, fungal) and non-infectious diseases (autoimmune diseases, cancer) that pose substantial global health challenges [<xref rid="B48-vaccines-13-00126" ref-type="bibr">48</xref>,<xref rid="B49-vaccines-13-00126" ref-type="bibr">49</xref>].</p><p>Despite significant advancements in nanovaccine development for combating infectious diseases, inflammatory conditions, allergic diseases, and cancers, several challenges persist. Firstly, ensuring consistent size, shape, and composition of NPs remains a complex task, as these properties are crucial for achieving optimal pharmacological, biological, and physicochemical characteristics [<xref rid="B149-vaccines-13-00126" ref-type="bibr">149</xref>,<xref rid="B150-vaccines-13-00126" ref-type="bibr">150</xref>]. Secondly, unintended immune reactions or toxicity can arise from nanoparticle accumulation in tissues and organs [<xref rid="B20-vaccines-13-00126" ref-type="bibr">20</xref>]. Thirdly, stability and shelf-life, under various environmental conditions, pose challenges, particularly for lipid NPs that are sensitive to temperature fluctuations [<xref rid="B151-vaccines-13-00126" ref-type="bibr">151</xref>,<xref rid="B152-vaccines-13-00126" ref-type="bibr">152</xref>]. Fourthly, regulatory hurdles, production costs, and safe waste disposal are additional considerations [<xref rid="B153-vaccines-13-00126" ref-type="bibr">153</xref>]. Lastly, mRNA-based nanovaccines face specific challenges, including the selection of appropriate antigens, the synthesis and purification of mRNA, and ensuring efficient encapsulation within lipid NPs [<xref rid="B154-vaccines-13-00126" ref-type="bibr">154</xref>].</p></sec></sec><sec id="sec3-vaccines-13-00126"><title>3. Types of NPs Used in Vaccines</title><p>Nanoparticles exhibit specific characteristics that render them more effective for enhancing the immune system and delivering antigens in a controlled and targeted manner [<xref rid="B57-vaccines-13-00126" ref-type="bibr">57</xref>,<xref rid="B155-vaccines-13-00126" ref-type="bibr">155</xref>,<xref rid="B156-vaccines-13-00126" ref-type="bibr">156</xref>]. Several types of NPs are being explored for vaccine development, including lipid-based NPs, polymeric NPs, self-assembled protein or peptide NPs, biomimetic NPs, and inorganic NPs (<xref rid="vaccines-13-00126-f003" ref-type="fig">Figure 3</xref>).</p><sec id="sec3dot1-vaccines-13-00126"><title>3.1. Lipid-Based NPs</title><p>Lipid-based nanoparticles (LNPs) are also known as lipid-based nanocarriers. They are spherical NPs that use ionizable lipids as their main structural component. These NPs can be categorized based on their structure and composition. In particular, LNPs offer advantages such as biodegradability, biocompatibility, and safety, which are ideal characteristics for a vaccine delivery system [<xref rid="B157-vaccines-13-00126" ref-type="bibr">157</xref>]. LPNs can facilitate the delivery of mRNA and protect it from rapid degradation by RNases [<xref rid="B68-vaccines-13-00126" ref-type="bibr">68</xref>]. Additionally, LNPs can interact with the immune system, enhancing cellular and humoral immunity. They have been pivotal in the development of vaccines and other nanomedicines [<xref rid="B68-vaccines-13-00126" ref-type="bibr">68</xref>,<xref rid="B158-vaccines-13-00126" ref-type="bibr">158</xref>]. Furthermore, there are many examples of lipid-based NP vaccines that have been widely used in preclinical and clinical studies (<xref rid="vaccines-13-00126-t003" ref-type="table">Table 3</xref>).</p><sec id="sec3dot1dot1-vaccines-13-00126"><title>3.1.1. Interbilayer-Crosslinked Multilamellar Vesicles (ICMVs)</title><p>ICMVs have an aqueous core surrounded by multilayers of lipids. Their robust lipid wall protects the particles from serum-mediated degradation, enabling stable delivery of vaccine components to lymphoid tissues and thus generating potent antibody responses. ICMVs can serve as a delivery system for both hydrophilic and hydrophobic antigens and adjuvants, showing promise as a vaccination strategy against cancers and intracellular pathogens [<xref rid="B181-vaccines-13-00126" ref-type="bibr">181</xref>]. Studies have demonstrated that ICMVs with both surface-conjugated and encapsulated malarial antigens offer superior vaccination protection compared to soluble antigens due to the prolonged persistence of antigens in the draining lymph nodes [<xref rid="B182-vaccines-13-00126" ref-type="bibr">182</xref>]. Despite these values, ICMVs have some disadvantages, such as the complexity of production, the risk of triggering an unintended immune response, the unpredictable release of encapsulated substances from ICMVs, and the fact that techniques used to produce ICMVs may not be easily scaled up for industrial production, limiting their widespread application [<xref rid="B181-vaccines-13-00126" ref-type="bibr">181</xref>].</p></sec><sec id="sec3dot1dot2-vaccines-13-00126"><title>3.1.2. Lipoproteins</title><p>Lipoproteins are complexes of proteins and lipids. They have been reported to transfer and target various lipids, hormones, proteins, vitamins, and endogenous microRNA to recipient cells [<xref rid="B183-vaccines-13-00126" ref-type="bibr">183</xref>]. They have a hydrophobic core and a hydrophilic surface, that can facilitate the delivery of a broad range of molecules and act as vaccine-delivery carriers [<xref rid="B184-vaccines-13-00126" ref-type="bibr">184</xref>]. Recombinant lipoproteins with built-in immune stimulators have been established for novel subunit vaccine development. This core platform technology has demonstrated safety in meningococcal group B subunit vaccine, dengue subunit vaccine, novel subunit vaccine against <italic toggle="yes">Clostridium difficile</italic> and HPV-based immunotherapeutic vaccines in animal model studies [<xref rid="B185-vaccines-13-00126" ref-type="bibr">185</xref>]. The main disadvantage of lipoprotein NPs is the stability issues as they can be unstable in the bloodstream, leading to premature release of their cargo [<xref rid="B186-vaccines-13-00126" ref-type="bibr">186</xref>]. Additionally, the manufacturing process can be complex and costly, requiring precise control over conditions to ensure consistency and efficacy [<xref rid="B187-vaccines-13-00126" ref-type="bibr">187</xref>]. They are potentially toxic and some lipoprotein NPs can trigger immune responses and cause adverse reactions [<xref rid="B188-vaccines-13-00126" ref-type="bibr">188</xref>,<xref rid="B189-vaccines-13-00126" ref-type="bibr">189</xref>].</p></sec><sec id="sec3dot1dot3-vaccines-13-00126"><title>3.1.3. Liposomes</title><p>Liposomes are composed of phospholipid bilayers and range in size from 50 to 500 nm in diameter. They are amphiphilic in nature, with hydrophobic surfaces and a hydrophilic core. Liposomes have gained significant attention in delivering immunostimulatory molecules, drugs, DNA, and RNA [<xref rid="B190-vaccines-13-00126" ref-type="bibr">190</xref>]. They are highly versatile, biocompatible, safe, and capable of creating different structures by modulating components of the lipid matrix. They act as carriers for vaccines and facilitate the targeted delivery of viral proteins, triggering antibody production. Liposome carriers influence antigen internalization by immunocompetent cells and immune response induction [<xref rid="B191-vaccines-13-00126" ref-type="bibr">191</xref>]. They can act as adjuvants employed in nanovaccines formulation, so prolong stability and trigger antigen-presenting cells to initiate an immune response. The impact of liposomes on antigen-presenting cells depends on many factors, such as size, charge, and lipid composition [<xref rid="B192-vaccines-13-00126" ref-type="bibr">192</xref>]. Immunostimulant components (ligands of pathogen-associated molecular pattern receptors) can be added to liposomal vaccine complexes to modulate the strength and type of immune response [<xref rid="B192-vaccines-13-00126" ref-type="bibr">192</xref>]. Furthermore, liposomes can induce immunologic reactions to antigens adsorbed on the surface or encapsulated internally [<xref rid="B193-vaccines-13-00126" ref-type="bibr">193</xref>]. Several studies have shown that liposome-based vaccines have been widely used in preclinical and clinical studies [<xref rid="B194-vaccines-13-00126" ref-type="bibr">194</xref>]. However, liposomes have some drawbacks as they can be prone to leakage and fusion with the encapsulated drug, which can reduce their effectiveness [<xref rid="B195-vaccines-13-00126" ref-type="bibr">195</xref>]. Moreover, the manufacturing process for liposomes is often expensive and complex and they may need to be stored at specific temperatures to maintain stability. They also have been reported to have a short half-life in the bloodstream, which can limit their effectiveness [<xref rid="B196-vaccines-13-00126" ref-type="bibr">196</xref>].</p></sec><sec id="sec3dot1dot4-vaccines-13-00126"><title>3.1.4. Solid Lipid Nanoparticles (SLNs)</title><p>SLNs are particulate carrier systems that are composed of a solid lipid core and a cationic lipid surface [<xref rid="B197-vaccines-13-00126" ref-type="bibr">197</xref>]. These SLNs can be used to bind DNA, forming an SLN/DNA complex or lipoplex, which shows promise as a potential vaccine [<xref rid="B198-vaccines-13-00126" ref-type="bibr">198</xref>]. SLNs offer several advantages, including the ability to encapsulate both hydrophilic and hydrophobic drugs, protecting them from degradation in the body and destruction by enzymes. These properties make SLNs suitable for delivering various active ingredients, including vaccines, thereby enhancing therapeutic efficacy [<xref rid="B199-vaccines-13-00126" ref-type="bibr">199</xref>,<xref rid="B200-vaccines-13-00126" ref-type="bibr">200</xref>]. SLNs have some limitations, as some biomolecules can be expelled from these NPs during storage. Additionally, the high water content in lipid dispersions can affect stability and drug concentration. SLNs also have a limited ability to deliver drugs through the skin [<xref rid="B201-vaccines-13-00126" ref-type="bibr">201</xref>].</p></sec><sec id="sec3dot1dot5-vaccines-13-00126"><title>3.1.5. Exosomes</title><p>Exosomes are small vesicles composed of lipophilic bilayers ranging from 50 to 100 nm in size and are used in the formation of nanovaccines. They can cross biological barriers, including the blood-brain barrier, and deliver biological and therapeutic antigens to specific tissues [<xref rid="B202-vaccines-13-00126" ref-type="bibr">202</xref>,<xref rid="B203-vaccines-13-00126" ref-type="bibr">203</xref>]. Exosomes are biocompatible and biodegradable particles, so they are safe for clinical use. Additionally, they are immunogenic and can induce the immune response to the vaccine antigen [<xref rid="B202-vaccines-13-00126" ref-type="bibr">202</xref>]. It has been reported that exosome-based vaccines can improve the therapeutic index against cancer and immunosuppressive conditions [<xref rid="B204-vaccines-13-00126" ref-type="bibr">204</xref>]. Ongoing research is evaluating the immune response of exosome-based vaccines against Ebola virus, influenza and COVID-19 [<xref rid="B107-vaccines-13-00126" ref-type="bibr">107</xref>,<xref rid="B205-vaccines-13-00126" ref-type="bibr">205</xref>].</p></sec><sec id="sec3dot1dot6-vaccines-13-00126"><title>3.1.6. Virosomes</title><p>Virosomes are structures composed of viral proteins and liposomes, ranging from 20 to 50 nm in diameter and with hydrophobic surfaces that facilitate antigen loading. The viral protein components could be glycoproteins of different viruses, such as herpes and influenza viruses [<xref rid="B206-vaccines-13-00126" ref-type="bibr">206</xref>]. Inflexal<sup>&#x000ae;</sup>V, an approved FDA nanovaccine, has been used as a subunit influenza vaccine that uses virosomes as carriers to enhance the immune responses against influenza H1N1, H3N2, and B [<xref rid="B207-vaccines-13-00126" ref-type="bibr">207</xref>].</p></sec><sec id="sec3dot1dot7-vaccines-13-00126"><title>3.1.7. Emulsions</title><p>Emulsions, typically consisting of oil-in-water dispersions, are widely used as delivery systems for vaccines. By incorporating antigens, surfactants, and adjuvants, these emulsions can enhance the immune response to the vaccine. Emulsion-based vaccines have shown significant potential for combating various infectious diseases, including human papillomavirus, hepatitis B virus, and influenza viruses. One notable example of an emulsion-based vaccine adjuvant is MF59, which is licensed for use in certain influenza vaccines [<xref rid="B208-vaccines-13-00126" ref-type="bibr">208</xref>,<xref rid="B209-vaccines-13-00126" ref-type="bibr">209</xref>].</p></sec></sec><sec id="sec3dot2-vaccines-13-00126"><title>3.2. Polymeric NPs</title><p>Polymeric nanoparticles (PNPs) have served as versatile carriers for active compounds, either absorbed onto their polymeric core or entrapped within the structure itself. PNPs can be synthetics that are chemically synthesized in the laboratory or natural, originating from biological sources such as polysaccharides, proteins, and lipids. Natural PNPs have more advantages over synthetic PNPs in terms of biodegradability, biocompatibility, and low toxicity [<xref rid="B210-vaccines-13-00126" ref-type="bibr">210</xref>]. There are different PNP design structures such as nanospheres, micelles, and polymerases. Poly (lactic-co-glycolic acid) (PLGA)-based NPs, chitosan, hyaluronic acid, silk fibroin, alginate, polyethyleneimine, polypropylene sulfide, and polystyrene NPs are the major types of polymeric NPs that are commonly used in vaccine adjuvant delivery systems [<xref rid="B211-vaccines-13-00126" ref-type="bibr">211</xref>,<xref rid="B212-vaccines-13-00126" ref-type="bibr">212</xref>]. The production of polymeric NPs generally follows two main strategies, the polymerization of monomers or the dispersion of preformed polymers [<xref rid="B213-vaccines-13-00126" ref-type="bibr">213</xref>].</p><p>PNPs can encapsulate multiple adjuvant materials or antigens within the polymer matrix or adsorb it onto the surface, this can protect these biomedical molecules from degradation and enhance their stability. The release of biomedical molecules can be controlled through diffusion, degradation of the polymer, or a combination of both, this allows sustained and targeted delivery. PNPs can be modified with ligands, antibodies, or other molecules that target specific cells or tissues to ensure that the biomedical molecules are delivered precisely to the desired site, reducing side effects and improving efficacy. Some PNPs are designed to release their payload in response to specific stimuli such as pH, temperature or enzymes present in the target tissue [<xref rid="B214-vaccines-13-00126" ref-type="bibr">214</xref>]. In addition, PNPs are often taken up by cells through endocytosis, a process where the cell membrane engulfs the NPs. Once inside the cell, NPs can release their biomedical molecules payload in tumors and inflamed tissues, meaning that PNP-based vaccines show significant potential as anti-tumor agents [<xref rid="B215-vaccines-13-00126" ref-type="bibr">215</xref>]. PNPs can also protect labile antigenic particles from enzymatic degradation in vivo [<xref rid="B216-vaccines-13-00126" ref-type="bibr">216</xref>,<xref rid="B217-vaccines-13-00126" ref-type="bibr">217</xref>]. Other biodegradable polymers, such as poly-lactic acid, polyethylene oxide, polyethylene glycol, and poly-&#x003b5;-caprolactone are also used as adjuvants to boost vaccine immunogenicity [<xref rid="B218-vaccines-13-00126" ref-type="bibr">218</xref>,<xref rid="B219-vaccines-13-00126" ref-type="bibr">219</xref>]. Polymeric micelles are self-assembled amphiphilic structures that can efficiently deliver viral proteins. The main advantage of micelle NPs is their ability to present antigens in native-like conformations; however, their poor stability in vivo is a major drawback [<xref rid="B220-vaccines-13-00126" ref-type="bibr">220</xref>,<xref rid="B221-vaccines-13-00126" ref-type="bibr">221</xref>]. Chitosan NPs have also been used to improve pulmonary immunity against TB by increasing immune responses at mucosal sites [<xref rid="B222-vaccines-13-00126" ref-type="bibr">222</xref>]. Overall, the main advantages of PNPs include precise control of particle characteristics, payload flexibility, and ease of surface modification. However, there are potential drawbacks, including the possibility of aggregation and toxicity [<xref rid="B223-vaccines-13-00126" ref-type="bibr">223</xref>], the complexity of their production, their stability under certain conditions, and the fact that some PNPs could be cytotoxic [<xref rid="B156-vaccines-13-00126" ref-type="bibr">156</xref>,<xref rid="B224-vaccines-13-00126" ref-type="bibr">224</xref>,<xref rid="B225-vaccines-13-00126" ref-type="bibr">225</xref>]. There are different applications of PNPs, either in cancer therapy for the targeted delivery of chemotherapeutic agents or in gene therapy applications through the delivery of genetic materials such as DNA or RNA [<xref rid="B215-vaccines-13-00126" ref-type="bibr">215</xref>,<xref rid="B226-vaccines-13-00126" ref-type="bibr">226</xref>]. They have also been investigated against malaria, HIV, COVID-19, and tuberculosis diseases [<xref rid="B227-vaccines-13-00126" ref-type="bibr">227</xref>]. The main examples of polymeric-based nanovaccines that have been widely used in pre-clinical and clinical trials include NVX-CoV2373, a vaccine produced by Novavax which delivers the spike protein from the original Wuhan strain of SARS-CoV-2. The spike proteins self-assemble into 3D structures called &#x0201c;trimers,&#x0201d; which are purified and mixed with an immune-stimulating substance (adjuvant) to form NPs [<xref rid="B86-vaccines-13-00126" ref-type="bibr">86</xref>]. Clinical trials in adults given two shots of this vaccine 21 days apart demonstrated about 90% efficacy in preventing infection after seven days from the second shot [<xref rid="B85-vaccines-13-00126" ref-type="bibr">85</xref>,<xref rid="B228-vaccines-13-00126" ref-type="bibr">228</xref>]. Another example of a PNP-based vaccine is GBP510, a candidate COVID-19 vaccine that has recently undergone a combined Phase 1/2 trial. GBP510 leverages nanoparticle bioengineering technology to stimulate immune responses against COVID-19 [<xref rid="B229-vaccines-13-00126" ref-type="bibr">229</xref>,<xref rid="B230-vaccines-13-00126" ref-type="bibr">230</xref>]. Additionally, the TAK-101 vaccine, which incorporates gliadin encapsulated within PLGA nanoparticles (NPs), has been developed for celiac disease and simian immunodeficiency virus (SIV). These PLGA NPs are co-formulated with TLR4 and TLR7/8 agonists, and have demonstrated the ability to induce a prolonged, robust, and high level of protection against SIV in macaque models [<xref rid="B231-vaccines-13-00126" ref-type="bibr">231</xref>].</p></sec><sec id="sec3dot3-vaccines-13-00126"><title>3.3. Inorganic NPs</title><p>Inorganic NPs are biocompatible, non-toxic, hydrophilic and highly stable particles, presenting significant advantages over their organic counterparts. They can be classified into solids (hydroxyapatite and calcium phosphate) or porous (porous silicon and mesoporous silica) particles. Inorganic NPs exhibit unique properties that hold great promise for enhancing immune responses, improving antigen delivery efficiency, and enabling applications in tumor imaging, drug delivery, vaccine development, and infectious disease prevention. These NPs offer advantages, such as enhanced stability, controlled release kinetics, and targeted delivery, which can significantly improve the efficacy of therapeutic interventions [<xref rid="B232-vaccines-13-00126" ref-type="bibr">232</xref>]. Gold nanoparticles (AuNPs), carbon nanotubes, quantum dots, and silica NPs are among the inorganic NPs.</p><p>AuNPs exhibit unique physical, chemical, and optical properties that differ significantly from bulk gold, making them valuable for a wide range of high-technological applications, such as organic photovoltaics, drug delivery, vaccine development, and catalysis [<xref rid="B233-vaccines-13-00126" ref-type="bibr">233</xref>,<xref rid="B234-vaccines-13-00126" ref-type="bibr">234</xref>]. AuNPs are commonly referred to as colloidal gold when dispersed in water. Their most pronounced properties are the intense absorbance and scattering of incident light at their surface plasmon resonance wavelength [<xref rid="B235-vaccines-13-00126" ref-type="bibr">235</xref>]. AuNPs have garnered attention in vaccine development due to their ability to enhance immune response, making them potential adjuvants for vaccines. AuNPs can be functionalized with drugs to enhance targeted delivery and reduce side effects [<xref rid="B236-vaccines-13-00126" ref-type="bibr">236</xref>,<xref rid="B237-vaccines-13-00126" ref-type="bibr">237</xref>,<xref rid="B238-vaccines-13-00126" ref-type="bibr">238</xref>]. Additionally, they provide stability to vaccine formulations during storage [<xref rid="B239-vaccines-13-00126" ref-type="bibr">239</xref>,<xref rid="B240-vaccines-13-00126" ref-type="bibr">240</xref>]. Several studies have demonstrated the potential of AuNPs in vaccine development; for example, conjugated antigenic peptides from the SARS-CoV-2 spike protein to AuNPs have shown no inherent toxicity and have been shown to induce significant IgG antibody levels in tested mice [<xref rid="B75-vaccines-13-00126" ref-type="bibr">75</xref>]. Another example is the increase in the efficacy of the influenza vaccine by over 25% in specific strains through chiral AuNPs [<xref rid="B241-vaccines-13-00126" ref-type="bibr">241</xref>]. Moreover, AuNPs can attach to and disrupt the cell membranes of bacteria and viruses, leading to cell lysis and death. Additionally, they can induce the production of reactive oxygen species, which cause oxidative stress and damage DNA, proteins, lipids, and other cellular components. They can also trigger apoptosis (programmed cell death) by activating various cellular pathways and can disrupt the metabolic processes of microbial cells through the inhibition of the activity of essential enzymes. AuNPs can induce cellular and humoral immune responses against enterohemorrhagic <italic toggle="yes">E. coli</italic> through increasing antigen uptake and processing [<xref rid="B242-vaccines-13-00126" ref-type="bibr">242</xref>]. Additionally, they can be loaded with platinum on copper nanosheets, and can promote the glucose oxidation process in tumor tissues, so are considered an optional therapeutic for cancer [<xref rid="B243-vaccines-13-00126" ref-type="bibr">243</xref>].</p><p>The primary limitations associated with AuNPs include (a) potential cytotoxicity at high concentrations, despite their inherent biocompatibility; (b) the requirement for specialized, often complex, and costly techniques for their synthesis and functionalization [<xref rid="B244-vaccines-13-00126" ref-type="bibr">244</xref>]; (c) their susceptibility to aggregation over time, which can compromise their stability and functionality [<xref rid="B245-vaccines-13-00126" ref-type="bibr">245</xref>]; and (d) the possibility that they might induce adverse effects like inflammation and immune responses [<xref rid="B246-vaccines-13-00126" ref-type="bibr">246</xref>].</p><p>Silica nanoparticles (SiO<sub>2</sub> NPs), also known as nanosilica are considered another type of inorganic NP. They are typically amorphous substances with a spherical morphology, although they can be synthesized in various shapes and sizes [<xref rid="B247-vaccines-13-00126" ref-type="bibr">247</xref>]. Their surfaces can be easily modified for specific purposes, making them suitable nanocarriers for drug delivery due to their high surface area and their ability to adsorb active components [<xref rid="B248-vaccines-13-00126" ref-type="bibr">248</xref>]. SiO<sub>2</sub> NPs possess several advantages including the following: (a) they exhibit low toxicity and are considered safe for biomedical applications; (b) they are thermally stable and can withstand high temperatures without significant degradation; (c) silica is abundant and cost-effective; and (d) their surfaces can be modified and functionalized for specific applications and have gained attention as potential adjuvants for vaccine development. For instance, mesoporous silica nanoparticles (MSNs) are nanomaterials with tunable particle size, high porosity, and versatile surface chemistry. They are commonly used for controlled drug release and delivery due to their low toxicity and biocompatibility [<xref rid="B249-vaccines-13-00126" ref-type="bibr">249</xref>]. Traditional MSNs have small pores (typically 2&#x02013;6 nm), which limit their utility for immunotherapy since many antigens and immunostimulatory factors are macromolecules (e.g., proteins, nucleic acids). Recently, MSNs have been developed with extra-large pores (20&#x02013;30 nm) to incorporate antigens for more effective cancer vaccines. Large-pore MSNs can efficiently load macromolecules, making them suitable for immunotherapy [<xref rid="B77-vaccines-13-00126" ref-type="bibr">77</xref>]. They target dendritic cells in lymph nodes, delivering tumor antigens and activating DCs, which leads to a cytotoxic T lymphocyte (CTL) antitumor response. Overall, silica-based nanomaterials are biodegradable, biocompatible, and easily conjugated with antigens and adjuvants [<xref rid="B250-vaccines-13-00126" ref-type="bibr">250</xref>]. They exert immunostimulatory effects, enhancing the immunogenicity of subunit vaccines and offering promise in cancer immunotherapy [<xref rid="B78-vaccines-13-00126" ref-type="bibr">78</xref>]. There are ongoing clinical trials for various cancers, including ovarian cancer, prostate cancer, and glioblastoma [<xref rid="B251-vaccines-13-00126" ref-type="bibr">251</xref>]. The primary drawbacks of SiO<sub>2</sub> NPs include the complexity of their synthesis processes and the potential long-term environmental impacts and health risks associated with exposure. These risks may include inflammation, oxidative stress, and cytotoxicity [<xref rid="B252-vaccines-13-00126" ref-type="bibr">252</xref>,<xref rid="B253-vaccines-13-00126" ref-type="bibr">253</xref>,<xref rid="B254-vaccines-13-00126" ref-type="bibr">254</xref>].</p></sec><sec id="sec3dot4-vaccines-13-00126"><title>3.4. Virus-like Particles (VLPs)</title><p>VLPs are non-infectious, non-replicating viral structural proteins that lack viral genetic material. They mimic the structure of real viruses and do not cause disease. VLPs are safe and effective immune stimulators [<xref rid="B255-vaccines-13-00126" ref-type="bibr">255</xref>], highly immunogenic, and capable of inducing both cellular and humoral immune responses. They serve as an alternative platform for developing vaccines against infectious diseases, including hepatitis B, malaria, and SARS-CoV-2. VLP-based vaccines have the advantages of efficacy, safety, stability, and diversity [<xref rid="B82-vaccines-13-00126" ref-type="bibr">82</xref>,<xref rid="B83-vaccines-13-00126" ref-type="bibr">83</xref>]. Most licensed VLP-based vaccines use classic aluminum adjuvants, which enhance antibody responses through complex cellular reactions and local antigen trapping at the injection site, ensuring slow release and prolonged stimulation of the immune system [<xref rid="B256-vaccines-13-00126" ref-type="bibr">256</xref>]. The main drawbacks of VLPs include the following: (1) they can be less stable compared to other NPs; (2) they degrade or lose their structural integrity under certain conditions, which can affect their efficacy; (3) the removal of impurities and the achievement of high purity levels of VLPs is a labor-intensive and time-consuming process; (4) their sensitivity to environmental conditions such as temperature and pH can limit their storage and handling options; and (5) VLPs produced in bacterial systems may contain endotoxins, which can cause severe immune reactions [<xref rid="B82-vaccines-13-00126" ref-type="bibr">82</xref>,<xref rid="B255-vaccines-13-00126" ref-type="bibr">255</xref>,<xref rid="B257-vaccines-13-00126" ref-type="bibr">257</xref>,<xref rid="B258-vaccines-13-00126" ref-type="bibr">258</xref>].</p><p>There are numerous examples of VLP-based vaccines in various stages of clinical and pre-clinical development. For instance, VLPs derived from the hepatitis B virus and human papillomavirus (HPV) have been successfully commercialized. Recently, VLP-based vaccines targeting emerging pathogens such as SARS-CoV-2 have shown significant promise. These include VLPs displaying the SARS-CoV-2 spike protein, which have entered clinical trials [<xref rid="B259-vaccines-13-00126" ref-type="bibr">259</xref>,<xref rid="B260-vaccines-13-00126" ref-type="bibr">260</xref>]. Additionally, VLP-based vaccines are being explored for other diseases such as influenza, HIV, and malaria. By mimicking the structure of native viruses, VLPs can induce strong immune responses, making them a versatile platform for vaccine development [<xref rid="B261-vaccines-13-00126" ref-type="bibr">261</xref>,<xref rid="B262-vaccines-13-00126" ref-type="bibr">262</xref>,<xref rid="B263-vaccines-13-00126" ref-type="bibr">263</xref>,<xref rid="B264-vaccines-13-00126" ref-type="bibr">264</xref>].</p></sec><sec id="sec3dot5-vaccines-13-00126"><title>3.5. Self-Assembling Peptide/Protein Nanovaccines</title><p>Self-assembling peptides and proteins can form diverse nanostructures, including nanofibers, NPs, and hydrogels. These structures offer unique advantages for vaccine delivery, such as controlled antigen release, enhanced immunogenicity, and targeted delivery to immune cells [<xref rid="B265-vaccines-13-00126" ref-type="bibr">265</xref>]. Recent advancements in peptide and protein engineering have enabled the development of self-assembling nanovaccines for various diseases. For example, ferritin-based NPs have been explored as a platform for delivering multiple antigens, including those targeting EBV, SARS-CoV-2, and cancer [<xref rid="B266-vaccines-13-00126" ref-type="bibr">266</xref>,<xref rid="B267-vaccines-13-00126" ref-type="bibr">267</xref>]. Additionally, peptide-based vaccines have been designed to induce specific immune responses against various pathogens [<xref rid="B267-vaccines-13-00126" ref-type="bibr">267</xref>,<xref rid="B268-vaccines-13-00126" ref-type="bibr">268</xref>].</p></sec></sec><sec id="sec4-vaccines-13-00126"><title>4. Mechanism of Action of Nanovaccines</title><p>NPs can be functionalized as antigen carriers through encapsulation or surface conjugation. In encapsulation, antigens are enclosed within the NP matrix, providing a controlled release mechanism. In surface conjugation, antigens are attached to the NP surface, facilitating direct interaction with the immune system [<xref rid="B59-vaccines-13-00126" ref-type="bibr">59</xref>,<xref rid="B269-vaccines-13-00126" ref-type="bibr">269</xref>]. The mechanism of action of NPs is governed by their structure, size, surface charge, concentration, dosage, uptake, and processing by the immune system cells [<xref rid="B270-vaccines-13-00126" ref-type="bibr">270</xref>]. The size of NPs enhances tissue penetration and enables immune cell interaction and activation at the infected site [<xref rid="B46-vaccines-13-00126" ref-type="bibr">46</xref>]. They can protect antigens from premature enzymatic degradation and facilitate a sustained release, thereby ensuring prolonged antigen exposure and enhancing the immune response [<xref rid="B55-vaccines-13-00126" ref-type="bibr">55</xref>,<xref rid="B271-vaccines-13-00126" ref-type="bibr">271</xref>]. NPs can mimic the invasion process of pathogens, enhancing the immune response by presenting antigens more naturally and effectively [<xref rid="B87-vaccines-13-00126" ref-type="bibr">87</xref>]. NPs can also be functionalized with ligands that attach to certain receptors on antigen-presenting cells, including dendritic cells or macrophages. This targeted approach increases the uptake of antigens by the key immune cells. Once inside the APCs, the NPs degrade, releasing the antigens that are processed and presented on the surface of APCs by major histocompatibility complex molecules [<xref rid="B272-vaccines-13-00126" ref-type="bibr">272</xref>]. Potentially, the immune response to nanovaccines involves antibodies generated for both the NP itself and the incorporated antigen [<xref rid="B273-vaccines-13-00126" ref-type="bibr">273</xref>].</p><p>Adjuvants can be defined as substances added to vaccines to enhance the immune response, improve antigen presentation, activate the immune cells, and prolong antigen exposure. NPs can act as effective adjuvants by gradually releasing antigens and being engineered to specifically reach antigen-presenting cells. This targeted delivery optimizes immunization strategies, allowing effective immune activation with lower antigen doses [<xref rid="B227-vaccines-13-00126" ref-type="bibr">227</xref>,<xref rid="B274-vaccines-13-00126" ref-type="bibr">274</xref>].</p><p>Various types of NPs, including gold, dendrimers, carbon, polymers and liposomes, can induce cytokine and antibody responses. LNPs are particularly effective in encapsulating mRNA and delivering antigens to immune cells, facilitating CD8+ T cell activation. These LNPs have demonstrated success in clinical applications, such as in mRNA vaccines for SARS-CoV-2, where they enable efficient delivery of spike proteins to antigen-presenting cells, thereby triggering a strong immune response [<xref rid="B189-vaccines-13-00126" ref-type="bibr">189</xref>,<xref rid="B275-vaccines-13-00126" ref-type="bibr">275</xref>]. Additionally, NPs allow for the delivery of multiple antigens within a single vaccine. For example, a single NP could encapsulate spike proteins from various coronaviruses, potentially offering broader protection against related pathogens [<xref rid="B276-vaccines-13-00126" ref-type="bibr">276</xref>].</p></sec><sec id="sec5-vaccines-13-00126"><title>5. Nanovaccines for Food Safety</title><p>Foodborne and waterborne bacterial pathogens continue to pose significant global health challenges, causing substantial morbidity and mortality worldwide. Recent advances in NP-based vaccines have also emerged to form a promising strategy to combat these pathogens through immunization.</p><p>Recent studies have demonstrated significant progress in developing nanovaccines against <italic toggle="yes">Salmonella</italic> spp. Chitosan NPs conjugated with <italic toggle="yes">Salmonella</italic> outer membrane proteins have been shown to induce robust immune responses in broilers, protecting against lethal challenges. The nanoformulation showed superior stability when compared with conventional vaccines and also increased mRNA expression of toll-like receptors [<xref rid="B277-vaccines-13-00126" ref-type="bibr">277</xref>]. Additionally, oral vaccine administration (<italic toggle="yes">S.</italic> Enteritidis immunogenic outer membrane proteins and flagellin entrapped in mannose chitosan NPs) elicited cross-protective mucosal immune responses against <italic toggle="yes">S.</italic> Typhimurium colonization in broilers [<xref rid="B278-vaccines-13-00126" ref-type="bibr">278</xref>]</p><p>Innovative approaches using gold NPs conjugated with <italic toggle="yes">E. coli</italic> O157:H7 antigens have shown promising results. Recent studies have shown that vaccination with gold NPs conjugated to <italic toggle="yes">E. coli</italic> O157:H7 antigens elicits strong systemic and mucosal immune responses, leading to significant protection against <italic toggle="yes">E. coli</italic> O157:H7 colonization [<xref rid="B279-vaccines-13-00126" ref-type="bibr">279</xref>]. Furthermore, nanoformulations, combining antibiotics, NPs, and polymeric carriers, can improve drug delivery and efficacy in the treatment of urinary tract infection (UTI) treatment, especially UTIs caused by <italic toggle="yes">E. coli</italic>. These nanoformulations can enhance drug solubility, target specific sites of infection, and control drug release, leading to improved therapeutic outcomes and reduced side effects. These advancements in nanotechnology hold the potential to revolutionize UTI treatment by providing more effective and targeted therapeutic options [<xref rid="B280-vaccines-13-00126" ref-type="bibr">280</xref>].</p><p>A novel lipid nanoparticle (NP)-based vaccine incorporating the cholera toxin B subunit has been developed to combat <italic toggle="yes">V. cholerae</italic>. This formulation has demonstrated enhanced mucosal immunity compared to traditional oral cholera vaccines. Additionally, it has shown improved stability under gastric conditions and increased bioavailability, making it a promising alternative for cholera prevention [<xref rid="B281-vaccines-13-00126" ref-type="bibr">281</xref>]. Complementary research has shown that nanoparticle-based vaccines combining <italic toggle="yes">V. cholerae</italic> outer membrane vesicles induced long-lasting immunity [<xref rid="B282-vaccines-13-00126" ref-type="bibr">282</xref>].</p><p>Engineered polymer-based NPs incorporating flagellin and outer membrane proteins of <italic toggle="yes">Campylobacter jejuni</italic> have shown a significant reduction in bacterial colonization, achieving protection in poultry models [<xref rid="B109-vaccines-13-00126" ref-type="bibr">109</xref>]. Additionally, hybrid NPs combining chitosan and alginate have shown enhanced mucosal adherence and improved immune responses against <italic toggle="yes">C. jejuni</italic> [<xref rid="B283-vaccines-13-00126" ref-type="bibr">283</xref>,<xref rid="B284-vaccines-13-00126" ref-type="bibr">284</xref>].</p><p>Advanced NP formulations targeting <italic toggle="yes">L. monocytogenes</italic> have emerged as potential preventive strategies, where developed NPs conjugated with listeriolysin O have demonstrated enhanced cellular immunity and effective cross-presentation to CD8+ T-cells [<xref rid="B285-vaccines-13-00126" ref-type="bibr">285</xref>]. In addition, NPs loaded with multiple listeria antigens achieved broad-spectrum protection against different serotypes [<xref rid="B285-vaccines-13-00126" ref-type="bibr">285</xref>].</p><p>Innovative approaches in <italic toggle="yes">Shigella</italic> nanovaccine development have shown significant progress using NPs encapsulating <italic toggle="yes">Shigella</italic> invasion plasmid antigens, demonstrating robust protection against multiple <italic toggle="yes">Shigella</italic> species [<xref rid="B286-vaccines-13-00126" ref-type="bibr">286</xref>]. Furthermore, success has been reported with pH-responsive NPs that specifically release antigens in the intestinal environment, enhancing the efficiency of immune response induction [<xref rid="B287-vaccines-13-00126" ref-type="bibr">287</xref>].</p></sec><sec id="sec6-vaccines-13-00126"><title>6. Nanoparticle-Based Vaccines in Veterinary Medicine</title><p>The advancements in nanotechnology have revolutionized the field of vaccination and drug delivery, significantly enhancing the diagnosis, prevention, and treatment of both infectious and non-infectious diseases in humans and animals [<xref rid="B269-vaccines-13-00126" ref-type="bibr">269</xref>,<xref rid="B288-vaccines-13-00126" ref-type="bibr">288</xref>]. NPs, when used in vaccines, enable targeted delivery, enhance immune response, and potentially offer prolonged immunity, making them particularly advantageous in veterinary medicine applications. By reducing the reliance on antimicrobials, these nanovaccines play an essential role in promoting animal welfare and addressing antimicrobial resistance, a growing concern in veterinary and public health [<xref rid="B289-vaccines-13-00126" ref-type="bibr">289</xref>,<xref rid="B290-vaccines-13-00126" ref-type="bibr">290</xref>]. In veterinary medicine, nanoparticle-based vaccines have demonstrated effectiveness in conferring specific and durable immunity against a range of clinically significant bacterial pathogens, including <italic toggle="yes">Salmonella</italic> spp., <italic toggle="yes">E. coli</italic>, <italic toggle="yes">Staphylococcus</italic> spp., <italic toggle="yes">Helicobacter</italic> spp., <italic toggle="yes">Mycobacterium</italic> spp., <italic toggle="yes">Clostridium</italic> spp., and <italic toggle="yes">Pseudomonas</italic> spp. For example, studies have demonstrated that nanoformulations can enhance antigen stability and allow for controlled release, which can improve vaccine efficacy and immune memory [<xref rid="B288-vaccines-13-00126" ref-type="bibr">288</xref>,<xref rid="B289-vaccines-13-00126" ref-type="bibr">289</xref>,<xref rid="B290-vaccines-13-00126" ref-type="bibr">290</xref>]. This technology is also being explored to develop novel vaccine platforms that may improve immune responses against difficult-to-treat pathogens and reduce disease burden in livestock industries [<xref rid="B290-vaccines-13-00126" ref-type="bibr">290</xref>].</p><p>Secreting membrane vesicles are nanostructures that can stimulate T-cell responses against different antibiotic-resistant bacteria such as <italic toggle="yes">S. aureus</italic> and avian pathogenic <italic toggle="yes">E. coli</italic>. These extracellular vesicles produced by resistant bacterial strain surfaces and coated with indocyanine-loaded magnetic silica NPs could significantly reduce surface infection, systemic invasiveness, and complications of <italic toggle="yes">S. aureus</italic> in experimental models [<xref rid="B97-vaccines-13-00126" ref-type="bibr">97</xref>]. The outer membrane vesicles of avian pathogenic <italic toggle="yes">E. coli</italic> serotype O2 have experimentally promoted strong specific and non-specific protective immune responses against homologous infection with <italic toggle="yes">E. coli</italic> in broilers, which was achieved via the reduction of bacterial loads, reduction of proinflammatory cytokine production and activation of T-cell responses [<xref rid="B98-vaccines-13-00126" ref-type="bibr">98</xref>].</p><p>Carbon nanotubes and poly-anhydrous NPs have been tested against anaplasmosis or inactivated <italic toggle="yes">M. paratuberculosis</italic> in murine experimental models. The carbon nanotubes absorbed and displayed the <italic toggle="yes">A. marginale</italic> MSP1 protein on both their outer and inner surfaces. They then traversed biological membranes without compromising their integrity. In contrast, the polyanhydrides encapsulated whole-cell lysates and <italic toggle="yes">M. paratuberculosis</italic> culture filtrates through nanoprecipitation. [<xref rid="B99-vaccines-13-00126" ref-type="bibr">99</xref>].</p><p>Furthermore, nanovaccines based on the oligo-polysaccharide antigen and poly (lactic-co-glycolic acid) NPs have shown promise against <italic toggle="yes">B. melitensis</italic> through efficient engulfment by macrophages and other phagocytic cells [<xref rid="B117-vaccines-13-00126" ref-type="bibr">117</xref>]. Polyanhydride NPs encapsulating pathogenic fusion proteins co-adjuvanted with noncanonical CDGs are among the latest innovations that rapidly induce specific protective immune responses against highly virulent <italic toggle="yes">B</italic>. <italic toggle="yes">anthracis</italic> and <italic toggle="yes">Y. pestis</italic> [<xref rid="B111-vaccines-13-00126" ref-type="bibr">111</xref>]. <italic toggle="yes">F. columnare</italic>, which is a highly contagious bacteria affecting tilapia, can be controlled and suppressed by the immersion of mucoadhesive polymer chitosan-complexed nanovaccine, which modulates the mucosal immune response of tilapia against columnaris disease [<xref rid="B103-vaccines-13-00126" ref-type="bibr">103</xref>]. Avian pathogenic <italic toggle="yes">E. coli</italic>, which is a highly infectious pathogen impacting poultry production worldwide, has been minimized in chickens by using chitosan-based nanovaccines. These chitosan nanovaccines can encapsulate and load the outer membrane protein and flagellar antigen, resulting in improved vaccine efficacy and protection against avian pathogenic <italic toggle="yes">E. coli</italic> [<xref rid="B108-vaccines-13-00126" ref-type="bibr">108</xref>].</p><p>Additionally, chitosan nanovaccines containing <italic toggle="yes">S. Enteritidis</italic> that are surface-coated with F-protein and O-F antigen have successfully reduced the load of <italic toggle="yes">S</italic>. Enteritidis in chicken and pig intestines by stimulating specific memory B and T cell responses [<xref rid="B109-vaccines-13-00126" ref-type="bibr">109</xref>,<xref rid="B110-vaccines-13-00126" ref-type="bibr">110</xref>,<xref rid="B291-vaccines-13-00126" ref-type="bibr">291</xref>]. Moreover, nanoparticle-based vaccines have been used for the prevention and treatment of different parasitic infections and infestations such as malaria, leishmaniasis, toxoplasmosis, schistosomiasis, anaplasmosis, theileriosis, trypanosomiasis, and coccidiosis. They have also been applied to parasitic vectors like fleas, mosquitoes, and ticks [<xref rid="B147-vaccines-13-00126" ref-type="bibr">147</xref>,<xref rid="B292-vaccines-13-00126" ref-type="bibr">292</xref>]. Inoculation of nanovaccines in experimental animals against <italic toggle="yes">T. cruzi</italic> has been developed and optimized for both the protection and control of parasite replication and dissemination [<xref rid="B112-vaccines-13-00126" ref-type="bibr">112</xref>]. Moreover, new nanovaccine platforms, such as antigen-absorbing silica vesicles, have been evaluated against tick-borne diseases in laboratory models and have shown very promising results [<xref rid="B113-vaccines-13-00126" ref-type="bibr">113</xref>]. Another novel nano vaccine has shown synergistic efficacy and balanced immune response against <italic toggle="yes">T. parva</italic> [<xref rid="B81-vaccines-13-00126" ref-type="bibr">81</xref>]. Furthermore, precisely engineered nanovaccines have provided stable, long-lasting immunological and less toxigenic responses against highly pathogenic and mutated viruses, including avian influenza, RSV, and RVF virus [<xref rid="B104-vaccines-13-00126" ref-type="bibr">104</xref>,<xref rid="B147-vaccines-13-00126" ref-type="bibr">147</xref>,<xref rid="B293-vaccines-13-00126" ref-type="bibr">293</xref>,<xref rid="B294-vaccines-13-00126" ref-type="bibr">294</xref>].</p></sec><sec id="sec7-vaccines-13-00126"><title>7. Current Research on Nanoparticle-Based Vaccines</title><p>The use of NPs in vaccines can improve immunogenicity and offer a promising platform for future vaccine development. Researchers are utilizing microfluidic platforms to evaluate the performance of NPs in preclinical studies. These platforms can mimic in vivo conditions, allowing a more accurate assessment of NPs&#x02019; efficacy and safety [<xref rid="B295-vaccines-13-00126" ref-type="bibr">295</xref>]. In addition, membrane-based nanovaccines are under investigation, with several candidates in preclinical and clinical phases for use as effective cancer nanovaccines to inhibit tumor growth and metastasis [<xref rid="B296-vaccines-13-00126" ref-type="bibr">296</xref>,<xref rid="B297-vaccines-13-00126" ref-type="bibr">297</xref>,<xref rid="B298-vaccines-13-00126" ref-type="bibr">298</xref>]. NPs are being explored to improve the delivery and efficacy of cancer treatments. For instance, in lung cancer therapy, NPs can deliver drugs directly to tumor cells, enhancing the precision and effectiveness of the treatment while minimizing side effects [<xref rid="B299-vaccines-13-00126" ref-type="bibr">299</xref>]. Different types of NPs, such as polymer NPs, liposomes, quantum dots, dendrimers, and gold NPs, are being studied for their unique properties and applications in targeting tumor tissues [<xref rid="B299-vaccines-13-00126" ref-type="bibr">299</xref>,<xref rid="B300-vaccines-13-00126" ref-type="bibr">300</xref>,<xref rid="B301-vaccines-13-00126" ref-type="bibr">301</xref>]. Animal models remain the appropriate tool in demonstrating the efficacy of nanoparticle-based vaccines. Rats, guinea pigs, mice, sheep, canines, rabbits, swine, and non-human primates like African green monkeys and Asian macaques are among the most commonly used animal models. Small animal models offer advantages in handling, housing, and maintenance costs; however, selecting a suitable animal model is crucial for translating experimental findings to clinical applications and overcoming developmental barriers. For example, mice are more resistant to classic TB disease which minimizes their utilization for evaluating TB vaccines. The encapsulation of antigens in suitable animal models using microparticles/NPs enhances the immune responses, resulting in better immunity and broader protection compared with conventional vaccines [<xref rid="B302-vaccines-13-00126" ref-type="bibr">302</xref>]. Self-assembled peptide nanovaccines (SAPNs) can act as innovative nanovaccines that enhance antigen-presenting cell uptake, with B-cell activation and lymph node trafficking, resulting in a robust immune response and protection against various animal infectious diseases [<xref rid="B303-vaccines-13-00126" ref-type="bibr">303</xref>]. Additionally, VLPs have shown promise in vaccine development and have effectively protected animal models against SARS-CoV-2 infection [<xref rid="B304-vaccines-13-00126" ref-type="bibr">304</xref>].</p></sec><sec id="sec8-vaccines-13-00126"><title>8. Hurdles for Nanoparticle-Based Vaccines</title><p>Regulatory approval pathways for NPs can be extremely complex due to their unique features and potential applications across various fields, including medicine, cosmetics, and food packaging. The U.S. Food and Drug Administration (FDA) regulates NPs under existing statutory authorities, tailored to the specific product type (e.g., drugs, biologics, devices). For nanomedicine, the FDA requires thorough evaluations of safety, quality, and efficacy and often involves laboratory and clinical studies due to their novel properties. The regulatory bodies perform a risk-benefit analysis tailored to the intended use of the nanoparticle product with continuous monitoring of nanoparticle products post-approval to ensure ongoing safety and effectiveness [<xref rid="B305-vaccines-13-00126" ref-type="bibr">305</xref>,<xref rid="B306-vaccines-13-00126" ref-type="bibr">306</xref>,<xref rid="B307-vaccines-13-00126" ref-type="bibr">307</xref>]. Regarding NP-based vaccines, key considerations include validation methods for antigen selection, formulation stability, antigen release rates, the characterization of carrier pharmacokinetics and biodistribution, and rigorous clinical trials and safety assessments that include Phase I, II, and III trials which assess safety, efficacy, and immunogenicity [<xref rid="B308-vaccines-13-00126" ref-type="bibr">308</xref>,<xref rid="B309-vaccines-13-00126" ref-type="bibr">309</xref>,<xref rid="B310-vaccines-13-00126" ref-type="bibr">310</xref>].</p><p>Several critical considerations and challenges pertain to NPs, including safety concerns related to adverse reactions, as NPs may accumulate in tissues and organs causing harm. Some NPs may trigger allergic reactions, inflammations, and oxidative stress and there is potential for NPs to induce DNA damage, which could result in mutations and genotoxicity [<xref rid="B311-vaccines-13-00126" ref-type="bibr">311</xref>]. Regulatory bodies like the FDA, European Medicines Agency (EMA), and National Medical Products Administration (NMPA) have set guidelines and standards to ensure the safety and efficacy of these nanoparticle-based vaccines. Another challenge is the cold chain requirements of LNPs, as they are sensitive to temperature fluctuations and thus require stringent cold chain maintenance during storage and distribution [<xref rid="B152-vaccines-13-00126" ref-type="bibr">152</xref>]. Global harmonization is another challenge, ensuring consistent standards and social considerations across different countries. The U.S. FDA has set specific guidelines, including preclinical studies, clinical trials, and post-marketing surveillance to ensure the quality, safety, and efficacy of nanoparticle-based vaccines. The European Medicines Agency (EMA) also has stringent regulations focusing on safety, efficacy, and quality control for the approval of NP-based vaccines. In China, the NMPA focuses on clinical trial data and post-marketing monitoring for the regulation and approval of NP-based vaccines. Furthermore, regarding social considerations, there may be different levels of vaccine hesitancy due to mistrust or due to misinformation from the healthcare system, because some communities may have philosophical or religious objections to certain vaccines, and also because there may be disparities in healthcare access and distribution, particularly in low-income countries. Global organizations, like the World Health Organization (WHO), are working to harmonize vaccine standards and guidelines to ensure consistency and safety across countries [<xref rid="B312-vaccines-13-00126" ref-type="bibr">312</xref>]. Ongoing efforts to overcome cultural barriers and educate and engage communities about the importance of vaccination and increase acceptance. The complexity of nanoparticle design is another challenge and requires careful manufacturing to achieve an ideal product with the appropriate pharmacological, biological, and physicochemical characteristics [<xref rid="B149-vaccines-13-00126" ref-type="bibr">149</xref>]. The ability to overcome biological barriers to deliver therapeutics effectively to the target sites is a further challenge. There are additional challenges for mRNA-based nanovaccines, which include selecting the appropriate target antigen, synthesizing, and purifying mRNA, and ensuring effective encapsulation of mRNA within lipid NPs. There are several manufacturing challenges for NPs, including top-down manufacturing approaches for breaking down bulk materials into NPs. These techniques, such as milling, lithography, and laser ablation, can be energy-intensive and may lead to issues like contamination and non-uniform particle sizes [<xref rid="B313-vaccines-13-00126" ref-type="bibr">313</xref>]. In contrast, bottom-up, such as chemical vapor deposition, sol-gel processes, and self-assembly, offer greater control over particle size and composition [<xref rid="B313-vaccines-13-00126" ref-type="bibr">313</xref>].</p><p>There are also scalability challenges for NPs, including the need for uniformity and to achieve consistent size, shape, and distribution of NPs on a large scale, which can affect the performance and safety of the final product [<xref rid="B313-vaccines-13-00126" ref-type="bibr">313</xref>]. Even small amounts of impurities can significantly alter the properties of NPs, making it crucial to maintain purity and prevent contamination during large-scale production [<xref rid="B314-vaccines-13-00126" ref-type="bibr">314</xref>]. Additionally, scaling up nanoparticle production can be expensive due to the need for specialized equipment and materials.</p><p>Current research focuses on optimizing the manufacturing processes for nanovaccines to enhance their scalability, effectiveness, and cost-efficiency. mRNA vaccines have gained attention due to their rapid design, potent immune responses, and safety. Additionally, they can be designed within days, allowing fast production and scalability [<xref rid="B315-vaccines-13-00126" ref-type="bibr">315</xref>]. LNPs acting as effective delivery platforms for mRNA vaccines can enhance immunogenicity, target delivery, and improve stability [<xref rid="B274-vaccines-13-00126" ref-type="bibr">274</xref>]. Interestingly, another platform, called the Silicon Scalable Lipid NP Generation platform, has been developed with a scalable and efficient solution for LNP production and for addressing the challenges exposed during the COVID-19 pandemic [<xref rid="B93-vaccines-13-00126" ref-type="bibr">93</xref>].</p><p>Different measures can help in achieving high-quality and consistent NPs, which are essential for their reliable performance in various applications. Advanced techniques like electron microscopy (scanning, and transmission), and dynamic light scattering are used to analyze the size, shape, and distribution of NPs. Developing standardized protocols for synthesis and characterization helps in maintaining consistency across different batches. Implementing strict control over the production process, including temperature, pH, and reactant concentrations, ensures reproducibility. Regular testing and validation of NPs against predefined criteria help in identifying and mitigating any deviations. Using automated systems for production and quality control can reduce human errors and improve consistency. Adhering to regulatory standards and guidelines ensures that the NPs meet safety and efficacy requirements. Furthermore, rigorous quality control and adherence to regulatory guidelines are essential for successful nanoparticle-based vaccine safety and efficacy. The US Pharmacopeia has developed analytical methods by which to assess attributes such as identity verification, impurity control, and content measurement for mRNA vaccine and these quality standards contribute to enhanced regulatory confidence [<xref rid="B316-vaccines-13-00126" ref-type="bibr">316</xref>,<xref rid="B317-vaccines-13-00126" ref-type="bibr">317</xref>,<xref rid="B318-vaccines-13-00126" ref-type="bibr">318</xref>]. Preclinical assessment of nanovaccines involves measuring physical, chemical, and stability properties, as well as assessing immunogenicity and toxicity in vitro and in vivo, which are essential to ensure comprehensive characterization throughout vaccine development [<xref rid="B319-vaccines-13-00126" ref-type="bibr">319</xref>].</p></sec><sec id="sec9-vaccines-13-00126"><title>9. Innovations in NP Development</title><sec id="sec9dot1-vaccines-13-00126"><title>9.1. Nanocages, Dendrimers, and Other Novel Structures</title><p>Various innovative structures, including nanocages and dendrimers, have emerged in biomedical research and vaccine development. Nanocages are nanoscale, hollow structures with porous walls. Nanocages offer unique properties, including porosity, high loading capacity, controlled release mechanisms, and customizable surface properties. These characteristics make nanocages highly effective for delivering therapeutic and biological molecules. Additionally, nanocages are not recognized as exogenous particles and can be biologically or chemically engineered. Nanocages can be classified into two groups: organic nanocages (e.g., protein nanocages, DNA nanocages, etc.) and inorganic nanocages (e.g., gold nanocages, silica nanocages, carbon-based nanocages, etc.) [<xref rid="B320-vaccines-13-00126" ref-type="bibr">320</xref>]. Organic nanocages, particularly protein nanocages derived from endogenous proteins, exhibit minimal interactions with living cells. In contrast, inorganic nanocages offer high antigen-loading capacity, controllable drug loading and release kinetics, flexible surface chemical modification, and in vivo safety. They can also incorporate luminescent, radioactive, or magnetic reporter molecules for tracing purposes.</p><p>Dendrimers are highly branched nanosized polymers with a central core and multiple layers of branching units. Their characteristics, such as chemical stability, polyvalency, electrostatic interactions, self-assembling, solubility, and low cytotoxicity, make them suitable candidates for functionalization with antigens, adjuvants, and other nucleic acid-based vaccines [<xref rid="B321-vaccines-13-00126" ref-type="bibr">321</xref>,<xref rid="B322-vaccines-13-00126" ref-type="bibr">322</xref>]. This technology facilitates a rapid response to vaccines, with broader efficacy and reduced vaccination frequency. Notably, dendrimer-RNA nanoparticles have demonstrated significant protective effects against lethal pathogens such as H1N1 influenza, Ebola, and <italic toggle="yes">T. gondii</italic>, with a single dose protecting challenged mouse models [<xref rid="B94-vaccines-13-00126" ref-type="bibr">94</xref>].</p><p>Outer membrane vesicles (OMVs) are spherical double-layered nanostructures (20 to 250 nm) derived from the surface of gram-negative bacteria. OMVs do not cause diseases because they mimic the structures found on the bacterial cell surface and cannot be replicated. They have a promising role in the creation of nanoparticle vaccines and can be engineered to display multiple antigens against different bacterial and viral infections and malignant tumors. OMVs can strongly stimulate the innate and adaptive immune responses [<xref rid="B323-vaccines-13-00126" ref-type="bibr">323</xref>]. However, there remain some challenges that are being addressed, including possible degradation by proteases, protein misfolding, and inefficient translocation of complex antigens [<xref rid="B324-vaccines-13-00126" ref-type="bibr">324</xref>].</p><p>Metal&#x02013;organic frameworks (MOFs) are examples of NPs that can be used in nanovaccines to enhance the immune response to antigens. MOFs can encapsulate and deliver viral proteins, such as the SARS-CoV-2 spike protein. Once inside the cells, MOFs break down and activate the innate immune system through toll-like receptors that lead to increased production of cytokines and other inflammatory molecules [<xref rid="B325-vaccines-13-00126" ref-type="bibr">325</xref>,<xref rid="B326-vaccines-13-00126" ref-type="bibr">326</xref>].</p><p>Nanogels show great potential as novel antigen-delivery vehicles. They are sub-micron structures with a network of cross-linked polymer chains. These nanogels can encapsulate biomolecules and target specific immune cells [<xref rid="B327-vaccines-13-00126" ref-type="bibr">327</xref>,<xref rid="B328-vaccines-13-00126" ref-type="bibr">328</xref>]. They also can be designed to release antigens in a controlled manner to prolong the immune response. In addition, nanogels can be designed to display multiple antigens to protect against multiple infectious agents [<xref rid="B329-vaccines-13-00126" ref-type="bibr">329</xref>].</p><p>Combinational nanovaccines can combine multiple antigens in a single formulation to induce a broader and stronger immune response. Despite the potential benefits of combinational nanovaccines, several challenges should be considered, as the multiple antigens and adjuvants in the combined nanovaccines can interfere with each other, resulting in adverse effects, while their design can be complex and requiring increased testing and evaluation. The other challenge is regarding combinational nanovaccines&#x02019; safety. There are different examples of combinational nanovaccines in the preclinical and clinical phases, including an influenza vaccine that can protect against multiple strains of influenza viruses [<xref rid="B330-vaccines-13-00126" ref-type="bibr">330</xref>], a tuberculosis vaccine that targets different TB antigens [<xref rid="B331-vaccines-13-00126" ref-type="bibr">331</xref>], a cancer vaccine that combines multiple cancer antigens [<xref rid="B332-vaccines-13-00126" ref-type="bibr">332</xref>] and an HIV combined vaccine that targets multiple strains of HIV [<xref rid="B333-vaccines-13-00126" ref-type="bibr">333</xref>].</p><p>Most traditional vaccines are administered through injection, which could be painful for some individuals. Needle-free nano vaccine administration (oral delivery, inhalation delivery, and transdermal delivery) offers several advantages, including simple administration, proven safety, reduced pain, and robust immunogenicity. For oral nanovaccine delivery to be suitable for GIT diseases, such as cholera and rotavirus infections, NPs must be designed to withstand the acidic pH of the stomach and to release the antigen in the lumen of the gut to initiate the immune response. Transdermal nanovaccine delivery is another delivery approach through which nanoparticle-based vaccines can penetrate the skin and reach the underlying tissues&#x02019; immune cells. The inhalation delivery of nanovaccine also ensures that nanoparticle-based vaccines can reach the immune cells in the lung and induce the desirable immune response [<xref rid="B334-vaccines-13-00126" ref-type="bibr">334</xref>,<xref rid="B335-vaccines-13-00126" ref-type="bibr">335</xref>,<xref rid="B336-vaccines-13-00126" ref-type="bibr">336</xref>,<xref rid="B337-vaccines-13-00126" ref-type="bibr">337</xref>,<xref rid="B338-vaccines-13-00126" ref-type="bibr">338</xref>]. Overall, needle-free nanovaccine administration offer many advantages, including reducing the risk of blood-borne disease transmission; reducing pain, especially in individuals with needle phobia; eliminating the need for specific equipment and trained personnel due to the ease of administration; and enhancing immunogenicity due to direct delivery of the vaccine to the immune cells.</p><p>Interestingly, there have been several suggestions regarding the utilization of spores of <italic toggle="yes">Bacillus</italic> spp. as a mucosal vaccine delivery carrier. These spores have the benefits of dormancy and extreme resistance properties. Many antigens have been presented on these spores through recombinant and non-recombinant methods and have exhibited robust antigen-specific immune responses. Additionally, probiotic-based spores have shown promise in enhancing immune responses by presenting antigens on probiotic strains [<xref rid="B339-vaccines-13-00126" ref-type="bibr">339</xref>,<xref rid="B340-vaccines-13-00126" ref-type="bibr">340</xref>].</p></sec><sec id="sec9dot2-vaccines-13-00126"><title>9.2. Using NPs with Other Advanced Technologies</title><p>Other important advances in gene therapy in which NPs play a crucial role include the advancement of cutting-edge technologies like Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/associated protein 9 (Cas9) and mRNA-based therapies. CRISPR/Cas9 technology is renowned for its precise gene-editing capabilities and is considered one of the most promising technologies for genome manipulation. However, CRISPR/Cas9 has low intracellular delivery efficiency, which severely affects its potency and clinical application, meaning that the development of an effective delivery system for CRISPR/Cas9 system is crucial. LNPs and other nanocarriers like liposomes, cationic polymers, and gold NPs, have emerged as efficient carriers for CRISPR/Cas9 components, overcoming challenges such as inadequate cellular entry, off-target effects, and nuclease degradation [<xref rid="B341-vaccines-13-00126" ref-type="bibr">341</xref>,<xref rid="B342-vaccines-13-00126" ref-type="bibr">342</xref>]. A notable advancement in tumor targeting involves the use of a multiplexed dendrimer with an LNP [<xref rid="B95-vaccines-13-00126" ref-type="bibr">95</xref>]. This system involves the co-delivery of Cas9 mRNA, focal adhesion kinase siRNA, and sgRNA (siFAK + CRISPR-LNPs) to enable tumor delivery and enhance gene-editing efficacy. The study demonstrated that gene editing was enhanced and increased by more than 10-fold in tumor spheroids, due to increased cellular uptake and NP penetration mediated by FAK-knockdown in tumor tissues.</p></sec><sec id="sec9dot3-vaccines-13-00126"><title>9.3. Personalized Vaccines</title><p>Personalized nanovaccines represent an exciting frontier in vaccine development, tailored to the genetic variations, existing immunity, age, sex, and disease history of individuals. Unlike traditional vaccines, which have a one-size-fits-all approach (standard antigen formulation and dose), personalized nanovaccines are specifically designed for each host&#x02019;s unique immune system. Researchers have been able to develop personalized vaccines after analyzing biomarkers that can predict the host immune response to vaccines. The main advantage of personalized vaccines lies in their ability to target the individual&#x02019;s unique immune system, thereby maximizing efficacy and minimizing adverse reactions [<xref rid="B343-vaccines-13-00126" ref-type="bibr">343</xref>]. However, their widespread adoption faces challenges including the need for biomarkers development, high costs, and logistical barriers [<xref rid="B181-vaccines-13-00126" ref-type="bibr">181</xref>,<xref rid="B276-vaccines-13-00126" ref-type="bibr">276</xref>,<xref rid="B344-vaccines-13-00126" ref-type="bibr">344</xref>]. Recent examples of engineered personalized nanovaccines include personalized flu vaccines and cancer immunotherapy. In cancer immunotherapy, the tailored nanovaccines not only enhance antigen presentation but also effectively modulate immunosuppression within the tumor microenvironment. A notable example is the mRNA-based personalized cancer vaccine mRNA-4157, which targets twenty tumor-associated antigens specifically expressed by cancer cells, demonstrating the potential for both immunostimulatory and antitumor activities [<xref rid="B345-vaccines-13-00126" ref-type="bibr">345</xref>]. Fluoropolymer-based nanovaccines represent another class of personalized nanovaccines. When used in combination with immune checkpoint blockade therapy, these tailored nanovaccines have exhibited prevention of post-surgical metastasis and tumor recurrence in breast cancer models [<xref rid="B96-vaccines-13-00126" ref-type="bibr">96</xref>]. Additionally, neoantigen nanovaccines, which target unique tumor-specific antigens arising from mutations in cancer cells, have shown promise as personalized nanovaccines. For example, a study has demonstrated that delivering neoantigen peptides along with a sting agonist through a nanoparticle-based system significantly improved the immune response and survival rates in a melanoma mouse model [<xref rid="B346-vaccines-13-00126" ref-type="bibr">346</xref>]. Moreover, the influenza virus is characterized by its rapid mutation, requiring traditional influenza vaccines to be updated periodically according to the circulating strains. However, all individuals cannot equally respond and be protected using these influenza vaccines. These challenges could be controlled with the development of personalized influenza vaccines that optimize the immune response of each individual.</p></sec></sec><sec id="sec10-vaccines-13-00126"><title>10. Artificial Intelligence in Nanoparticle-Based Vaccines</title><p>Artificial intelligence (AI) has emerged as a transformative force in the development of NP-based vaccines, revolutionizing multiple aspects of the development pipeline from initial design to clinical implementation. The integration of AI technologies, particularly machine learning, and deep learning approaches, has significantly accelerated the vaccine development process while improving efficiency and predictive accuracy [<xref rid="B347-vaccines-13-00126" ref-type="bibr">347</xref>]. These advanced computational tools have enabled researchers to optimize antigen design, predict immune responses, and enhance the overall efficacy of NP-based vaccine platforms.</p><p>In the field of antigen design and NPs optimization, AI algorithms have demonstrated remarkable capabilities in predicting optimal epitope sequences and enhancing antigen stability. These systems can analyze vast datasets of protein structures and immunological responses to identify the most promising vaccine candidates, significantly reducing the time and resources required for traditional experimental approaches [<xref rid="B348-vaccines-13-00126" ref-type="bibr">348</xref>]. AI-driven platforms have revolutionized the characterization of nanoparticle properties, enabling precise control over particle size, shape, and surface chemistry, which are crucial parameters for vaccine efficacy [<xref rid="B349-vaccines-13-00126" ref-type="bibr">349</xref>].</p><p>The application of machine learning in formulation development has particularly enhanced our ability to optimize nanoparticle composition and predict stability profiles. These AI systems can analyze complex relationships between formulation parameters and vaccine performance, leading to more stable and effective vaccine candidates [<xref rid="B350-vaccines-13-00126" ref-type="bibr">350</xref>]. Additionally, AI models have proven invaluable in predicting immunological responses and potential adverse reactions, allowing researchers to optimize vaccine formulations before clinical trials begin [<xref rid="B351-vaccines-13-00126" ref-type="bibr">351</xref>].</p><p>Looking toward the future, the integration of multiple AI technologies presents exciting opportunities for nanovaccine development. The combination of big data analytics with sophisticated AI models is expected to enable more personalized vaccine approaches and improve prediction accuracy. However, challenges remain, including the need for larger, more diverse datasets and the validation of AI predictions in biological systems. As these technologies continue to evolve, they are expected to play an increasingly crucial role in developing next-generation nanovaccines that are more effective, safer, and more readily available to global populations.</p></sec><sec sec-type="conclusions" id="sec11-vaccines-13-00126"><title>11. Conclusions</title><p>Nanoparticle-based vaccines hold immense promise for revolutionizing immunization strategies. These vaccine platforms offer several advantages over traditional approaches, including enhanced immunogenicity, targeted delivery, and sustained antigen release. The ability to incorporate multiple antigens and adjuvants into a single nanoparticle formulation further simplifies vaccine administration and improves efficacy. However, significant challenges remain in translating these promising technologies into practical applications. Overcoming manufacturing hurdles, ensuring long-term stability, and conducting rigorous clinical trials are essential to bringing NP-based vaccines to market. Addressing potential toxicity and immune side effects is crucial for ensuring their safety and efficacy. Researchers can develop highly effective and personalized vaccines by combining nanotechnology with advancements in artificial intelligence and bioengineering. This interdisciplinary approach will facilitate the creation of vaccines capable of combating emerging infectious diseases, reducing the burden of chronic illnesses, and improving global health outcomes.</p></sec></body><back><fn-group><fn><p><bold>Disclaimer/Publisher&#x02019;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><notes><title>Author Contributions</title><p>Conceptualization, supervision, and funding, Y.A.H.; data curation, M.S. and Y.A.H.; original draft preparation, M.S., A.E.-M., A.H.E., W.I.A.S. and Y.A.H.; Review and editing, M.S., A.E.-M., A.H.E., W.I.A.S. and Y.A.H. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>Not applicable.</p></notes><notes><title>Informed Consent Statement</title><p>Not applicable.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>All data were included in the published paper.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></notes><ref-list><title>References</title><ref id="B1-vaccines-13-00126"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hedman</surname><given-names>H.D.</given-names></name>
<name><surname>Krawczyk</surname><given-names>E.</given-names></name>
<name><surname>Helmy</surname><given-names>Y.A.</given-names></name>
<name><surname>Zhang</surname><given-names>L.</given-names></name>
<name><surname>Varga</surname><given-names>C.</given-names></name>
</person-group><article-title>Host Diversity and Potential Transmission Pathways of SARS-CoV-2 at the Human-Animal Interface</article-title><source>Pathogens</source><year>2021</year><volume>10</volume><elocation-id>180</elocation-id><pub-id pub-id-type="doi">10.3390/pathogens10020180</pub-id><pub-id pub-id-type="pmid">33567598</pub-id>
</element-citation></ref><ref id="B2-vaccines-13-00126"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hemelaar</surname><given-names>J.</given-names></name>
<name><surname>Elangovan</surname><given-names>R.</given-names></name>
<name><surname>Yun</surname><given-names>J.</given-names></name>
<name><surname>Dickson-Tetteh</surname><given-names>L.</given-names></name>
<name><surname>Fleminger</surname><given-names>I.</given-names></name>
<name><surname>Kirtley</surname><given-names>S.</given-names></name>
<name><surname>Williams</surname><given-names>B.</given-names></name>
<name><surname>Gouws-Williams</surname><given-names>E.</given-names></name>
<name><surname>Ghys</surname><given-names>P.D.</given-names></name>
<name><surname>Alash&#x02019;le</surname><given-names>G.A.</given-names></name>
</person-group><article-title>Global and regional molecular epidemiology of HIV-1, 1990&#x02013;2015: A systematic review, global survey, and trend analysis</article-title><source>Lancet Infect. Dis.</source><year>2019</year><volume>19</volume><fpage>143</fpage><lpage>155</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(18)30647-9</pub-id><pub-id pub-id-type="pmid">30509777</pub-id>
</element-citation></ref><ref id="B3-vaccines-13-00126"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ksiazek</surname><given-names>T.G.</given-names></name>
<name><surname>Erdman</surname><given-names>D.</given-names></name>
<name><surname>Goldsmith</surname><given-names>C.S.</given-names></name>
<name><surname>Zaki</surname><given-names>S.R.</given-names></name>
<name><surname>Peret</surname><given-names>T.</given-names></name>
<name><surname>Emery</surname><given-names>S.</given-names></name>
<name><surname>Tong</surname><given-names>S.</given-names></name>
<name><surname>Urbani</surname><given-names>C.</given-names></name>
<name><surname>Comer</surname><given-names>J.A.</given-names></name>
<name><surname>Lim</surname><given-names>W.</given-names></name>
</person-group><article-title>A novel coronavirus associated with severe acute respiratory syndrome</article-title><source>N. Engl. J. Med.</source><year>2003</year><volume>348</volume><fpage>1953</fpage><lpage>1966</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa030781</pub-id><pub-id pub-id-type="pmid">12690092</pub-id>
</element-citation></ref><ref id="B4-vaccines-13-00126"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mehendale</surname><given-names>R.</given-names></name>
<name><surname>Joshi</surname><given-names>M.</given-names></name>
<name><surname>Patravale</surname><given-names>V.B.</given-names></name>
</person-group><article-title>Nanomedicines for treatment of viral diseases</article-title><source>Crit. Rev. &#x02122; Ther. Drug Carr. Syst.</source><year>2013</year><volume>30</volume><fpage>1</fpage><lpage>49</lpage><pub-id pub-id-type="doi">10.1615/CritRevTherDrugCarrierSyst.2013005469</pub-id><pub-id pub-id-type="pmid">23510109</pub-id>
</element-citation></ref><ref id="B5-vaccines-13-00126"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Salem</surname><given-names>M.</given-names></name>
<name><surname>El-Metwally</surname><given-names>M.</given-names></name>
<name><surname>Saber</surname><given-names>W.</given-names></name>
<name><surname>Negm</surname><given-names>S.</given-names></name>
<name><surname>El-Kott</surname><given-names>A.</given-names></name>
<name><surname>Mazroua</surname><given-names>Y.</given-names></name>
<name><surname>Makhlouf</surname><given-names>A.</given-names></name>
<name><surname>Moustafa</surname><given-names>M.</given-names></name>
</person-group><article-title>Secondary antiviral metabolites from fungi with special reference to coronaviruses</article-title><source>Biocell</source><year>2022</year><volume>46</volume><fpage>1979</fpage><lpage>1988</lpage><pub-id pub-id-type="doi">10.32604/biocell.2022.019301</pub-id></element-citation></ref><ref id="B6-vaccines-13-00126"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Helmy</surname><given-names>Y.A.</given-names></name>
<name><surname>Taha-Abdelaziz</surname><given-names>K.</given-names></name>
<name><surname>Hawwas</surname><given-names>H.A.E.-H.</given-names></name>
<name><surname>Ghosh</surname><given-names>S.</given-names></name>
<name><surname>AlKafaas</surname><given-names>S.S.</given-names></name>
<name><surname>Moawad</surname><given-names>M.M.M.</given-names></name>
<name><surname>Saied</surname><given-names>E.M.</given-names></name>
<name><surname>Kassem</surname><given-names>I.I.</given-names></name>
<name><surname>Mawad</surname><given-names>A.M.M.</given-names></name>
</person-group><article-title>Antimicrobial Resistance and Recent Alternatives to Antibiotics for the Control of Bacterial Pathogens with an Emphasis on Foodborne Pathogens</article-title><source>Antibiotics</source><year>2023</year><volume>12</volume><elocation-id>274</elocation-id><pub-id pub-id-type="doi">10.3390/antibiotics12020274</pub-id><pub-id pub-id-type="pmid">36830185</pub-id>
</element-citation></ref><ref id="B7-vaccines-13-00126"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kabir</surname><given-names>A.</given-names></name>
<name><surname>Lamichhane</surname><given-names>B.</given-names></name>
<name><surname>Habib</surname><given-names>T.</given-names></name>
<name><surname>Adams</surname><given-names>A.</given-names></name>
<name><surname>El-Sheikh Ali</surname><given-names>H.</given-names></name>
<name><surname>Slovis</surname><given-names>N.M.</given-names></name>
<name><surname>Troedsson</surname><given-names>M.H.T.</given-names></name>
<name><surname>Helmy</surname><given-names>Y.A.</given-names></name>
</person-group><article-title>Antimicrobial Resistance in Equines: A Growing Threat to Horse Health and Beyond&#x02014;A Comprehensive Review</article-title><source>Antibiotics</source><year>2024</year><volume>13</volume><elocation-id>713</elocation-id><pub-id pub-id-type="doi">10.3390/antibiotics13080713</pub-id><pub-id pub-id-type="pmid">39200013</pub-id>
</element-citation></ref><ref id="B8-vaccines-13-00126"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Roope</surname><given-names>L.S.</given-names></name>
<name><surname>Smith</surname><given-names>R.D.</given-names></name>
<name><surname>Pouwels</surname><given-names>K.B.</given-names></name>
<name><surname>Buchanan</surname><given-names>J.</given-names></name>
<name><surname>Abel</surname><given-names>L.</given-names></name>
<name><surname>Eibich</surname><given-names>P.</given-names></name>
<name><surname>Butler</surname><given-names>C.C.</given-names></name>
<name><surname>Tan</surname><given-names>P.S.</given-names></name>
<name><surname>Walker</surname><given-names>A.S.</given-names></name>
<name><surname>Robotham</surname><given-names>J.V.</given-names></name>
</person-group><article-title>The challenge of antimicrobial resistance: What economics can contribute</article-title><source>Science</source><year>2019</year><volume>364</volume><fpage>eaau4679</fpage><pub-id pub-id-type="doi">10.1126/science.aau4679</pub-id><pub-id pub-id-type="pmid">30948524</pub-id>
</element-citation></ref><ref id="B9-vaccines-13-00126"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lamichhane</surname><given-names>B.</given-names></name>
<name><surname>Mawad</surname><given-names>A.M.M.</given-names></name>
<name><surname>Saleh</surname><given-names>M.</given-names></name>
<name><surname>Kelley</surname><given-names>W.G.</given-names></name>
<name><surname>Harrington</surname><given-names>P.J.</given-names></name>
<name><surname>Lovestad</surname><given-names>C.W.</given-names></name>
<name><surname>Amezcua</surname><given-names>J.</given-names></name>
<name><surname>Sarhan</surname><given-names>M.M.</given-names></name>
<name><surname>El Zowalaty</surname><given-names>M.E.</given-names></name>
<name><surname>Ramadan</surname><given-names>H.</given-names></name>
<etal/>
</person-group><article-title>Salmonellosis: An Overview of Epidemiology, Pathogenesis, and Innovative Approaches to Mitigate the Antimicrobial Resistant Infections</article-title><source>Antibiotics</source><year>2024</year><volume>13</volume><elocation-id>76</elocation-id><pub-id pub-id-type="doi">10.3390/antibiotics13010076</pub-id><pub-id pub-id-type="pmid">38247636</pub-id>
</element-citation></ref><ref id="B10-vaccines-13-00126"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mullins</surname><given-names>L.P.</given-names></name>
<name><surname>Mason</surname><given-names>E.</given-names></name>
<name><surname>Winter</surname><given-names>K.</given-names></name>
<name><surname>Sadarangani</surname><given-names>M.</given-names></name>
</person-group><article-title>Vaccination is an integral strategy to combat antimicrobial resistance</article-title><source>PLoS Pathog.</source><year>2023</year><volume>19</volume><elocation-id>e1011379</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1011379</pub-id><pub-id pub-id-type="pmid">37319164</pub-id>
</element-citation></ref><ref id="B11-vaccines-13-00126"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fawzy</surname><given-names>M.</given-names></name>
<name><surname>Helmy</surname><given-names>Y.A.</given-names></name>
</person-group><article-title>The One Health Approach is Necessary for the Control of Rift Valley Fever Infections in Egypt: A Comprehensive Review</article-title><source>Viruses</source><year>2019</year><volume>11</volume><elocation-id>139</elocation-id><pub-id pub-id-type="doi">10.3390/v11020139</pub-id><pub-id pub-id-type="pmid">30736362</pub-id>
</element-citation></ref><ref id="B12-vaccines-13-00126"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Helmy</surname><given-names>Y.A.</given-names></name>
<name><surname>El-Adawy</surname><given-names>H.</given-names></name>
<name><surname>Abdelwhab</surname><given-names>E.M.</given-names></name>
</person-group><article-title>A Comprehensive Review of Common Bacterial, Parasitic and Viral Zoonoses at the Human-Animal Interface in Egypt</article-title><source>Pathogens</source><year>2017</year><volume>6</volume><elocation-id>33</elocation-id><pub-id pub-id-type="doi">10.3390/pathogens6030033</pub-id><pub-id pub-id-type="pmid">28754024</pub-id>
</element-citation></ref><ref id="B13-vaccines-13-00126"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Heng</surname><given-names>W.T.</given-names></name>
<name><surname>Yew</surname><given-names>J.S.</given-names></name>
<name><surname>Poh</surname><given-names>C.L.</given-names></name>
</person-group><article-title>Nanovaccines against viral infectious diseases</article-title><source>Pharmaceutics</source><year>2022</year><volume>14</volume><elocation-id>2554</elocation-id><pub-id pub-id-type="doi">10.3390/pharmaceutics14122554</pub-id><pub-id pub-id-type="pmid">36559049</pub-id>
</element-citation></ref><ref id="B14-vaccines-13-00126"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Helmy</surname><given-names>Y.A.</given-names></name>
<name><surname>Kassem</surname><given-names>I.I.</given-names></name>
<name><surname>Rajashekara</surname><given-names>G.</given-names></name>
</person-group><article-title>Immuno-modulatory effect of probiotic <italic toggle="yes">E. coli</italic> Nissle 1917 in polarized human colonic cells against <italic toggle="yes">Campylobacter jejuni</italic> infection</article-title><source>Gut Microbes</source><year>2021</year><volume>13</volume><fpage>1857514</fpage><pub-id pub-id-type="doi">10.1080/19490976.2020.1857514</pub-id><pub-id pub-id-type="pmid">33382951</pub-id>
</element-citation></ref><ref id="B15-vaccines-13-00126"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zepp</surname><given-names>F.</given-names></name>
</person-group><article-title>Principles of vaccine design&#x02014;Lessons from nature</article-title><source>Vaccine</source><year>2010</year><volume>28</volume><fpage>C14</fpage><lpage>C24</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2010.07.020</pub-id><pub-id pub-id-type="pmid">20713252</pub-id>
</element-citation></ref><ref id="B16-vaccines-13-00126"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kiboneka</surname><given-names>A.N.</given-names></name>
</person-group><article-title>Basic concepts in clinical immunology: A review</article-title><source>World J. Adv. Res. Rev.</source><year>2021</year><volume>12</volume><fpage>490</fpage><lpage>496</lpage><pub-id pub-id-type="doi">10.30574/wjarr.2021.12.3.0745</pub-id></element-citation></ref><ref id="B17-vaccines-13-00126"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sim</surname><given-names>S.</given-names></name>
<name><surname>Wong</surname><given-names>N.K.</given-names></name>
</person-group><article-title>Nanotechnology and its use in imaging and drug delivery</article-title><source>Biomed. Rep.</source><year>2021</year><volume>14</volume><elocation-id>42</elocation-id><pub-id pub-id-type="doi">10.3892/br.2021.1418</pub-id><pub-id pub-id-type="pmid">33728048</pub-id>
</element-citation></ref><ref id="B18-vaccines-13-00126"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Abdelaziz</surname><given-names>K.</given-names></name>
<name><surname>Helmy</surname><given-names>Y.A.</given-names></name>
<name><surname>Yitbarek</surname><given-names>A.</given-names></name>
<name><surname>Hodgins</surname><given-names>D.C.</given-names></name>
<name><surname>Sharafeldin</surname><given-names>T.A.</given-names></name>
<name><surname>Selim</surname><given-names>M.S.H.</given-names></name>
</person-group><article-title>Advances in Poultry Vaccines: Leveraging Biotechnology for Improving Vaccine Development, Stability, and Delivery</article-title><source>Vaccines</source><year>2024</year><volume>12</volume><elocation-id>134</elocation-id><pub-id pub-id-type="doi">10.3390/vaccines12020134</pub-id><pub-id pub-id-type="pmid">38400118</pub-id>
</element-citation></ref><ref id="B19-vaccines-13-00126"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Elaish</surname><given-names>M.</given-names></name>
<name><surname>Ngunjiri</surname><given-names>J.M.</given-names></name>
<name><surname>Ali</surname><given-names>A.</given-names></name>
<name><surname>Xia</surname><given-names>M.</given-names></name>
<name><surname>Ibrahim</surname><given-names>M.</given-names></name>
<name><surname>Jang</surname><given-names>H.</given-names></name>
<name><surname>Hiremath</surname><given-names>J.</given-names></name>
<name><surname>Dhakal</surname><given-names>S.</given-names></name>
<name><surname>Helmy</surname><given-names>Y.A.</given-names></name>
<name><surname>Jiang</surname><given-names>X.</given-names></name>
</person-group><article-title>Supplementation of inactivated influenza vaccine with norovirus P particle-M2e chimeric vaccine enhances protection against heterologous virus challenge in chickens</article-title><source>PLoS ONE</source><year>2017</year><volume>12</volume><elocation-id>e0171174</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0171174</pub-id><pub-id pub-id-type="pmid">28151964</pub-id>
</element-citation></ref><ref id="B20-vaccines-13-00126"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Murugan</surname><given-names>B.</given-names></name>
<name><surname>Sagadevan</surname><given-names>S.</given-names></name>
</person-group><article-title>Nano-Vaccines: Opportunities and Challenges in Biomaterial-Based Vaccine Delivery</article-title><source>Biomater. -Inspired Nanomed. Target. Ther.</source><year>2024</year><fpage>101</fpage><lpage>116</lpage><pub-id pub-id-type="doi">10.1007/978-981-97-3925-7_4</pub-id></element-citation></ref><ref id="B21-vaccines-13-00126"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Peek</surname><given-names>L.J.</given-names></name>
<name><surname>Middaugh</surname><given-names>C.R.</given-names></name>
<name><surname>Berkland</surname><given-names>C.</given-names></name>
</person-group><article-title>Nanotechnology in vaccine delivery</article-title><source>Adv. Drug Deliv. Rev.</source><year>2008</year><volume>60</volume><fpage>915</fpage><lpage>928</lpage><pub-id pub-id-type="doi">10.1016/j.addr.2007.05.017</pub-id><pub-id pub-id-type="pmid">18325628</pub-id>
</element-citation></ref><ref id="B22-vaccines-13-00126"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Azharuddin</surname><given-names>M.</given-names></name>
<name><surname>Zhu</surname><given-names>G.H.</given-names></name>
<name><surname>Sengupta</surname><given-names>A.</given-names></name>
<name><surname>Hinkula</surname><given-names>J.</given-names></name>
<name><surname>Slater</surname><given-names>N.K.</given-names></name>
<name><surname>Patra</surname><given-names>H.K.</given-names></name>
</person-group><article-title>Nano toolbox in immune modulation and nanovaccines</article-title><source>Trends Biotechnol.</source><year>2022</year><volume>40</volume><fpage>1195</fpage><lpage>1212</lpage><pub-id pub-id-type="doi">10.1016/j.tibtech.2022.03.011</pub-id><pub-id pub-id-type="pmid">35450779</pub-id>
</element-citation></ref><ref id="B23-vaccines-13-00126"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Machhi</surname><given-names>J.</given-names></name>
<name><surname>Shahjin</surname><given-names>F.</given-names></name>
<name><surname>Das</surname><given-names>S.</given-names></name>
<name><surname>Patel</surname><given-names>M.</given-names></name>
<name><surname>Abdelmoaty</surname><given-names>M.M.</given-names></name>
<name><surname>Cohen</surname><given-names>J.D.</given-names></name>
<name><surname>Singh</surname><given-names>P.A.</given-names></name>
<name><surname>Baldi</surname><given-names>A.</given-names></name>
<name><surname>Bajwa</surname><given-names>N.</given-names></name>
<name><surname>Kumar</surname><given-names>R.</given-names></name>
</person-group><article-title>Nanocarrier vaccines for SARS-CoV-2</article-title><source>Adv. Drug Deliv. Rev.</source><year>2021</year><volume>171</volume><fpage>215</fpage><lpage>239</lpage><pub-id pub-id-type="doi">10.1016/j.addr.2021.01.002</pub-id><pub-id pub-id-type="pmid">33428995</pub-id>
</element-citation></ref><ref id="B24-vaccines-13-00126"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lu</surname><given-names>W.</given-names></name>
<name><surname>Cui</surname><given-names>C.</given-names></name>
<name><surname>Wang</surname><given-names>Y.</given-names></name>
<name><surname>Sun</surname><given-names>X.</given-names></name>
<name><surname>Wang</surname><given-names>S.</given-names></name>
<name><surname>Yang</surname><given-names>M.</given-names></name>
<name><surname>Yu</surname><given-names>Y.</given-names></name>
<name><surname>Wang</surname><given-names>L.</given-names></name>
</person-group><article-title>CpG ODN as an adjuvant arouses the vigor of B cells by relieving the negative regulation of surface TLR9 to enhance the antibody response to vaccine</article-title><source>Appl. Microbiol. Biotechnol.</source><year>2021</year><volume>105</volume><fpage>4213</fpage><lpage>4224</lpage><pub-id pub-id-type="doi">10.1007/s00253-021-11316-9</pub-id><pub-id pub-id-type="pmid">33950279</pub-id>
</element-citation></ref><ref id="B25-vaccines-13-00126"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lozano</surname><given-names>D.</given-names></name>
<name><surname>Larraga</surname><given-names>V.</given-names></name>
<name><surname>Vallet-Reg&#x000ed;</surname><given-names>M.</given-names></name>
<name><surname>Manzano</surname><given-names>M.</given-names></name>
</person-group><article-title>An overview of the use of nanoparticles in vaccine development</article-title><source>Nanomaterials</source><year>2023</year><volume>13</volume><elocation-id>1828</elocation-id><pub-id pub-id-type="doi">10.3390/nano13121828</pub-id><pub-id pub-id-type="pmid">37368258</pub-id>
</element-citation></ref><ref id="B26-vaccines-13-00126"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fredriksen</surname><given-names>B.N.</given-names></name>
<name><surname>Grip</surname><given-names>J.</given-names></name>
</person-group><article-title>PLGA/PLA micro-and nanoparticle formulations serve as antigen depots and induce elevated humoral responses after immunization of Atlantic salmon (<italic toggle="yes">Salmo salar</italic> L.)</article-title><source>Vaccine</source><year>2012</year><volume>30</volume><fpage>656</fpage><lpage>667</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2011.10.105</pub-id><pub-id pub-id-type="pmid">22100638</pub-id>
</element-citation></ref><ref id="B27-vaccines-13-00126"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Saleh</surname><given-names>A.</given-names></name>
<name><surname>Qamar</surname><given-names>S.</given-names></name>
<name><surname>Tekin</surname><given-names>A.</given-names></name>
<name><surname>Singh</surname><given-names>R.</given-names></name>
<name><surname>Kashyap</surname><given-names>R.</given-names></name>
</person-group><article-title>Vaccine development throughout history</article-title><source>Cureus</source><year>2021</year><volume>13</volume><fpage>e16635</fpage><pub-id pub-id-type="doi">10.7759/cureus.16635</pub-id><pub-id pub-id-type="pmid">34462676</pub-id>
</element-citation></ref><ref id="B28-vaccines-13-00126"><label>28.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Taylor</surname><given-names>M.W.</given-names></name>
<name><surname>Taylor</surname><given-names>M.W.</given-names></name>
</person-group><source>Smallpox</source><publisher-name>Springer</publisher-name><publisher-loc>Berlin/Heidelberg, Germany</publisher-loc><year>2014</year></element-citation></ref><ref id="B29-vaccines-13-00126"><label>29.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Davidson</surname><given-names>T.</given-names></name>
</person-group><source>Vaccines: History, Science, and Issues</source><publisher-name>Bloomsbury Publishing USA</publisher-name><publisher-loc>New York, NY, USA</publisher-loc><year>2017</year></element-citation></ref><ref id="B30-vaccines-13-00126"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mamelund</surname><given-names>S.-E.</given-names></name>
</person-group><article-title>Influenza, historical</article-title><source>Medicine</source><year>2008</year><volume>54</volume><fpage>361</fpage><lpage>371</lpage></element-citation></ref><ref id="B31-vaccines-13-00126"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lombard</surname><given-names>M.</given-names></name>
<name><surname>Pastoret</surname><given-names>P.-P.</given-names></name>
<name><surname>Moulin</surname><given-names>A.</given-names></name>
</person-group><article-title>A brief history of vaccines and vaccination</article-title><source>Rev. Sci. Tech. Off. Int. Epizoot.</source><year>2007</year><volume>26</volume><fpage>29</fpage><lpage>48</lpage><pub-id pub-id-type="doi">10.20506/rst.26.1.1724</pub-id></element-citation></ref><ref id="B32-vaccines-13-00126"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Meeusen</surname><given-names>E.N.</given-names></name>
<name><surname>Walker</surname><given-names>J.</given-names></name>
<name><surname>Peters</surname><given-names>A.</given-names></name>
<name><surname>Pastoret</surname><given-names>P.-P.</given-names></name>
<name><surname>Jungersen</surname><given-names>G.</given-names></name>
</person-group><article-title>Current status of veterinary vaccines</article-title><source>Clin. Microbiol. Rev.</source><year>2007</year><volume>20</volume><fpage>489</fpage><lpage>510</lpage><pub-id pub-id-type="doi">10.1128/CMR.00005-07</pub-id><pub-id pub-id-type="pmid">17630337</pub-id>
</element-citation></ref><ref id="B33-vaccines-13-00126"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Karin</surname><given-names>H.</given-names></name>
<name><surname>Lisa</surname><given-names>B.</given-names></name>
<name><surname>Damer</surname><given-names>P.</given-names></name>
</person-group><article-title>Vaccines as alternatives to antibiotics for food producing animals. Part 1: Challenges and needs</article-title><source>Vet. Res.</source><year>2018</year><volume>49</volume><fpage>64</fpage><pub-id pub-id-type="pmid">30060757</pub-id>
</element-citation></ref><ref id="B34-vaccines-13-00126"><label>34.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Palomino-Tapia</surname><given-names>V.</given-names></name>
</person-group><article-title>Autogenous Vaccines in the Poultry Industry: A Field Perspective</article-title><source>Poultry Farming-New Perspectives and Applications</source><publisher-name>IntechOpen</publisher-name><publisher-loc>Rijeka, Croatia</publisher-loc><year>2023</year></element-citation></ref><ref id="B35-vaccines-13-00126"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nagpal</surname><given-names>G.</given-names></name>
<name><surname>Usmani</surname><given-names>S.S.</given-names></name>
<name><surname>Raghava</surname><given-names>G.P.</given-names></name>
</person-group><article-title>A web resource for designing subunit vaccine against major pathogenic species of bacteria</article-title><source>Front. Immunol.</source><year>2018</year><volume>9</volume><elocation-id>2280</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2018.02280</pub-id><pub-id pub-id-type="pmid">30356876</pub-id>
</element-citation></ref><ref id="B36-vaccines-13-00126"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Malik</surname><given-names>H.</given-names></name>
<name><surname>Khan</surname><given-names>F.H.</given-names></name>
<name><surname>Ahsan</surname><given-names>H.</given-names></name>
</person-group><article-title>Human papillomavirus: Current status and issues of vaccination</article-title><source>Arch. Virol.</source><year>2014</year><volume>159</volume><fpage>199</fpage><lpage>205</lpage><pub-id pub-id-type="doi">10.1007/s00705-013-1827-z</pub-id><pub-id pub-id-type="pmid">24022639</pub-id>
</element-citation></ref><ref id="B37-vaccines-13-00126"><label>37.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Dai</surname><given-names>X.</given-names></name>
<name><surname>Xiong</surname><given-names>Y.</given-names></name>
<name><surname>Li</surname><given-names>N.</given-names></name>
<name><surname>Jian</surname><given-names>C.</given-names></name>
</person-group><article-title>Vaccine types</article-title><source>Vaccines&#x02014;The History and Future</source><publisher-name>IntechOpen</publisher-name><publisher-loc>Rijeka, Croatia</publisher-loc><year>2019</year></element-citation></ref><ref id="B38-vaccines-13-00126"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Liljeqvist</surname><given-names>S.</given-names></name>
<name><surname>St&#x000e5;hl</surname><given-names>S.</given-names></name>
</person-group><article-title>Production of recombinant subunit vaccines: Protein immunogens, live delivery systems and nucleic acid vaccines</article-title><source>J. Biotechnol.</source><year>1999</year><volume>73</volume><fpage>1</fpage><lpage>33</lpage><pub-id pub-id-type="doi">10.1016/S0168-1656(99)00107-8</pub-id><pub-id pub-id-type="pmid">10483112</pub-id>
</element-citation></ref><ref id="B39-vaccines-13-00126"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jones</surname><given-names>R.G.</given-names></name>
<name><surname>Liu</surname><given-names>Y.</given-names></name>
<name><surname>Rigsby</surname><given-names>P.</given-names></name>
<name><surname>Sesardic</surname><given-names>D.</given-names></name>
</person-group><article-title>An improved method for development of toxoid vaccines and antitoxins</article-title><source>J. Immunol. Methods</source><year>2008</year><volume>337</volume><fpage>42</fpage><lpage>48</lpage><pub-id pub-id-type="doi">10.1016/j.jim.2008.05.009</pub-id><pub-id pub-id-type="pmid">18571196</pub-id>
</element-citation></ref><ref id="B40-vaccines-13-00126"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Andey</surname><given-names>T.</given-names></name>
<name><surname>Soni</surname><given-names>S.</given-names></name>
<name><surname>Modi</surname><given-names>S.</given-names></name>
</person-group><article-title>Conventional vaccination methods: Inactivated and live attenuated vaccines</article-title><source>Adv. Vaccin. Technol. Infect. Chronic Dis.</source><year>2024</year><fpage>37</fpage><lpage>50</lpage><pub-id pub-id-type="doi">10.1016/B978-0-443-18564-9.00030-8</pub-id></element-citation></ref><ref id="B41-vaccines-13-00126"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lee</surname><given-names>S.</given-names></name>
<name><surname>Nguyen</surname><given-names>M.T.</given-names></name>
</person-group><article-title>Recent advances of vaccine adjuvants for infectious diseases</article-title><source>Immune Netw.</source><year>2015</year><volume>15</volume><fpage>51</fpage><lpage>57</lpage><pub-id pub-id-type="doi">10.4110/in.2015.15.2.51</pub-id><pub-id pub-id-type="pmid">25922593</pub-id>
</element-citation></ref><ref id="B42-vaccines-13-00126"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Minor</surname><given-names>P.D.</given-names></name>
</person-group><article-title>Live attenuated vaccines: Historical successes and current challenges</article-title><source>Virology</source><year>2015</year><volume>479</volume><fpage>379</fpage><lpage>392</lpage><pub-id pub-id-type="doi">10.1016/j.virol.2015.03.032</pub-id><pub-id pub-id-type="pmid">25864107</pub-id>
</element-citation></ref><ref id="B43-vaccines-13-00126"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lopez</surname><given-names>S.M.</given-names></name>
<name><surname>Sato</surname><given-names>A.I.</given-names></name>
<name><surname>Chatterjee</surname><given-names>A.</given-names></name>
</person-group><article-title>Vaccines: An overview</article-title><source>Viral Parasit. Bact. Fungal Infect.</source><year>2023</year><volume>56</volume><fpage>699</fpage><lpage>717</lpage></element-citation></ref><ref id="B44-vaccines-13-00126"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Taha-Abdelaziz</surname><given-names>K.</given-names></name>
<name><surname>Singh</surname><given-names>M.</given-names></name>
<name><surname>Sharif</surname><given-names>S.</given-names></name>
<name><surname>Sharma</surname><given-names>S.</given-names></name>
<name><surname>Kulkarni</surname><given-names>R.R.</given-names></name>
<name><surname>Alizadeh</surname><given-names>M.</given-names></name>
<name><surname>Yitbarek</surname><given-names>A.</given-names></name>
<name><surname>Helmy</surname><given-names>Y.A.</given-names></name>
</person-group><article-title>Intervention Strategies to Control <italic toggle="yes">Campylobacter</italic> at Different Stages of the Food Chain</article-title><source>Microorganisms</source><year>2023</year><volume>11</volume><elocation-id>113</elocation-id><pub-id pub-id-type="doi">10.3390/microorganisms11010113</pub-id><pub-id pub-id-type="pmid">36677405</pub-id>
</element-citation></ref><ref id="B45-vaccines-13-00126"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Teulon</surname><given-names>J.-M.</given-names></name>
<name><surname>Godon</surname><given-names>C.</given-names></name>
<name><surname>Chantalat</surname><given-names>L.</given-names></name>
<name><surname>Moriscot</surname><given-names>C.</given-names></name>
<name><surname>Cambedouzou</surname><given-names>J.</given-names></name>
<name><surname>Odorico</surname><given-names>M.</given-names></name>
<name><surname>Ravaux</surname><given-names>J.</given-names></name>
<name><surname>Podor</surname><given-names>R.</given-names></name>
<name><surname>Gerdil</surname><given-names>A.</given-names></name>
<name><surname>Habert</surname><given-names>A.</given-names></name>
</person-group><article-title>On the operational aspects of measuring nanoparticle sizes</article-title><source>Nanomaterials</source><year>2018</year><volume>9</volume><elocation-id>18</elocation-id><pub-id pub-id-type="doi">10.3390/nano9010018</pub-id><pub-id pub-id-type="pmid">30583592</pub-id>
</element-citation></ref><ref id="B46-vaccines-13-00126"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cai</surname><given-names>T.</given-names></name>
<name><surname>Liu</surname><given-names>H.</given-names></name>
<name><surname>Zhang</surname><given-names>S.</given-names></name>
<name><surname>Hu</surname><given-names>J.</given-names></name>
<name><surname>Zhang</surname><given-names>L.</given-names></name>
</person-group><article-title>Delivery of nanovaccine towards lymphoid organs: Recent strategies in enhancing cancer immunotherapy</article-title><source>J. Nanobiotechnol.</source><year>2021</year><volume>19</volume><fpage>1</fpage><lpage>23</lpage><pub-id pub-id-type="doi">10.1186/s12951-021-01146-2</pub-id><pub-id pub-id-type="pmid">34823541</pub-id>
</element-citation></ref><ref id="B47-vaccines-13-00126"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Elattar</surname><given-names>K.M.</given-names></name>
<name><surname>Al-Otibi</surname><given-names>F.O.</given-names></name>
<name><surname>El-Hersh</surname><given-names>M.S.</given-names></name>
<name><surname>Attia</surname><given-names>A.A.</given-names></name>
<name><surname>Eldadamony</surname><given-names>N.M.</given-names></name>
<name><surname>Elsayed</surname><given-names>A.</given-names></name>
<name><surname>Menaa</surname><given-names>F.</given-names></name>
<name><surname>Saber</surname><given-names>W.I.</given-names></name>
</person-group><article-title>Multifaceted chemical and bioactive features of Ag@ TiO<sub>2</sub> and Ag@ SeO<sub>2</sub> core/shell nanoparticles biosynthesized using <italic toggle="yes">Beta vulgaris</italic> L. extract</article-title><source>Heliyon</source><year>2024</year><volume>10</volume><fpage>e28359</fpage><pub-id pub-id-type="doi">10.1016/j.heliyon.2024.e28359</pub-id><pub-id pub-id-type="pmid">38560145</pub-id>
</element-citation></ref><ref id="B48-vaccines-13-00126"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chattopadhyay</surname><given-names>S.</given-names></name>
<name><surname>Chen</surname><given-names>J.-Y.</given-names></name>
<name><surname>Chen</surname><given-names>H.-W.</given-names></name>
<name><surname>Hu</surname><given-names>C.-M.J.</given-names></name>
</person-group><article-title>Nanoparticle vaccines adopting virus-like features for enhanced immune potentiation</article-title><source>Nanotheranostics</source><year>2017</year><volume>1</volume><fpage>244</fpage><pub-id pub-id-type="doi">10.7150/ntno.19796</pub-id><pub-id pub-id-type="pmid">29071191</pub-id>
</element-citation></ref><ref id="B49-vaccines-13-00126"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhang</surname><given-names>W.</given-names></name>
<name><surname>Wang</surname><given-names>L.</given-names></name>
<name><surname>Liu</surname><given-names>Y.</given-names></name>
<name><surname>Chen</surname><given-names>X.</given-names></name>
<name><surname>Liu</surname><given-names>Q.</given-names></name>
<name><surname>Jia</surname><given-names>J.</given-names></name>
<name><surname>Yang</surname><given-names>T.</given-names></name>
<name><surname>Qiu</surname><given-names>S.</given-names></name>
<name><surname>Ma</surname><given-names>G.</given-names></name>
</person-group><article-title>Immune responses to vaccines involving a combined antigen&#x02013;nanoparticle mixture and nanoparticle-encapsulated antigen formulation</article-title><source>Biomaterials</source><year>2014</year><volume>35</volume><fpage>6086</fpage><lpage>6097</lpage><pub-id pub-id-type="doi">10.1016/j.biomaterials.2014.04.022</pub-id><pub-id pub-id-type="pmid">24780166</pub-id>
</element-citation></ref><ref id="B50-vaccines-13-00126"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bhardwaj</surname><given-names>P.</given-names></name>
<name><surname>Bhatia</surname><given-names>E.</given-names></name>
<name><surname>Sharma</surname><given-names>S.</given-names></name>
<name><surname>Ahamad</surname><given-names>N.</given-names></name>
<name><surname>Banerjee</surname><given-names>R.</given-names></name>
</person-group><article-title>Advancements in prophylactic and therapeutic nanovaccines</article-title><source>Acta Biomater.</source><year>2020</year><volume>108</volume><fpage>1</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1016/j.actbio.2020.03.020</pub-id><pub-id pub-id-type="pmid">32268235</pub-id>
</element-citation></ref><ref id="B51-vaccines-13-00126"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yin</surname><given-names>Q.</given-names></name>
<name><surname>Wang</surname><given-names>Y.</given-names></name>
<name><surname>Xiang</surname><given-names>Y.</given-names></name>
<name><surname>Xu</surname><given-names>F.</given-names></name>
</person-group><article-title>Nanovaccines: Merits, and diverse roles in boosting antitumor immune responses</article-title><source>Hum. Vaccines Immunother.</source><year>2022</year><volume>18</volume><fpage>2119020</fpage><pub-id pub-id-type="doi">10.1080/21645515.2022.2119020</pub-id></element-citation></ref><ref id="B52-vaccines-13-00126"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Li</surname><given-names>M.</given-names></name>
<name><surname>Kaminskas</surname><given-names>L.M.</given-names></name>
<name><surname>Marasini</surname><given-names>N.</given-names></name>
</person-group><article-title>Recent advances in nano/microparticle-based oral vaccines</article-title><source>J. Pharm. Investig.</source><year>2021</year><volume>51</volume><fpage>425</fpage><lpage>438</lpage><pub-id pub-id-type="doi">10.1007/s40005-021-00537-9</pub-id><pub-id pub-id-type="pmid">34150345</pub-id>
</element-citation></ref><ref id="B53-vaccines-13-00126"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sabourian</surname><given-names>P.</given-names></name>
<name><surname>Yazdani</surname><given-names>G.</given-names></name>
<name><surname>Ashraf</surname><given-names>S.S.</given-names></name>
<name><surname>Frounchi</surname><given-names>M.</given-names></name>
<name><surname>Mashayekhan</surname><given-names>S.</given-names></name>
<name><surname>Kiani</surname><given-names>S.</given-names></name>
<name><surname>Kakkar</surname><given-names>A.</given-names></name>
</person-group><article-title>Effect of physico-chemical properties of nanoparticles on their intracellular uptake</article-title><source>Int. J. Mol. Sci.</source><year>2020</year><volume>21</volume><elocation-id>8019</elocation-id><pub-id pub-id-type="doi">10.3390/ijms21218019</pub-id><pub-id pub-id-type="pmid">33126533</pub-id>
</element-citation></ref><ref id="B54-vaccines-13-00126"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gonz&#x000e1;lez-Garc&#x000ed;a</surname><given-names>L.E.</given-names></name>
<name><surname>MacGregor</surname><given-names>M.N.</given-names></name>
<name><surname>Visalakshan</surname><given-names>R.M.</given-names></name>
<name><surname>Lazarian</surname><given-names>A.</given-names></name>
<name><surname>Cavallaro</surname><given-names>A.A.</given-names></name>
<name><surname>Morsbach</surname><given-names>S.</given-names></name>
<name><surname>Mierczynska-Vasilev</surname><given-names>A.</given-names></name>
<name><surname>Mail&#x000e4;nder</surname><given-names>V.</given-names></name>
<name><surname>Landfester</surname><given-names>K.</given-names></name>
<name><surname>Vasilev</surname><given-names>K.</given-names></name>
</person-group><article-title>Nanoparticles surface chemistry influence on protein corona composition and inflammatory responses</article-title><source>Nanomaterials</source><year>2022</year><volume>12</volume><elocation-id>682</elocation-id><pub-id pub-id-type="doi">10.3390/nano12040682</pub-id><pub-id pub-id-type="pmid">35215013</pub-id>
</element-citation></ref><ref id="B55-vaccines-13-00126"><label>55.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Diaz-Ar&#x000e9;valo</surname><given-names>D.</given-names></name>
<name><surname>Zeng</surname><given-names>M.</given-names></name>
</person-group><article-title>Nanoparticle-based vaccines: Opportunities and limitations</article-title><source>Nanopharmaceuticals</source><publisher-name>Elsevier</publisher-name><publisher-loc>Amsterdam, The Netherlands</publisher-loc><year>2020</year><fpage>135</fpage><lpage>150</lpage></element-citation></ref><ref id="B56-vaccines-13-00126"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kirtane</surname><given-names>A.R.</given-names></name>
<name><surname>Verma</surname><given-names>M.</given-names></name>
<name><surname>Karandikar</surname><given-names>P.</given-names></name>
<name><surname>Furin</surname><given-names>J.</given-names></name>
<name><surname>Langer</surname><given-names>R.</given-names></name>
<name><surname>Traverso</surname><given-names>G.</given-names></name>
</person-group><article-title>Nanotechnology approaches for global infectious diseases</article-title><source>Nat. Nanotechnol.</source><year>2021</year><volume>16</volume><fpage>369</fpage><lpage>384</lpage><pub-id pub-id-type="doi">10.1038/s41565-021-00866-8</pub-id><pub-id pub-id-type="pmid">33753915</pub-id>
</element-citation></ref><ref id="B57-vaccines-13-00126"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gregory</surname><given-names>A.E.</given-names></name>
<name><surname>Titball</surname><given-names>R.</given-names></name>
<name><surname>Williamson</surname><given-names>D.</given-names></name>
</person-group><article-title>Vaccine delivery using nanoparticles</article-title><source>Front. Cell. Infect. Microbiol.</source><year>2013</year><volume>3</volume><elocation-id>13</elocation-id><pub-id pub-id-type="doi">10.3389/fcimb.2013.00013</pub-id><pub-id pub-id-type="pmid">23532930</pub-id>
</element-citation></ref><ref id="B58-vaccines-13-00126"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Manju</surname><given-names>K.</given-names></name>
<name><surname>Raj</surname><given-names>S.N.</given-names></name>
<name><surname>Ranjini</surname><given-names>H.</given-names></name>
<name><surname>Nayaka</surname><given-names>S.C.</given-names></name>
<name><surname>Ashwini</surname><given-names>P.</given-names></name>
<name><surname>Satish</surname><given-names>S.</given-names></name>
<name><surname>Prasad</surname><given-names>M.N.</given-names></name>
<name><surname>Chouhan</surname><given-names>R.S.</given-names></name>
<name><surname>Baker</surname><given-names>S.</given-names></name>
</person-group><article-title>Nanovaccines to combat drug resistance: The next-generation immunisation</article-title><source>Future J. Pharm. Sci.</source><year>2023</year><volume>9</volume><fpage>64</fpage><pub-id pub-id-type="doi">10.1186/s43094-023-00515-y</pub-id></element-citation></ref><ref id="B59-vaccines-13-00126"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kheirollahpour</surname><given-names>M.</given-names></name>
<name><surname>Mehrabi</surname><given-names>M.</given-names></name>
<name><surname>Dounighi</surname><given-names>N.M.</given-names></name>
<name><surname>Mohammadi</surname><given-names>M.</given-names></name>
<name><surname>Masoudi</surname><given-names>A.</given-names></name>
</person-group><article-title>Nanoparticles and vaccine development</article-title><source>Pharm. Nanotechnol.</source><year>2020</year><volume>8</volume><fpage>6</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.2174/2211738507666191024162042</pub-id><pub-id pub-id-type="pmid">31647394</pub-id>
</element-citation></ref><ref id="B60-vaccines-13-00126"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Liu</surname><given-names>J.</given-names></name>
<name><surname>Zhang</surname><given-names>R.</given-names></name>
<name><surname>Xu</surname><given-names>Z.P.</given-names></name>
</person-group><article-title>Nanoparticle-based nanomedicines to promote cancer immunotherapy: Recent advances and future directions</article-title><source>Small</source><year>2019</year><volume>15</volume><fpage>1900262</fpage><pub-id pub-id-type="doi">10.1002/smll.201900262</pub-id></element-citation></ref><ref id="B61-vaccines-13-00126"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kumru</surname><given-names>O.S.</given-names></name>
<name><surname>Joshi</surname><given-names>S.B.</given-names></name>
<name><surname>Smith</surname><given-names>D.E.</given-names></name>
<name><surname>Middaugh</surname><given-names>C.R.</given-names></name>
<name><surname>Prusik</surname><given-names>T.</given-names></name>
<name><surname>Volkin</surname><given-names>D.B.</given-names></name>
</person-group><article-title>Vaccine instability in the cold chain: Mechanisms, analysis and formulation strategies</article-title><source>Biologicals</source><year>2014</year><volume>42</volume><fpage>237</fpage><lpage>259</lpage><pub-id pub-id-type="doi">10.1016/j.biologicals.2014.05.007</pub-id><pub-id pub-id-type="pmid">24996452</pub-id>
</element-citation></ref><ref id="B62-vaccines-13-00126"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Torres-Sangiao</surname><given-names>E.</given-names></name>
<name><surname>Holban</surname><given-names>A.M.</given-names></name>
<name><surname>Gestal</surname><given-names>M.C.</given-names></name>
</person-group><article-title>Advanced nanobiomaterials: Vaccines, diagnosis and treatment of infectious diseases</article-title><source>Molecules</source><year>2016</year><volume>21</volume><elocation-id>867</elocation-id><pub-id pub-id-type="doi">10.3390/molecules21070867</pub-id><pub-id pub-id-type="pmid">27376260</pub-id>
</element-citation></ref><ref id="B63-vaccines-13-00126"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Abusalah</surname><given-names>M.A.H.</given-names></name>
<name><surname>Chopra</surname><given-names>H.</given-names></name>
<name><surname>Sharma</surname><given-names>A.</given-names></name>
<name><surname>Mustafa</surname><given-names>S.A.</given-names></name>
<name><surname>Choudhary</surname><given-names>O.P.</given-names></name>
<name><surname>Sharma</surname><given-names>M.</given-names></name>
<name><surname>Dhawan</surname><given-names>M.</given-names></name>
<name><surname>Khosla</surname><given-names>R.</given-names></name>
<name><surname>Loshali</surname><given-names>A.</given-names></name>
<name><surname>Sundriyal</surname><given-names>A.</given-names></name>
</person-group><article-title>Nanovaccines: A game changing approach in the fight against infectious diseases</article-title><source>Biomed. Pharmacother.</source><year>2023</year><volume>167</volume><elocation-id>115597</elocation-id><pub-id pub-id-type="pmid">37783148</pub-id>
</element-citation></ref><ref id="B64-vaccines-13-00126"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jazayeri</surname><given-names>S.D.</given-names></name>
<name><surname>Lim</surname><given-names>H.X.</given-names></name>
<name><surname>Shameli</surname><given-names>K.</given-names></name>
<name><surname>Yeap</surname><given-names>S.K.</given-names></name>
<name><surname>Poh</surname><given-names>C.L.</given-names></name>
</person-group><article-title>Nano and microparticles as potential oral vaccine carriers and adjuvants against infectious diseases</article-title><source>Front. Pharmacol.</source><year>2021</year><volume>12</volume><elocation-id>682286</elocation-id><pub-id pub-id-type="doi">10.3389/fphar.2021.682286</pub-id><pub-id pub-id-type="pmid">34149426</pub-id>
</element-citation></ref><ref id="B65-vaccines-13-00126"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rosenbaum</surname><given-names>P.</given-names></name>
<name><surname>Tchitchek</surname><given-names>N.</given-names></name>
<name><surname>Joly</surname><given-names>C.</given-names></name>
<name><surname>Rodriguez Pozo</surname><given-names>A.</given-names></name>
<name><surname>Stimmer</surname><given-names>L.</given-names></name>
<name><surname>Langlois</surname><given-names>S.</given-names></name>
<name><surname>Hocini</surname><given-names>H.</given-names></name>
<name><surname>Gosse</surname><given-names>L.</given-names></name>
<name><surname>Pejoski</surname><given-names>D.</given-names></name>
<name><surname>Cosma</surname><given-names>A.</given-names></name>
</person-group><article-title>Vaccine inoculation route modulates early immunity and consequently antigen-specific immune response</article-title><source>Front. Immunol.</source><year>2021</year><volume>12</volume><elocation-id>645210</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2021.645210</pub-id><pub-id pub-id-type="pmid">33959127</pub-id>
</element-citation></ref><ref id="B66-vaccines-13-00126"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Xie</surname><given-names>S.</given-names></name>
<name><surname>Pan</surname><given-names>B.</given-names></name>
<name><surname>Wang</surname><given-names>M.</given-names></name>
<name><surname>Zhu</surname><given-names>L.</given-names></name>
<name><surname>Wang</surname><given-names>F.</given-names></name>
<name><surname>Dong</surname><given-names>Z.</given-names></name>
<name><surname>Wang</surname><given-names>X.</given-names></name>
<name><surname>Zhou</surname><given-names>W.</given-names></name>
</person-group><article-title>Formulation, characterization and pharmacokinetics of praziquantel-loaded hydrogenated castor oil solid lipid nanoparticles</article-title><source>Nanomedicine</source><year>2010</year><volume>5</volume><fpage>693</fpage><lpage>701</lpage><pub-id pub-id-type="doi">10.2217/nnm.10.42</pub-id><pub-id pub-id-type="pmid">20662641</pub-id>
</element-citation></ref><ref id="B67-vaccines-13-00126"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Heidari-Kharaji</surname><given-names>M.</given-names></name>
<name><surname>Taheri</surname><given-names>T.</given-names></name>
<name><surname>Doroud</surname><given-names>D.</given-names></name>
<name><surname>Habibzadeh</surname><given-names>S.</given-names></name>
<name><surname>Badirzadeh</surname><given-names>A.</given-names></name>
<name><surname>Rafati</surname><given-names>S.</given-names></name>
</person-group><article-title>Enhanced paromomycin efficacy by solid lipid nanoparticle formulation against Leishmania in mice model</article-title><source>Parasite Immunol.</source><year>2016</year><volume>38</volume><fpage>599</fpage><lpage>608</lpage><pub-id pub-id-type="doi">10.1111/pim.12340</pub-id><pub-id pub-id-type="pmid">27213964</pub-id>
</element-citation></ref><ref id="B68-vaccines-13-00126"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Thi</surname><given-names>T.T.H.</given-names></name>
<name><surname>Suys</surname><given-names>E.J.</given-names></name>
<name><surname>Lee</surname><given-names>J.S.</given-names></name>
<name><surname>Nguyen</surname><given-names>D.H.</given-names></name>
<name><surname>Park</surname><given-names>K.D.</given-names></name>
<name><surname>Truong</surname><given-names>N.P.</given-names></name>
</person-group><article-title>Lipid-based nanoparticles in the clinic and clinical trials: From cancer nanomedicine to COVID-19 vaccines</article-title><source>Vaccines</source><year>2021</year><volume>9</volume><elocation-id>359</elocation-id><pub-id pub-id-type="doi">10.3390/vaccines9040359</pub-id><pub-id pub-id-type="pmid">33918072</pub-id>
</element-citation></ref><ref id="B69-vaccines-13-00126"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kondel</surname><given-names>R.</given-names></name>
<name><surname>Shafiq</surname><given-names>N.</given-names></name>
<name><surname>Kaur</surname><given-names>I.P.</given-names></name>
<name><surname>Singh</surname><given-names>M.P.</given-names></name>
<name><surname>Pandey</surname><given-names>A.K.</given-names></name>
<name><surname>Ratho</surname><given-names>R.K.</given-names></name>
<name><surname>Malhotra</surname><given-names>S.</given-names></name>
</person-group><article-title>Effect of acyclovir solid lipid nanoparticles for the treatment of herpes simplex virus (HSV) infection in an animal model of HSV-1 infection</article-title><source>Pharm. Nanotechnol.</source><year>2019</year><volume>7</volume><fpage>389</fpage><lpage>403</lpage><pub-id pub-id-type="doi">10.2174/2211738507666190829161737</pub-id><pub-id pub-id-type="pmid">31465287</pub-id>
</element-citation></ref><ref id="B70-vaccines-13-00126"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lee</surname><given-names>B.</given-names></name>
<name><surname>Park</surname><given-names>J.</given-names></name>
<name><surname>Ryu</surname><given-names>M.</given-names></name>
<name><surname>Kim</surname><given-names>S.</given-names></name>
<name><surname>Joo</surname><given-names>M.</given-names></name>
<name><surname>Yeom</surname><given-names>J.-H.</given-names></name>
<name><surname>Kim</surname><given-names>S.</given-names></name>
<name><surname>Park</surname><given-names>Y.</given-names></name>
<name><surname>Lee</surname><given-names>K.</given-names></name>
<name><surname>Bae</surname><given-names>J.</given-names></name>
</person-group><article-title>Antimicrobial peptide-loaded gold nanoparticle-DNA aptamer conjugates as highly effective antibacterial therapeutics against <italic toggle="yes">Vibrio vulnificus</italic></article-title><source>Sci. Rep.</source><year>2017</year><volume>7</volume><elocation-id>13572</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-017-14127-z</pub-id><pub-id pub-id-type="pmid">29051620</pub-id>
</element-citation></ref><ref id="B71-vaccines-13-00126"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chowdhury</surname><given-names>R.</given-names></name>
<name><surname>Ilyas</surname><given-names>H.</given-names></name>
<name><surname>Ghosh</surname><given-names>A.</given-names></name>
<name><surname>Ali</surname><given-names>H.</given-names></name>
<name><surname>Ghorai</surname><given-names>A.</given-names></name>
<name><surname>Midya</surname><given-names>A.</given-names></name>
<name><surname>Jana</surname><given-names>N.R.</given-names></name>
<name><surname>Das</surname><given-names>S.</given-names></name>
<name><surname>Bhunia</surname><given-names>A.</given-names></name>
</person-group><article-title>Multivalent gold nanoparticle&#x02013;peptide conjugates for targeting intracellular bacterial infections</article-title><source>Nanoscale</source><year>2017</year><volume>9</volume><fpage>14074</fpage><lpage>14093</lpage><pub-id pub-id-type="doi">10.1039/C7NR04062H</pub-id><pub-id pub-id-type="pmid">28901372</pub-id>
</element-citation></ref><ref id="B72-vaccines-13-00126"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gregory</surname><given-names>A.E.</given-names></name>
<name><surname>Judy</surname><given-names>B.M.</given-names></name>
<name><surname>Qazi</surname><given-names>O.</given-names></name>
<name><surname>Blumentritt</surname><given-names>C.A.</given-names></name>
<name><surname>Brown</surname><given-names>K.A.</given-names></name>
<name><surname>Shaw</surname><given-names>A.M.</given-names></name>
<name><surname>Torres</surname><given-names>A.G.</given-names></name>
<name><surname>Titball</surname><given-names>R.W.</given-names></name>
</person-group><article-title>A gold nanoparticle-linked glycoconjugate vaccine against <italic toggle="yes">Burkholderia mallei</italic></article-title><source>Nanomed. Nanotechnol. Biol. Med.</source><year>2015</year><volume>11</volume><fpage>447</fpage><lpage>456</lpage><pub-id pub-id-type="doi">10.1016/j.nano.2014.08.005</pub-id></element-citation></ref><ref id="B73-vaccines-13-00126"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chen</surname><given-names>Y.-S.</given-names></name>
<name><surname>Hung</surname><given-names>Y.-C.</given-names></name>
<name><surname>Lin</surname><given-names>W.-H.</given-names></name>
<name><surname>Huang</surname><given-names>G.S.</given-names></name>
</person-group><article-title>Assessment of gold nanoparticles as a size-dependent vaccine carrier for enhancing the antibody response against synthetic foot-and-mouth disease virus peptide</article-title><source>Nanotechnology</source><year>2010</year><volume>21</volume><fpage>195101</fpage><pub-id pub-id-type="doi">10.1088/0957-4484/21/19/195101</pub-id><pub-id pub-id-type="pmid">20400818</pub-id>
</element-citation></ref><ref id="B74-vaccines-13-00126"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lee</surname><given-names>M.-Y.</given-names></name>
<name><surname>Yang</surname><given-names>J.-A.</given-names></name>
<name><surname>Jung</surname><given-names>H.S.</given-names></name>
<name><surname>Beack</surname><given-names>S.</given-names></name>
<name><surname>Choi</surname><given-names>J.E.</given-names></name>
<name><surname>Hur</surname><given-names>W.</given-names></name>
<name><surname>Koo</surname><given-names>H.</given-names></name>
<name><surname>Kim</surname><given-names>K.</given-names></name>
<name><surname>Yoon</surname><given-names>S.K.</given-names></name>
<name><surname>Hahn</surname><given-names>S.K.</given-names></name>
</person-group><article-title>Hyaluronic acid&#x02013;gold nanoparticle/interferon &#x003b1; complex for targeted treatment of hepatitis C virus infection</article-title><source>ACS Nano</source><year>2012</year><volume>6</volume><fpage>9522</fpage><lpage>9531</lpage><pub-id pub-id-type="doi">10.1021/nn302538y</pub-id><pub-id pub-id-type="pmid">23092111</pub-id>
</element-citation></ref><ref id="B75-vaccines-13-00126"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Farf&#x000e1;n-Castro</surname><given-names>S.</given-names></name>
<name><surname>Garc&#x000ed;a-Soto</surname><given-names>M.J.</given-names></name>
<name><surname>Betancourt-Mendiola</surname><given-names>L.</given-names></name>
<name><surname>Cervantes</surname><given-names>J.</given-names></name>
<name><surname>Segura</surname><given-names>R.</given-names></name>
<name><surname>Gonz&#x000e1;lez-Ortega</surname><given-names>O.</given-names></name>
<name><surname>Rosales-Mendoza</surname><given-names>S.</given-names></name>
</person-group><article-title>Synthesis and evaluation of gold nanoparticles conjugated with five antigenic peptides derived from the spike protein of SARS-CoV-2 for vaccine development</article-title><source>Front. Nanotechnol.</source><year>2024</year><volume>6</volume><elocation-id>1335346</elocation-id><pub-id pub-id-type="doi">10.3389/fnano.2024.1335346</pub-id></element-citation></ref><ref id="B76-vaccines-13-00126"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Halwani</surname><given-names>M.</given-names></name>
<name><surname>Yebio</surname><given-names>B.</given-names></name>
<name><surname>Suntres</surname><given-names>Z.</given-names></name>
<name><surname>Alipour</surname><given-names>M.</given-names></name>
<name><surname>Azghani</surname><given-names>A.</given-names></name>
<name><surname>Omri</surname><given-names>A.</given-names></name>
</person-group><article-title>Co-encapsulation of gallium with gentamicin in liposomes enhances antimicrobial activity of gentamicin against <italic toggle="yes">Pseudomonas aeruginosa</italic></article-title><source>J. Antimicrob. Chemother.</source><year>2008</year><volume>62</volume><fpage>1291</fpage><lpage>1297</lpage><pub-id pub-id-type="doi">10.1093/jac/dkn422</pub-id><pub-id pub-id-type="pmid">18931388</pub-id>
</element-citation></ref><ref id="B77-vaccines-13-00126"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Theivendran</surname><given-names>S.</given-names></name>
<name><surname>Lazarev</surname><given-names>S.</given-names></name>
<name><surname>Yu</surname><given-names>C.</given-names></name>
</person-group><article-title>Mesoporous silica/organosilica nanoparticles for cancer immunotherapy</article-title><source>Exploration</source><year>2023</year><volume>3</volume><fpage>20220086</fpage><pub-id pub-id-type="doi">10.1002/EXP.20220086</pub-id><pub-id pub-id-type="pmid">37933387</pub-id>
</element-citation></ref><ref id="B78-vaccines-13-00126"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Song</surname><given-names>C.</given-names></name>
<name><surname>Li</surname><given-names>F.</given-names></name>
<name><surname>Wang</surname><given-names>S.</given-names></name>
<name><surname>Wang</surname><given-names>J.</given-names></name>
<name><surname>Wei</surname><given-names>W.</given-names></name>
<name><surname>Ma</surname><given-names>G.</given-names></name>
</person-group><article-title>Recent advances in particulate adjuvants for cancer vaccination</article-title><source>Adv. Ther.</source><year>2020</year><volume>3</volume><fpage>1900115</fpage><pub-id pub-id-type="doi">10.1002/adtp.201900115</pub-id></element-citation></ref><ref id="B79-vaccines-13-00126"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Madapong</surname><given-names>A.</given-names></name>
<name><surname>Petro-Turnquist</surname><given-names>E.M.</given-names></name>
<name><surname>Webby</surname><given-names>R.J.</given-names></name>
<name><surname>McCormick</surname><given-names>A.A.</given-names></name>
<name><surname>Weaver</surname><given-names>E.A.</given-names></name>
</person-group><article-title>Immunity and Protective Efficacy of a Plant-Based Tobacco Mosaic Virus-like Nanoparticle Vaccine against Influenza a Virus in Mice</article-title><source>Vaccines</source><year>2024</year><volume>12</volume><elocation-id>1100</elocation-id><pub-id pub-id-type="doi">10.3390/vaccines12101100</pub-id><pub-id pub-id-type="pmid">39460267</pub-id>
</element-citation></ref><ref id="B80-vaccines-13-00126"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Huertas-D&#x000ed;az</surname><given-names>M.C.</given-names></name>
<name><surname>Phan</surname><given-names>S.</given-names></name>
<name><surname>Elson</surname><given-names>A.</given-names></name>
<name><surname>Nu&#x000f1;ez</surname><given-names>I.</given-names></name>
<name><surname>Wei</surname><given-names>H.</given-names></name>
<name><surname>Sakamoto</surname><given-names>K.</given-names></name>
<name><surname>He</surname><given-names>B.</given-names></name>
</person-group><article-title>Parainfluenza virus 5 (PIV5) amplifying virus-like particles expressing respiratory syncytial virus (RSV) antigens protect mice against RSV infection</article-title><source>Vaccine</source><year>2019</year><volume>37</volume><fpage>2925</fpage><lpage>2934</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2019.04.042</pub-id><pub-id pub-id-type="pmid">31010715</pub-id>
</element-citation></ref><ref id="B81-vaccines-13-00126"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lacasta</surname><given-names>A.</given-names></name>
<name><surname>Mody</surname><given-names>K.T.</given-names></name>
<name><surname>De Goeyse</surname><given-names>I.</given-names></name>
<name><surname>Yu</surname><given-names>C.</given-names></name>
<name><surname>Zhang</surname><given-names>J.</given-names></name>
<name><surname>Nyagwange</surname><given-names>J.</given-names></name>
<name><surname>Mwalimu</surname><given-names>S.</given-names></name>
<name><surname>Awino</surname><given-names>E.</given-names></name>
<name><surname>Saya</surname><given-names>R.</given-names></name>
<name><surname>Njoroge</surname><given-names>T.</given-names></name>
</person-group><article-title>Synergistic effect of two nanotechnologies enhances the protective capacity of the <italic toggle="yes">Theileria parva</italic> sporozoite p67C antigen in cattle</article-title><source>J. Immunol.</source><year>2021</year><volume>206</volume><fpage>686</fpage><lpage>699</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.2000442</pub-id><pub-id pub-id-type="pmid">33419770</pub-id>
</element-citation></ref><ref id="B82-vaccines-13-00126"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tariq</surname><given-names>H.</given-names></name>
<name><surname>Batool</surname><given-names>S.</given-names></name>
<name><surname>Asif</surname><given-names>S.</given-names></name>
<name><surname>Ali</surname><given-names>M.</given-names></name>
<name><surname>Abbasi</surname><given-names>B.H.</given-names></name>
</person-group><article-title>Virus-like particles: Revolutionary platforms for developing vaccines against emerging infectious diseases</article-title><source>Front. Microbiol.</source><year>2022</year><volume>12</volume><elocation-id>790121</elocation-id><pub-id pub-id-type="doi">10.3389/fmicb.2021.790121</pub-id><pub-id pub-id-type="pmid">35046918</pub-id>
</element-citation></ref><ref id="B83-vaccines-13-00126"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dai</surname><given-names>S.</given-names></name>
<name><surname>Wang</surname><given-names>H.</given-names></name>
<name><surname>Deng</surname><given-names>F.</given-names></name>
</person-group><article-title>Advances and challenges in enveloped virus-like particle (VLP)-based vaccines</article-title><source>J. Immunol. Sci.</source><year>2018</year><volume>2</volume><fpage>36</fpage><lpage>41</lpage></element-citation></ref><ref id="B84-vaccines-13-00126"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Michel</surname><given-names>M.-L.</given-names></name>
<name><surname>Tiollais</surname><given-names>P.</given-names></name>
</person-group><article-title>Hepatitis B vaccines: Protective efficacy and therapeutic potential</article-title><source>Pathol. Biol.</source><year>2010</year><volume>58</volume><fpage>288</fpage><lpage>295</lpage><pub-id pub-id-type="doi">10.1016/j.patbio.2010.01.006</pub-id><pub-id pub-id-type="pmid">20382485</pub-id>
</element-citation></ref><ref id="B85-vaccines-13-00126"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Keech</surname><given-names>C.</given-names></name>
<name><surname>Albert</surname><given-names>G.</given-names></name>
<name><surname>Cho</surname><given-names>I.</given-names></name>
<name><surname>Robertson</surname><given-names>A.</given-names></name>
<name><surname>Reed</surname><given-names>P.</given-names></name>
<name><surname>Neal</surname><given-names>S.</given-names></name>
<name><surname>Plested</surname><given-names>J.S.</given-names></name>
<name><surname>Zhu</surname><given-names>M.</given-names></name>
<name><surname>Cloney-Clark</surname><given-names>S.</given-names></name>
<name><surname>Zhou</surname><given-names>H.</given-names></name>
</person-group><article-title>Phase 1&#x02013;2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine</article-title><source>N. Engl. J. Med.</source><year>2020</year><volume>383</volume><fpage>2320</fpage><lpage>2332</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2026920</pub-id><pub-id pub-id-type="pmid">32877576</pub-id>
</element-citation></ref><ref id="B86-vaccines-13-00126"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Vu</surname><given-names>M.N.</given-names></name>
<name><surname>Kelly</surname><given-names>H.G.</given-names></name>
<name><surname>Kent</surname><given-names>S.J.</given-names></name>
<name><surname>Wheatley</surname><given-names>A.K.</given-names></name>
</person-group><article-title>Current and future nanoparticle vaccines for COVID-19</article-title><source>EBioMedicine</source><year>2021</year><volume>74</volume><elocation-id>103699</elocation-id><pub-id pub-id-type="doi">10.1016/j.ebiom.2021.103699</pub-id><pub-id pub-id-type="pmid">34801965</pub-id>
</element-citation></ref><ref id="B87-vaccines-13-00126"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Liao</surname><given-names>Z.</given-names></name>
<name><surname>Huang</surname><given-names>J.</given-names></name>
<name><surname>Lo</surname><given-names>P.-C.</given-names></name>
<name><surname>Lovell</surname><given-names>J.F.</given-names></name>
<name><surname>Jin</surname><given-names>H.</given-names></name>
<name><surname>Yang</surname><given-names>K.</given-names></name>
</person-group><article-title>Self-adjuvanting cancer nanovaccines</article-title><source>J. Nanobiotechnol.</source><year>2022</year><volume>20</volume><elocation-id>345</elocation-id><pub-id pub-id-type="doi">10.1186/s12951-022-01545-z</pub-id></element-citation></ref><ref id="B88-vaccines-13-00126"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Li</surname><given-names>Y.</given-names></name>
<name><surname>Su</surname><given-names>T.</given-names></name>
<name><surname>Zhang</surname><given-names>Y.</given-names></name>
<name><surname>Huang</surname><given-names>X.</given-names></name>
<name><surname>Li</surname><given-names>J.</given-names></name>
<name><surname>Li</surname><given-names>C.</given-names></name>
</person-group><article-title>Liposomal co-delivery of daptomycin and clarithromycin at an optimized ratio for treatment of methicillin-resistant <italic toggle="yes">Staphylococcus aureus</italic> infection</article-title><source>Drug Deliv.</source><year>2015</year><volume>22</volume><fpage>627</fpage><lpage>637</lpage><pub-id pub-id-type="doi">10.3109/10717544.2014.880756</pub-id><pub-id pub-id-type="pmid">24471983</pub-id>
</element-citation></ref><ref id="B89-vaccines-13-00126"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wang</surname><given-names>J.</given-names></name>
<name><surname>Li</surname><given-names>P.</given-names></name>
<name><surname>Yu</surname><given-names>Y.</given-names></name>
<name><surname>Fu</surname><given-names>Y.</given-names></name>
<name><surname>Jiang</surname><given-names>H.</given-names></name>
<name><surname>Lu</surname><given-names>M.</given-names></name>
<name><surname>Sun</surname><given-names>Z.</given-names></name>
<name><surname>Jiang</surname><given-names>S.</given-names></name>
<name><surname>Lu</surname><given-names>L.</given-names></name>
<name><surname>Wu</surname><given-names>M.X.</given-names></name>
</person-group><article-title>Pulmonary surfactant&#x02013;biomimetic nanoparticles potentiate heterosubtypic influenza immunity</article-title><source>Science</source><year>2020</year><volume>367</volume><fpage>eaau0810</fpage><pub-id pub-id-type="doi">10.1126/science.aau0810</pub-id><pub-id pub-id-type="pmid">32079747</pub-id>
</element-citation></ref><ref id="B90-vaccines-13-00126"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hanson</surname><given-names>M.C.</given-names></name>
<name><surname>Abraham</surname><given-names>W.</given-names></name>
<name><surname>Crespo</surname><given-names>M.P.</given-names></name>
<name><surname>Chen</surname><given-names>S.H.</given-names></name>
<name><surname>Liu</surname><given-names>H.</given-names></name>
<name><surname>Szeto</surname><given-names>G.L.</given-names></name>
<name><surname>Kim</surname><given-names>M.</given-names></name>
<name><surname>Reinherz</surname><given-names>E.L.</given-names></name>
<name><surname>Irvine</surname><given-names>D.J.</given-names></name>
</person-group><article-title>Liposomal vaccines incorporating molecular adjuvants and intrastructural T-cell help promote the immunogenicity of HIV membrane-proximal external region peptides</article-title><source>Vaccine</source><year>2015</year><volume>33</volume><fpage>861</fpage><lpage>868</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2014.12.045</pub-id><pub-id pub-id-type="pmid">25559188</pub-id>
</element-citation></ref><ref id="B91-vaccines-13-00126"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Smith</surname><given-names>L.R.</given-names></name>
<name><surname>Wloch</surname><given-names>M.K.</given-names></name>
<name><surname>Ye</surname><given-names>M.</given-names></name>
<name><surname>Reyes</surname><given-names>L.R.</given-names></name>
<name><surname>Boutsaboualoy</surname><given-names>S.</given-names></name>
<name><surname>Dunne</surname><given-names>C.E.</given-names></name>
<name><surname>Chaplin</surname><given-names>J.A.</given-names></name>
<name><surname>Rusalov</surname><given-names>D.</given-names></name>
<name><surname>Rolland</surname><given-names>A.P.</given-names></name>
<name><surname>Fisher</surname><given-names>C.L.</given-names></name>
</person-group><article-title>Phase 1 clinical trials of the safety and immunogenicity of adjuvanted plasmid DNA vaccines encoding influenza A virus H5 hemagglutinin</article-title><source>Vaccine</source><year>2010</year><volume>28</volume><fpage>2565</fpage><lpage>2572</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2010.01.029</pub-id><pub-id pub-id-type="pmid">20117262</pub-id>
</element-citation></ref><ref id="B92-vaccines-13-00126"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bovier</surname><given-names>P.A.</given-names></name>
</person-group><article-title>Epaxal<sup>&#x000ae;</sup>: A virosomal vaccine to prevent hepatitis A infection</article-title><source>Expert Rev. Vaccines</source><year>2008</year><volume>7</volume><fpage>1141</fpage><lpage>1150</lpage><pub-id pub-id-type="doi">10.1586/14760584.7.8.1141</pub-id><pub-id pub-id-type="pmid">18844588</pub-id>
</element-citation></ref><ref id="B93-vaccines-13-00126"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Huang</surname><given-names>X.</given-names></name>
<name><surname>Ma</surname><given-names>Y.</given-names></name>
<name><surname>Ma</surname><given-names>G.</given-names></name>
<name><surname>Xia</surname><given-names>Y.</given-names></name>
</person-group><article-title>Unlocking the therapeutic applicability of LNP-mRNA: Chemistry, formulation, and clinical strategies</article-title><source>Research</source><year>2024</year><volume>7</volume><fpage>0370</fpage><pub-id pub-id-type="doi">10.34133/research.0370</pub-id><pub-id pub-id-type="pmid">38894715</pub-id>
</element-citation></ref><ref id="B94-vaccines-13-00126"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chahal</surname><given-names>J.S.</given-names></name>
<name><surname>Khan</surname><given-names>O.F.</given-names></name>
<name><surname>Cooper</surname><given-names>C.L.</given-names></name>
<name><surname>McPartlan</surname><given-names>J.S.</given-names></name>
<name><surname>Tsosie</surname><given-names>J.K.</given-names></name>
<name><surname>Tilley</surname><given-names>L.D.</given-names></name>
<name><surname>Sidik</surname><given-names>S.M.</given-names></name>
<name><surname>Lourido</surname><given-names>S.</given-names></name>
<name><surname>Langer</surname><given-names>R.</given-names></name>
<name><surname>Bavari</surname><given-names>S.</given-names></name>
</person-group><article-title>Dendrimer-RNA nanoparticles generate protective immunity against lethal Ebola, H1N1 influenza, and <italic toggle="yes">Toxoplasma gondii</italic> challenges with a single dose</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2016</year><volume>113</volume><fpage>E4133</fpage><lpage>E4142</lpage><pub-id pub-id-type="doi">10.1073/pnas.1600299113</pub-id><pub-id pub-id-type="pmid">27382155</pub-id>
</element-citation></ref><ref id="B95-vaccines-13-00126"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhang</surname><given-names>D.</given-names></name>
<name><surname>Wang</surname><given-names>G.</given-names></name>
<name><surname>Yu</surname><given-names>X.</given-names></name>
<name><surname>Wei</surname><given-names>T.</given-names></name>
<name><surname>Farbiak</surname><given-names>L.</given-names></name>
<name><surname>Johnson</surname><given-names>L.T.</given-names></name>
<name><surname>Taylor</surname><given-names>A.M.</given-names></name>
<name><surname>Xu</surname><given-names>J.</given-names></name>
<name><surname>Hong</surname><given-names>Y.</given-names></name>
<name><surname>Zhu</surname><given-names>H.</given-names></name>
</person-group><article-title>Enhancing CRISPR/Cas gene editing through modulating cellular mechanical properties for cancer therapy</article-title><source>Nat. Nanotechnol.</source><year>2022</year><volume>17</volume><fpage>777</fpage><lpage>787</lpage><pub-id pub-id-type="doi">10.1038/s41565-022-01122-3</pub-id><pub-id pub-id-type="pmid">35551240</pub-id>
</element-citation></ref><ref id="B96-vaccines-13-00126"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Xu</surname><given-names>J.</given-names></name>
<name><surname>Lv</surname><given-names>J.</given-names></name>
<name><surname>Zhuang</surname><given-names>Q.</given-names></name>
<name><surname>Yang</surname><given-names>Z.</given-names></name>
<name><surname>Cao</surname><given-names>Z.</given-names></name>
<name><surname>Xu</surname><given-names>L.</given-names></name>
<name><surname>Pei</surname><given-names>P.</given-names></name>
<name><surname>Wang</surname><given-names>C.</given-names></name>
<name><surname>Wu</surname><given-names>H.</given-names></name>
<name><surname>Dong</surname><given-names>Z.</given-names></name>
</person-group><article-title>A general strategy towards personalized nanovaccines based on fluoropolymers for post-surgical cancer immunotherapy</article-title><source>Nat. Nanotechnol.</source><year>2020</year><volume>15</volume><fpage>1043</fpage><lpage>1052</lpage><pub-id pub-id-type="doi">10.1038/s41565-020-00781-4</pub-id><pub-id pub-id-type="pmid">33139933</pub-id>
</element-citation></ref><ref id="B97-vaccines-13-00126"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chen</surname><given-names>G.</given-names></name>
<name><surname>Bai</surname><given-names>Y.</given-names></name>
<name><surname>Li</surname><given-names>Z.</given-names></name>
<name><surname>Wang</surname><given-names>F.</given-names></name>
<name><surname>Fan</surname><given-names>X.</given-names></name>
<name><surname>Zhou</surname><given-names>X.</given-names></name>
</person-group><article-title>Bacterial extracellular vesicle-coated multi-antigenic nanovaccines protect against drug-resistant <italic toggle="yes">Staphylococcus aureus</italic> infection by modulating antigen processing and presentation pathways</article-title><source>Theranostics</source><year>2020</year><volume>10</volume><fpage>7131</fpage><pub-id pub-id-type="doi">10.7150/thno.44564</pub-id><pub-id pub-id-type="pmid">32641983</pub-id>
</element-citation></ref><ref id="B98-vaccines-13-00126"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hu</surname><given-names>R.</given-names></name>
<name><surname>Liu</surname><given-names>H.</given-names></name>
<name><surname>Wang</surname><given-names>M.</given-names></name>
<name><surname>Li</surname><given-names>J.</given-names></name>
<name><surname>Lin</surname><given-names>H.</given-names></name>
<name><surname>Liang</surname><given-names>M.</given-names></name>
<name><surname>Gao</surname><given-names>Y.</given-names></name>
<name><surname>Yang</surname><given-names>M.</given-names></name>
</person-group><article-title>An OMV-based nanovaccine confers safety and protection against pathogenic <italic toggle="yes">Escherichia coli</italic> via both humoral and predominantly Th1 immune responses in poultry</article-title><source>Nanomaterials</source><year>2020</year><volume>10</volume><elocation-id>2293</elocation-id><pub-id pub-id-type="doi">10.3390/nano10112293</pub-id><pub-id pub-id-type="pmid">33233490</pub-id>
</element-citation></ref><ref id="B99-vaccines-13-00126"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Thukral</surname><given-names>A.</given-names></name>
<name><surname>Ross</surname><given-names>K.</given-names></name>
<name><surname>Hansen</surname><given-names>C.</given-names></name>
<name><surname>Phanse</surname><given-names>Y.</given-names></name>
<name><surname>Narasimhan</surname><given-names>B.</given-names></name>
<name><surname>Steinberg</surname><given-names>H.</given-names></name>
<name><surname>Talaat</surname><given-names>A.M.</given-names></name>
</person-group><article-title>A single dose polyanhydride-based nanovaccine against paratuberculosis infection</article-title><source>npj Vaccines</source><year>2020</year><volume>5</volume><fpage>15</fpage><pub-id pub-id-type="doi">10.1038/s41541-020-0164-y</pub-id><pub-id pub-id-type="pmid">32128256</pub-id>
</element-citation></ref><ref id="B100-vaccines-13-00126"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Etewa</surname><given-names>S.E.</given-names></name>
<name><surname>El-Maaty</surname><given-names>D.A.A.</given-names></name>
<name><surname>Hamza</surname><given-names>R.S.</given-names></name>
<name><surname>Metwaly</surname><given-names>A.S.</given-names></name>
<name><surname>Sarhan</surname><given-names>M.H.</given-names></name>
<name><surname>Abdel-Rahman</surname><given-names>S.A.</given-names></name>
<name><surname>Fathy</surname><given-names>G.M.</given-names></name>
<name><surname>El-Shafey</surname><given-names>M.A.</given-names></name>
</person-group><article-title>Assessment of spiramycin-loaded chitosan nanoparticles treatment on acute and chronic toxoplasmosis in mice</article-title><source>J. Parasit. Dis.</source><year>2018</year><volume>42</volume><fpage>102</fpage><lpage>113</lpage><pub-id pub-id-type="doi">10.1007/s12639-017-0973-8</pub-id><pub-id pub-id-type="pmid">29491568</pub-id>
</element-citation></ref><ref id="B101-vaccines-13-00126"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhang</surname><given-names>J.</given-names></name>
<name><surname>Sun</surname><given-names>H.</given-names></name>
<name><surname>Gao</surname><given-names>C.</given-names></name>
<name><surname>Wang</surname><given-names>Y.</given-names></name>
<name><surname>Cheng</surname><given-names>X.</given-names></name>
<name><surname>Yang</surname><given-names>Y.</given-names></name>
<name><surname>Gou</surname><given-names>Q.</given-names></name>
<name><surname>Lei</surname><given-names>L.</given-names></name>
<name><surname>Chen</surname><given-names>Y.</given-names></name>
<name><surname>Wang</surname><given-names>X.</given-names></name>
</person-group><article-title>Development of a chitosan--modified PLGA nanoparticle vaccine for protection against <italic toggle="yes">Escherichia coli</italic> K1 caused meningitis in mice</article-title><source>J. Nanobiotechnol.</source><year>2021</year><volume>19</volume><fpage>1</fpage><lpage>15</lpage><pub-id pub-id-type="doi">10.1186/s12951-021-00812-9</pub-id><pub-id pub-id-type="pmid">33673858</pub-id>
</element-citation></ref><ref id="B102-vaccines-13-00126"><label>102.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tao</surname><given-names>J.</given-names></name>
<name><surname>Zhang</surname><given-names>Y.</given-names></name>
<name><surname>Shen</surname><given-names>A.</given-names></name>
<name><surname>Yang</surname><given-names>Y.</given-names></name>
<name><surname>Diao</surname><given-names>L.</given-names></name>
<name><surname>Wang</surname><given-names>L.</given-names></name>
<name><surname>Cai</surname><given-names>D.</given-names></name>
<name><surname>Hu</surname><given-names>Y.</given-names></name>
</person-group><article-title>Injectable chitosan-based thermosensitive hydrogel/nanoparticle-loaded system for local delivery of vancomycin in the treatment of osteomyelitis</article-title><source>Int. J. Nanomed.</source><year>2020</year><volume>15</volume><fpage>5855</fpage><lpage>5871</lpage><pub-id pub-id-type="doi">10.2147/IJN.S247088</pub-id><pub-id pub-id-type="pmid">32848394</pub-id>
</element-citation></ref><ref id="B103-vaccines-13-00126"><label>103.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kitiyodom</surname><given-names>S.</given-names></name>
<name><surname>Trull&#x000e0;s</surname><given-names>C.</given-names></name>
<name><surname>Rodkhum</surname><given-names>C.</given-names></name>
<name><surname>Thompson</surname><given-names>K.D.</given-names></name>
<name><surname>Katagiri</surname><given-names>T.</given-names></name>
<name><surname>Temisak</surname><given-names>S.</given-names></name>
<name><surname>Namdee</surname><given-names>K.</given-names></name>
<name><surname>Yata</surname><given-names>T.</given-names></name>
<name><surname>Pirarat</surname><given-names>N.</given-names></name>
</person-group><article-title>Modulation of the mucosal immune response of red tilapia (<italic toggle="yes">Oreochromis</italic> sp.) against columnaris disease using a biomimetic-mucoadhesive nanovaccine</article-title><source>Fish Shellfish. Immunol.</source><year>2021</year><volume>112</volume><fpage>81</fpage><lpage>91</lpage><pub-id pub-id-type="doi">10.1016/j.fsi.2021.02.017</pub-id><pub-id pub-id-type="pmid">33675991</pub-id>
</element-citation></ref><ref id="B104-vaccines-13-00126"><label>104.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>El-Sissi</surname><given-names>A.F.</given-names></name>
<name><surname>Mohamed</surname><given-names>F.H.</given-names></name>
<name><surname>Danial</surname><given-names>N.M.</given-names></name>
<name><surname>Gaballah</surname><given-names>A.Q.</given-names></name>
<name><surname>Ali</surname><given-names>K.A.</given-names></name>
</person-group><article-title>Chitosan and chitosan nanoparticles as adjuvant in local Rift Valley Fever inactivated vaccine</article-title><source>3 Biotech</source><year>2020</year><volume>10</volume><elocation-id>88</elocation-id><pub-id pub-id-type="doi">10.1007/s13205-020-2076-y</pub-id></element-citation></ref><ref id="B105-vaccines-13-00126"><label>105.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nevagi</surname><given-names>R.J.</given-names></name>
<name><surname>Khalil</surname><given-names>Z.G.</given-names></name>
<name><surname>Hussein</surname><given-names>W.M.</given-names></name>
<name><surname>Powell</surname><given-names>J.</given-names></name>
<name><surname>Batzloff</surname><given-names>M.R.</given-names></name>
<name><surname>Capon</surname><given-names>R.J.</given-names></name>
<name><surname>Good</surname><given-names>M.F.</given-names></name>
<name><surname>Skwarczynski</surname><given-names>M.</given-names></name>
<name><surname>Toth</surname><given-names>I.</given-names></name>
</person-group><article-title>Polyglutamic acid-trimethyl chitosan-based intranasal peptide nano-vaccine induces potent immune responses against group A streptococcus</article-title><source>Acta Biomater.</source><year>2018</year><volume>80</volume><fpage>278</fpage><lpage>287</lpage><pub-id pub-id-type="doi">10.1016/j.actbio.2018.09.037</pub-id><pub-id pub-id-type="pmid">30266637</pub-id>
</element-citation></ref><ref id="B106-vaccines-13-00126"><label>106.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhao</surname><given-names>K.</given-names></name>
<name><surname>Chen</surname><given-names>G.</given-names></name>
<name><surname>Shi</surname><given-names>X.-m.</given-names></name>
<name><surname>Gao</surname><given-names>T.-t.</given-names></name>
<name><surname>Li</surname><given-names>W.</given-names></name>
<name><surname>Zhao</surname><given-names>Y.</given-names></name>
<name><surname>Zhang</surname><given-names>F.-q.</given-names></name>
<name><surname>Wu</surname><given-names>J.</given-names></name>
<name><surname>Cui</surname><given-names>X.</given-names></name>
<name><surname>Wang</surname><given-names>Y.-F.</given-names></name>
</person-group><article-title>Preparation and efficacy of a live newcastle disease virus vaccine encapsulated in chitosan nanoparticles</article-title><source>PLoS ONE</source><year>2012</year><volume>7</volume><elocation-id>e53314</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0053314</pub-id><pub-id pub-id-type="pmid">23285276</pub-id>
</element-citation></ref><ref id="B107-vaccines-13-00126"><label>107.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Das</surname><given-names>I.</given-names></name>
<name><surname>Padhi</surname><given-names>A.</given-names></name>
<name><surname>Mukherjee</surname><given-names>S.</given-names></name>
<name><surname>Dash</surname><given-names>D.P.</given-names></name>
<name><surname>Kar</surname><given-names>S.</given-names></name>
<name><surname>Sonawane</surname><given-names>A.</given-names></name>
</person-group><article-title>Biocompatible chitosan nanoparticles as an efficient delivery vehicle for <italic toggle="yes">Mycobacterium tuberculosis</italic> lipids to induce potent cytokines and antibody response through activation of &#x003b3;&#x003b4; T cells in mice</article-title><source>Nanotechnology</source><year>2017</year><volume>28</volume><fpage>165101</fpage><pub-id pub-id-type="doi">10.1088/1361-6528/aa60fd</pub-id><pub-id pub-id-type="pmid">28206982</pub-id>
</element-citation></ref><ref id="B108-vaccines-13-00126"><label>108.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mohammed</surname><given-names>G.M.</given-names></name>
<name><surname>ElZorkany</surname><given-names>H.E.</given-names></name>
<name><surname>Farroh</surname><given-names>K.Y.</given-names></name>
<name><surname>Abd El-Aziz</surname><given-names>W.R.</given-names></name>
<name><surname>Elshoky</surname><given-names>H.A.</given-names></name>
</person-group><article-title>Potential improvement of the immune response of chickens against <italic toggle="yes">E. coli</italic> vaccine by using two forms of chitosan nanoparticles</article-title><source>Int. J. Biol. Macromol.</source><year>2021</year><volume>167</volume><fpage>395</fpage><lpage>404</lpage><pub-id pub-id-type="doi">10.1016/j.ijbiomac.2020.11.200</pub-id><pub-id pub-id-type="pmid">33275976</pub-id>
</element-citation></ref><ref id="B109-vaccines-13-00126"><label>109.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Renu</surname><given-names>S.</given-names></name>
<name><surname>Renukaradhya</surname><given-names>G.J.</given-names></name>
</person-group><article-title>Chitosan nanoparticle based mucosal vaccines delivered against infectious diseases of poultry and pigs</article-title><source>Front. Bioeng. Biotechnol.</source><year>2020</year><volume>8</volume><elocation-id>558349</elocation-id><pub-id pub-id-type="doi">10.3389/fbioe.2020.558349</pub-id><pub-id pub-id-type="pmid">33282847</pub-id>
</element-citation></ref><ref id="B110-vaccines-13-00126"><label>110.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Acevedo-Villanueva</surname><given-names>K.</given-names></name>
<name><surname>Renu</surname><given-names>S.</given-names></name>
<name><surname>Gourapura</surname><given-names>R.</given-names></name>
<name><surname>Selvaraj</surname><given-names>R.</given-names></name>
</person-group><article-title>Efficacy of a nanoparticle vaccine administered in-ovo against <italic toggle="yes">Salmonella</italic> in broilers</article-title><source>PLoS ONE</source><year>2021</year><volume>16</volume><elocation-id>e0247938</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0247938</pub-id><pub-id pub-id-type="pmid">33822791</pub-id>
</element-citation></ref><ref id="B111-vaccines-13-00126"><label>111.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kelly</surname><given-names>S.M.</given-names></name>
<name><surname>Larsen</surname><given-names>K.R.</given-names></name>
<name><surname>Darling</surname><given-names>R.</given-names></name>
<name><surname>Petersen</surname><given-names>A.C.</given-names></name>
<name><surname>Bellaire</surname><given-names>B.H.</given-names></name>
<name><surname>Wannemuehler</surname><given-names>M.J.</given-names></name>
<name><surname>Narasimhan</surname><given-names>B.</given-names></name>
</person-group><article-title>Single-dose combination nanovaccine induces both rapid and durable humoral immunity and toxin neutralizing antibody responses against <italic toggle="yes">Bacillus anthracis</italic></article-title><source>Vaccine</source><year>2021</year><volume>39</volume><fpage>3862</fpage><lpage>3870</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2021.05.077</pub-id><pub-id pub-id-type="pmid">34090702</pub-id>
</element-citation></ref><ref id="B112-vaccines-13-00126"><label>112.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chowdhury</surname><given-names>I.H.</given-names></name>
<name><surname>Lokugamage</surname><given-names>N.</given-names></name>
<name><surname>Garg</surname><given-names>N.J.</given-names></name>
</person-group><article-title>Experimental nanovaccine offers protection against repeat exposures <italic toggle="yes">to Trypanosoma cruzi</italic> through activation of polyfunctional T cell response</article-title><source>Front. Immunol.</source><year>2020</year><volume>11</volume><elocation-id>595039</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2020.595039</pub-id><pub-id pub-id-type="pmid">33414785</pub-id>
</element-citation></ref><ref id="B113-vaccines-13-00126"><label>113.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mody</surname><given-names>K.T.</given-names></name>
<name><surname>Zhang</surname><given-names>B.</given-names></name>
<name><surname>Li</surname><given-names>X.</given-names></name>
<name><surname>Fletcher</surname><given-names>N.L.</given-names></name>
<name><surname>Akhter</surname><given-names>D.T.</given-names></name>
<name><surname>Jarrett</surname><given-names>S.</given-names></name>
<name><surname>Zhang</surname><given-names>J.</given-names></name>
<name><surname>Yu</surname><given-names>C.</given-names></name>
<name><surname>Thurecht</surname><given-names>K.J.</given-names></name>
<name><surname>Mahony</surname><given-names>T.J.</given-names></name>
</person-group><article-title>Characterization of the biodistribution of a silica vesicle nanovaccine carrying a <italic toggle="yes">Rhipicephalus</italic> (<italic toggle="yes">Boophilus</italic>) microplus protective antigen with in vivo live animal imaging</article-title><source>Front. Bioeng. Biotechnol.</source><year>2021</year><volume>8</volume><elocation-id>606652</elocation-id><pub-id pub-id-type="doi">10.3389/fbioe.2020.606652</pub-id><pub-id pub-id-type="pmid">33537291</pub-id>
</element-citation></ref><ref id="B114-vaccines-13-00126"><label>114.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ghaffari</surname><given-names>H.</given-names></name>
<name><surname>Tavakoli</surname><given-names>A.</given-names></name>
<name><surname>Moradi</surname><given-names>A.</given-names></name>
<name><surname>Tabarraei</surname><given-names>A.</given-names></name>
<name><surname>Bokharaei-Salim</surname><given-names>F.</given-names></name>
<name><surname>Zahmatkeshan</surname><given-names>M.</given-names></name>
<name><surname>Farahmand</surname><given-names>M.</given-names></name>
<name><surname>Javanmard</surname><given-names>D.</given-names></name>
<name><surname>Kiani</surname><given-names>S.J.</given-names></name>
<name><surname>Esghaei</surname><given-names>M.</given-names></name>
</person-group><article-title>Inhibition of H1N1 influenza virus infection by zinc oxide nanoparticles: Another emerging application of nanomedicine</article-title><source>J. Biomed. Sci.</source><year>2019</year><volume>26</volume><fpage>1</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1186/s12929-019-0563-4</pub-id><pub-id pub-id-type="pmid">30602371</pub-id>
</element-citation></ref><ref id="B115-vaccines-13-00126"><label>115.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rajeshkumar</surname><given-names>S.</given-names></name>
<name><surname>Bharath</surname><given-names>L.</given-names></name>
</person-group><article-title>Controlling of food borne pathogens by nanoparticles</article-title><source>Bioorganic Phase Nat. Food Overv.</source><year>2018</year><volume>15</volume><fpage>293</fpage><lpage>322</lpage></element-citation></ref><ref id="B116-vaccines-13-00126"><label>116.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Vinayamohan</surname><given-names>P.G.</given-names></name>
<name><surname>Joseph</surname><given-names>D.</given-names></name>
<name><surname>Viju</surname><given-names>L.S.</given-names></name>
<name><surname>Venkitanarayanan</surname><given-names>K.</given-names></name>
</person-group><article-title>Efficacy of selenium for controlling infectious diseases</article-title><source>Selenium and Human Health</source><publisher-name>IntechOpen</publisher-name><publisher-loc>Rijeka, Croatia</publisher-loc><year>2023</year></element-citation></ref><ref id="B117-vaccines-13-00126"><label>117.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Maleki</surname><given-names>M.</given-names></name>
<name><surname>Salouti</surname><given-names>M.</given-names></name>
<name><surname>Shafiee Ardestani</surname><given-names>M.</given-names></name>
<name><surname>Talebzadeh</surname><given-names>A.</given-names></name>
</person-group><article-title>Preparation of a nanovaccine against Brucella melitensis M16 based on PLGA nanoparticles and oligopolysaccharide antigen</article-title><source>Artif. Cells Nanomed. Biotechnol.</source><year>2019</year><volume>47</volume><fpage>4248</fpage><lpage>4256</lpage><pub-id pub-id-type="doi">10.1080/21691401.2019.1687490</pub-id><pub-id pub-id-type="pmid">31718300</pub-id>
</element-citation></ref><ref id="B118-vaccines-13-00126"><label>118.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lee</surname><given-names>J.-A.</given-names></name>
<name><surname>Jung</surname><given-names>B.-G.</given-names></name>
<name><surname>Kim</surname><given-names>T.-H.</given-names></name>
<name><surname>Kim</surname><given-names>Y.-M.</given-names></name>
<name><surname>Park</surname><given-names>M.-H.</given-names></name>
<name><surname>Hyun</surname><given-names>P.-m.</given-names></name>
<name><surname>Jeon</surname><given-names>J.-w.</given-names></name>
<name><surname>Park</surname><given-names>J.-k.</given-names></name>
<name><surname>Cho</surname><given-names>C.-W.</given-names></name>
<name><surname>Suh</surname><given-names>G.-H.</given-names></name>
</person-group><article-title>Poly d, l-lactide-co-glycolide (PLGA) nanoparticle-encapsulated honeybee (<italic toggle="yes">Apis melifera</italic>) venom promotes clearance of <italic toggle="yes">Salmonella enterica serovar Typhimurium</italic> infection in experimentally challenged pigs through the up-regulation of T helper type 1 specific immune responses</article-title><source>Vet. Immunol. Immunopathol.</source><year>2014</year><volume>161</volume><fpage>193</fpage><lpage>204</lpage><pub-id pub-id-type="pmid">25193467</pub-id>
</element-citation></ref><ref id="B119-vaccines-13-00126"><label>119.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Demento</surname><given-names>S.L.</given-names></name>
<name><surname>Cui</surname><given-names>W.</given-names></name>
<name><surname>Criscione</surname><given-names>J.M.</given-names></name>
<name><surname>Stern</surname><given-names>E.</given-names></name>
<name><surname>Tulipan</surname><given-names>J.</given-names></name>
<name><surname>Kaech</surname><given-names>S.M.</given-names></name>
<name><surname>Fahmy</surname><given-names>T.M.</given-names></name>
</person-group><article-title>Role of sustained antigen release from nanoparticle vaccines in shaping the T cell memory phenotype</article-title><source>Biomaterials</source><year>2012</year><volume>33</volume><fpage>4957</fpage><lpage>4964</lpage><pub-id pub-id-type="doi">10.1016/j.biomaterials.2012.03.041</pub-id><pub-id pub-id-type="pmid">22484047</pub-id>
</element-citation></ref><ref id="B120-vaccines-13-00126"><label>120.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tan</surname><given-names>Z.</given-names></name>
<name><surname>Liu</surname><given-names>W.</given-names></name>
<name><surname>Liu</surname><given-names>H.</given-names></name>
<name><surname>Li</surname><given-names>C.</given-names></name>
<name><surname>Zhang</surname><given-names>Y.</given-names></name>
<name><surname>Meng</surname><given-names>X.</given-names></name>
<name><surname>Tang</surname><given-names>T.</given-names></name>
<name><surname>Xi</surname><given-names>T.</given-names></name>
<name><surname>Xing</surname><given-names>Y.</given-names></name>
</person-group><article-title>Oral Helicobacter pylori vaccine-encapsulated acid-resistant HP55/PLGA nanoparticles promote immune protection</article-title><source>Eur. J. Pharm. Biopharm.</source><year>2017</year><volume>111</volume><fpage>33</fpage><lpage>43</lpage><pub-id pub-id-type="doi">10.1016/j.ejpb.2016.11.007</pub-id><pub-id pub-id-type="pmid">27865932</pub-id>
</element-citation></ref><ref id="B121-vaccines-13-00126"><label>121.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Toti</surname><given-names>U.S.</given-names></name>
<name><surname>Guru</surname><given-names>B.R.</given-names></name>
<name><surname>Hali</surname><given-names>M.</given-names></name>
<name><surname>McPharlin</surname><given-names>C.M.</given-names></name>
<name><surname>Wykes</surname><given-names>S.M.</given-names></name>
<name><surname>Panyam</surname><given-names>J.</given-names></name>
<name><surname>Whittum-Hudson</surname><given-names>J.A.</given-names></name>
</person-group><article-title>Targeted delivery of antibiotics to intracellular chlamydial infections using PLGA nanoparticles</article-title><source>Biomaterials</source><year>2011</year><volume>32</volume><fpage>6606</fpage><lpage>6613</lpage><pub-id pub-id-type="doi">10.1016/j.biomaterials.2011.05.038</pub-id><pub-id pub-id-type="pmid">21652065</pub-id>
</element-citation></ref><ref id="B122-vaccines-13-00126"><label>122.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ramteke</surname><given-names>S.</given-names></name>
<name><surname>Ganesh</surname><given-names>N.</given-names></name>
<name><surname>Bhattacharya</surname><given-names>S.</given-names></name>
<name><surname>Jain</surname><given-names>N.K.</given-names></name>
</person-group><article-title>Amoxicillin, clarithromycin, and omeprazole based targeted nanoparticles for the treatment of <italic toggle="yes">H. pylori</italic></article-title><source>J. Drug Target.</source><year>2009</year><volume>17</volume><fpage>225</fpage><lpage>234</lpage><pub-id pub-id-type="doi">10.1080/10611860902718649</pub-id><pub-id pub-id-type="pmid">19241256</pub-id>
</element-citation></ref><ref id="B123-vaccines-13-00126"><label>123.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ardestani</surname><given-names>M.S.</given-names></name>
<name><surname>Fordoei</surname><given-names>A.S.</given-names></name>
<name><surname>Abdoli</surname><given-names>A.</given-names></name>
<name><surname>Ahangari Cohan</surname><given-names>R.</given-names></name>
<name><surname>Bahramali</surname><given-names>G.</given-names></name>
<name><surname>Sadat</surname><given-names>S.M.</given-names></name>
<name><surname>Siadat</surname><given-names>S.D.</given-names></name>
<name><surname>Moloudian</surname><given-names>H.</given-names></name>
<name><surname>Nassiri Koopaei</surname><given-names>N.</given-names></name>
<name><surname>Bolhasani</surname><given-names>A.</given-names></name>
</person-group><article-title>Nanosilver based anionic linear globular dendrimer with a special significant antiretroviral activity</article-title><source>J. Mater. Sci. Mater. Med.</source><year>2015</year><volume>26</volume><fpage>1</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1007/s10856-015-5510-7</pub-id></element-citation></ref><ref id="B124-vaccines-13-00126"><label>124.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Park</surname><given-names>S.</given-names></name>
<name><surname>Park</surname><given-names>H.H.</given-names></name>
<name><surname>Kim</surname><given-names>S.Y.</given-names></name>
<name><surname>Kim</surname><given-names>S.J.</given-names></name>
<name><surname>Woo</surname><given-names>K.</given-names></name>
<name><surname>Ko</surname><given-names>G.</given-names></name>
</person-group><article-title>Antiviral properties of silver nanoparticles on a magnetic hybrid colloid</article-title><source>Appl. Environ. Microbiol.</source><year>2014</year><volume>80</volume><fpage>2343</fpage><lpage>2350</lpage><pub-id pub-id-type="doi">10.1128/AEM.03427-13</pub-id><pub-id pub-id-type="pmid">24487537</pub-id>
</element-citation></ref><ref id="B125-vaccines-13-00126"><label>125.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Huy</surname><given-names>T.Q.</given-names></name>
<name><surname>Thanh</surname><given-names>N.T.H.</given-names></name>
<name><surname>Thuy</surname><given-names>N.T.</given-names></name>
<name><surname>Van Chung</surname><given-names>P.</given-names></name>
<name><surname>Hung</surname><given-names>P.N.</given-names></name>
<name><surname>Le</surname><given-names>A.-T.</given-names></name>
<name><surname>Hanh</surname><given-names>N.T.H.</given-names></name>
</person-group><article-title>Cytotoxicity and antiviral activity of electrochemical&#x02013;synthesized silver nanoparticles against poliovirus</article-title><source>J. Virol. Methods</source><year>2017</year><volume>241</volume><fpage>52</fpage><lpage>57</lpage><pub-id pub-id-type="doi">10.1016/j.jviromet.2016.12.015</pub-id><pub-id pub-id-type="pmid">28040515</pub-id>
</element-citation></ref><ref id="B126-vaccines-13-00126"><label>126.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chen</surname><given-names>N.</given-names></name>
<name><surname>Zheng</surname><given-names>Y.</given-names></name>
<name><surname>Yin</surname><given-names>J.</given-names></name>
<name><surname>Li</surname><given-names>X.</given-names></name>
<name><surname>Zheng</surname><given-names>C.</given-names></name>
</person-group><article-title>Inhibitory effects of silver nanoparticles against adenovirus type 3 in vitro</article-title><source>J. Virol. Methods</source><year>2013</year><volume>193</volume><fpage>470</fpage><lpage>477</lpage><pub-id pub-id-type="doi">10.1016/j.jviromet.2013.07.020</pub-id><pub-id pub-id-type="pmid">23886562</pub-id>
</element-citation></ref><ref id="B127-vaccines-13-00126"><label>127.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sanchez-Villamil</surname><given-names>J.I.</given-names></name>
<name><surname>Tapia</surname><given-names>D.</given-names></name>
<name><surname>Torres</surname><given-names>A.G.</given-names></name>
</person-group><article-title>Development of a gold nanoparticle vaccine against enterohemorrhagic <italic toggle="yes">Escherichia coli</italic> O157: H7</article-title><source>mBio</source><year>2019</year><volume>10</volume><pub-id pub-id-type="doi">10.1128/mBio.01869-19</pub-id><pub-id pub-id-type="pmid">31409688</pub-id>
</element-citation></ref><ref id="B128-vaccines-13-00126"><label>128.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chen</surname><given-names>Y.-N.</given-names></name>
<name><surname>Hsueh</surname><given-names>Y.-H.</given-names></name>
<name><surname>Hsieh</surname><given-names>C.-T.</given-names></name>
<name><surname>Tzou</surname><given-names>D.-Y.</given-names></name>
<name><surname>Chang</surname><given-names>P.-L.</given-names></name>
</person-group><article-title>Antiviral activity of graphene&#x02013;silver nanocomposites against non-enveloped and enveloped viruses</article-title><source>Int. J. Environ. Res. Public Health</source><year>2016</year><volume>13</volume><elocation-id>430</elocation-id><pub-id pub-id-type="doi">10.3390/ijerph13040430</pub-id><pub-id pub-id-type="pmid">27104546</pub-id>
</element-citation></ref><ref id="B129-vaccines-13-00126"><label>129.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chen</surname><given-names>P.</given-names></name>
<name><surname>Wu</surname><given-names>Z.</given-names></name>
<name><surname>Leung</surname><given-names>A.</given-names></name>
<name><surname>Chen</surname><given-names>X.</given-names></name>
<name><surname>Landao-Bassonga</surname><given-names>E.</given-names></name>
<name><surname>Gao</surname><given-names>J.</given-names></name>
<name><surname>Chen</surname><given-names>L.</given-names></name>
<name><surname>Zheng</surname><given-names>M.</given-names></name>
<name><surname>Yao</surname><given-names>F.</given-names></name>
<name><surname>Yang</surname><given-names>H.</given-names></name>
</person-group><article-title>Fabrication of a silver nanoparticle-coated collagen membrane with anti-bacterial and anti-inflammatory activities for guided bone regeneration</article-title><source>Biomed. Mater.</source><year>2018</year><volume>13</volume><elocation-id>065014</elocation-id><pub-id pub-id-type="doi">10.1088/1748-605X/aae15b</pub-id><pub-id pub-id-type="pmid">30213920</pub-id>
</element-citation></ref><ref id="B130-vaccines-13-00126"><label>130.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Baram-Pinto</surname><given-names>D.</given-names></name>
<name><surname>Shukla</surname><given-names>S.</given-names></name>
<name><surname>Perkas</surname><given-names>N.</given-names></name>
<name><surname>Gedanken</surname><given-names>A.</given-names></name>
<name><surname>Sarid</surname><given-names>R.</given-names></name>
</person-group><article-title>Inhibition of herpes simplex virus type 1 infection by silver nanoparticles capped with mercaptoethane sulfonate</article-title><source>Bioconjugate Chem.</source><year>2009</year><volume>20</volume><fpage>1497</fpage><lpage>1502</lpage><pub-id pub-id-type="doi">10.1021/bc900215b</pub-id></element-citation></ref><ref id="B131-vaccines-13-00126"><label>131.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tiwari</surname><given-names>V.</given-names></name>
<name><surname>Tiwari</surname><given-names>M.</given-names></name>
<name><surname>Solanki</surname><given-names>V.</given-names></name>
</person-group><article-title>Polyvinylpyrrolidone-capped silver nanoparticle inhibits infection of carbapenem-resistant strain of <italic toggle="yes">Acinetobacter baumannii</italic> in the human pulmonary epithelial cell</article-title><source>Front. Immunol.</source><year>2017</year><volume>8</volume><elocation-id>973</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2017.00973</pub-id><pub-id pub-id-type="pmid">28861082</pub-id>
</element-citation></ref><ref id="B132-vaccines-13-00126"><label>132.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Borrego</surname><given-names>B.</given-names></name>
<name><surname>Lorenzo</surname><given-names>G.</given-names></name>
<name><surname>Mota-Morales</surname><given-names>J.D.</given-names></name>
<name><surname>Almanza-Reyes</surname><given-names>H.</given-names></name>
<name><surname>Mateos</surname><given-names>F.</given-names></name>
<name><surname>L&#x000f3;pez-Gil</surname><given-names>E.</given-names></name>
<name><surname>de la Losa</surname><given-names>N.</given-names></name>
<name><surname>Burmistrov</surname><given-names>V.A.</given-names></name>
<name><surname>Pestryakov</surname><given-names>A.N.</given-names></name>
<name><surname>Brun</surname><given-names>A.</given-names></name>
</person-group><article-title>Potential application of silver nanoparticles to control the infectivity of Rift Valley fever virus in vitro and in vivo</article-title><source>Nanomed. Nanotechnol. Biol. Med.</source><year>2016</year><volume>12</volume><fpage>1185</fpage><lpage>1192</lpage><pub-id pub-id-type="doi">10.1016/j.nano.2016.01.021</pub-id><pub-id pub-id-type="pmid">26970026</pub-id>
</element-citation></ref><ref id="B133-vaccines-13-00126"><label>133.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yang</surname><given-names>X.X.</given-names></name>
<name><surname>Li</surname><given-names>C.M.</given-names></name>
<name><surname>Huang</surname><given-names>C.Z.</given-names></name>
</person-group><article-title>Curcumin modified silver nanoparticles for highly efficient inhibition of respiratory syncytial virus infection</article-title><source>Nanoscale</source><year>2016</year><volume>8</volume><fpage>3040</fpage><lpage>3048</lpage><pub-id pub-id-type="doi">10.1039/C5NR07918G</pub-id><pub-id pub-id-type="pmid">26781043</pub-id>
</element-citation></ref><ref id="B134-vaccines-13-00126"><label>134.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pangestika</surname><given-names>R.</given-names></name>
<name><surname>Ernawati</surname><given-names>R.</given-names></name>
</person-group><article-title>Antiviral activity effect of silver nanoparticles (Agnps) solution against the growth of infectious bursal disease virus on embryonated chicken eggs with Elisa test</article-title><source>KnE Life Sci.</source><year>2017</year><volume>3</volume><fpage>536</fpage><lpage>548</lpage><pub-id pub-id-type="doi">10.18502/kls.v3i6.1181</pub-id></element-citation></ref><ref id="B135-vaccines-13-00126"><label>135.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kuppan</surname><given-names>G.</given-names></name>
<name><surname>Sangeeta</surname><given-names>K.</given-names></name>
</person-group><article-title>Dose and Size-Dependent Antiviral Effects of Silver Nanoparticles on Feline Calicivirus, a Human Norovirus Surrogate</article-title><source>Foodborne Pathog Dis.</source><year>2016</year><volume>13</volume><fpage>239</fpage><lpage>244</lpage><pub-id pub-id-type="pmid">26938256</pub-id>
</element-citation></ref><ref id="B136-vaccines-13-00126"><label>136.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Xiang</surname><given-names>D.</given-names></name>
<name><surname>Zheng</surname><given-names>Y.</given-names></name>
<name><surname>Duan</surname><given-names>W.</given-names></name>
<name><surname>Li</surname><given-names>X.</given-names></name>
<name><surname>Yin</surname><given-names>J.</given-names></name>
<name><surname>Shigdar</surname><given-names>S.</given-names></name>
<name><surname>O&#x02019;Connor</surname><given-names>M.L.</given-names></name>
<name><surname>Marappan</surname><given-names>M.</given-names></name>
<name><surname>Zhao</surname><given-names>X.</given-names></name>
<name><surname>Miao</surname><given-names>Y.</given-names></name>
</person-group><article-title>Inhibition of A/Human/Hubei/3/2005 (H3N2) influenza virus infection by silver nanoparticles in vitro and in vivo</article-title><source>Int. J. Nanomed.</source><year>2013</year><volume>8</volume><fpage>4103</fpage><lpage>4114</lpage><pub-id pub-id-type="doi">10.2147/IJN.S53622</pub-id></element-citation></ref><ref id="B137-vaccines-13-00126"><label>137.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Folliero</surname><given-names>V.</given-names></name>
<name><surname>Zannella</surname><given-names>C.</given-names></name>
<name><surname>Chianese</surname><given-names>A.</given-names></name>
<name><surname>Stelitano</surname><given-names>D.</given-names></name>
<name><surname>Ambrosino</surname><given-names>A.</given-names></name>
<name><surname>De Filippis</surname><given-names>A.</given-names></name>
<name><surname>Galdiero</surname><given-names>M.</given-names></name>
<name><surname>Franci</surname><given-names>G.</given-names></name>
<name><surname>Galdiero</surname><given-names>M.</given-names></name>
</person-group><article-title>Application of dendrimers for treating parasitic diseases</article-title><source>Pharmaceutics</source><year>2021</year><volume>13</volume><elocation-id>343</elocation-id><pub-id pub-id-type="doi">10.3390/pharmaceutics13030343</pub-id><pub-id pub-id-type="pmid">33808016</pub-id>
</element-citation></ref><ref id="B138-vaccines-13-00126"><label>138.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>El Bissati</surname><given-names>K.</given-names></name>
<name><surname>Zhou</surname><given-names>Y.</given-names></name>
<name><surname>Paulillo</surname><given-names>S.M.</given-names></name>
<name><surname>Raman</surname><given-names>S.K.</given-names></name>
<name><surname>Karch</surname><given-names>C.P.</given-names></name>
<name><surname>Roberts</surname><given-names>C.W.</given-names></name>
<name><surname>Lanar</surname><given-names>D.E.</given-names></name>
<name><surname>Reed</surname><given-names>S.</given-names></name>
<name><surname>Fox</surname><given-names>C.</given-names></name>
<name><surname>Carter</surname><given-names>D.</given-names></name>
</person-group><article-title>Protein nanovaccine confers robust immunity against Toxoplasma</article-title><source>npj Vaccines</source><year>2017</year><volume>2</volume><fpage>24</fpage><pub-id pub-id-type="doi">10.1038/s41541-017-0024-6</pub-id><pub-id pub-id-type="pmid">29263879</pub-id>
</element-citation></ref><ref id="B139-vaccines-13-00126"><label>139.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kwon</surname><given-names>E.J.</given-names></name>
<name><surname>Skalak</surname><given-names>M.</given-names></name>
<name><surname>Bertucci</surname><given-names>A.</given-names></name>
<name><surname>Braun</surname><given-names>G.</given-names></name>
<name><surname>Ricci</surname><given-names>F.</given-names></name>
<name><surname>Ruoslahti</surname><given-names>E.</given-names></name>
<name><surname>Sailor</surname><given-names>M.J.</given-names></name>
<name><surname>Bhatia</surname><given-names>S.N.</given-names></name>
</person-group><article-title>Porous silicon nanoparticle delivery of tandem peptide anti-infectives for the treatment of Pseudomonas aeruginosa lung infections</article-title><source>Adv. Mater.</source><year>2017</year><volume>29</volume><fpage>1701527</fpage><pub-id pub-id-type="doi">10.1002/adma.201701527</pub-id></element-citation></ref><ref id="B140-vaccines-13-00126"><label>140.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gowri</surname><given-names>M.</given-names></name>
<name><surname>Latha</surname><given-names>N.</given-names></name>
<name><surname>Suganya</surname><given-names>K.</given-names></name>
<name><surname>Murugan</surname><given-names>M.</given-names></name>
<name><surname>Rajan</surname><given-names>M.</given-names></name>
</person-group><article-title>Calcium alginate nanoparticle crosslinked phosphorylated polyallylamine to the controlled release of clindamycin for osteomyelitis treatment</article-title><source>Drug Dev. Ind. Pharm.</source><year>2021</year><volume>47</volume><fpage>280</fpage><lpage>291</lpage><pub-id pub-id-type="doi">10.1080/03639045.2021.1879835</pub-id><pub-id pub-id-type="pmid">33493022</pub-id>
</element-citation></ref><ref id="B141-vaccines-13-00126"><label>141.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wang</surname><given-names>L.</given-names></name>
<name><surname>Xing</surname><given-names>D.</given-names></name>
<name><surname>Le Van</surname><given-names>A.</given-names></name>
<name><surname>Jerse</surname><given-names>A.E.</given-names></name>
<name><surname>Wang</surname><given-names>S.</given-names></name>
</person-group><article-title>Structure-based design of ferritin nanoparticle immunogens displaying antigenic loops of <italic toggle="yes">Neisseria gonorrhoeae</italic></article-title><source>FEBS Open Bio</source><year>2017</year><volume>7</volume><fpage>1196</fpage><lpage>1207</lpage><pub-id pub-id-type="doi">10.1002/2211-5463.12267</pub-id><pub-id pub-id-type="pmid">28781959</pub-id>
</element-citation></ref><ref id="B142-vaccines-13-00126"><label>142.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lemke</surname><given-names>A.</given-names></name>
<name><surname>Kiderlen</surname><given-names>A.F.</given-names></name>
<name><surname>Petri</surname><given-names>B.</given-names></name>
<name><surname>Kayser</surname><given-names>O.</given-names></name>
</person-group><article-title>Delivery of amphotericin B nanosuspensions to the brain and determination of activity against <italic toggle="yes">Balamuthia mandrillaris amebas</italic></article-title><source>Nanomed. Nanotechnol. Biol. Med.</source><year>2010</year><volume>6</volume><fpage>597</fpage><lpage>603</lpage><pub-id pub-id-type="doi">10.1016/j.nano.2009.12.004</pub-id></element-citation></ref><ref id="B143-vaccines-13-00126"><label>143.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhong</surname><given-names>J.</given-names></name>
<name><surname>Xia</surname><given-names>Y.</given-names></name>
<name><surname>Hua</surname><given-names>L.</given-names></name>
<name><surname>Liu</surname><given-names>X.</given-names></name>
<name><surname>Xiao</surname><given-names>M.</given-names></name>
<name><surname>Xu</surname><given-names>T.</given-names></name>
<name><surname>Zhu</surname><given-names>B.</given-names></name>
<name><surname>Cao</surname><given-names>H.</given-names></name>
</person-group><article-title>Functionalized selenium nanoparticles enhance the anti-EV71 activity of oseltamivir in human astrocytoma cell model</article-title><source>Artif. Cells Nanomed. Biotechnol.</source><year>2019</year><volume>47</volume><fpage>3485</fpage><lpage>3491</lpage><pub-id pub-id-type="doi">10.1080/21691401.2019.1640716</pub-id><pub-id pub-id-type="pmid">31422717</pub-id>
</element-citation></ref><ref id="B144-vaccines-13-00126"><label>144.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Thi</surname><given-names>E.P.</given-names></name>
<name><surname>Mire</surname><given-names>C.E.</given-names></name>
<name><surname>Lee</surname><given-names>A.C.</given-names></name>
<name><surname>Geisbert</surname><given-names>J.B.</given-names></name>
<name><surname>Zhou</surname><given-names>J.Z.</given-names></name>
<name><surname>Agans</surname><given-names>K.N.</given-names></name>
<name><surname>Snead</surname><given-names>N.M.</given-names></name>
<name><surname>Deer</surname><given-names>D.J.</given-names></name>
<name><surname>Barnard</surname><given-names>T.R.</given-names></name>
<name><surname>Fenton</surname><given-names>K.A.</given-names></name>
</person-group><article-title>Lipid nanoparticle siRNA treatment of Ebola-virus-Makona-infected nonhuman primates</article-title><source>Nature</source><year>2015</year><volume>521</volume><fpage>362</fpage><lpage>365</lpage><pub-id pub-id-type="doi">10.1038/nature14442</pub-id><pub-id pub-id-type="pmid">25901685</pub-id>
</element-citation></ref><ref id="B145-vaccines-13-00126"><label>145.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lauster</surname><given-names>D.</given-names></name>
<name><surname>Glanz</surname><given-names>M.</given-names></name>
<name><surname>Bardua</surname><given-names>M.</given-names></name>
<name><surname>Ludwig</surname><given-names>K.</given-names></name>
<name><surname>Hellmund</surname><given-names>M.</given-names></name>
<name><surname>Hoffmann</surname><given-names>U.</given-names></name>
<name><surname>Hamann</surname><given-names>A.</given-names></name>
<name><surname>B&#x000f6;ttcher</surname><given-names>C.</given-names></name>
<name><surname>Haag</surname><given-names>R.</given-names></name>
<name><surname>Hackenberger</surname><given-names>C.P.</given-names></name>
</person-group><article-title>Multivalent peptide&#x02013;nanoparticle conjugates for influenza-virus inhibition</article-title><source>Angew. Chem. Int. Ed.</source><year>2017</year><volume>56</volume><fpage>5931</fpage><lpage>5936</lpage><pub-id pub-id-type="doi">10.1002/anie.201702005</pub-id></element-citation></ref><ref id="B146-vaccines-13-00126"><label>146.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rodrigues-Jesus</surname><given-names>M.</given-names></name>
<name><surname>Fotoran</surname><given-names>W.L.</given-names></name>
<name><surname>Cardoso</surname><given-names>R.M.</given-names></name>
<name><surname>Araki</surname><given-names>K.</given-names></name>
<name><surname>Wunderlich</surname><given-names>G.</given-names></name>
<name><surname>Ferreira</surname><given-names>L.C.</given-names></name>
</person-group><article-title>Nano-multilamellar lipid vesicles (NMVs) enhance protective antibody responses against Shiga toxin (Stx2a) produced by enterohemorrhagic <italic toggle="yes">Escherichia coli</italic> strains (EHEC)</article-title><source>Braz. J. Microbiol.</source><year>2019</year><volume>50</volume><fpage>67</fpage><lpage>77</lpage><pub-id pub-id-type="doi">10.1007/s42770-018-0035-0</pub-id><pub-id pub-id-type="pmid">30637647</pub-id>
</element-citation></ref><ref id="B147-vaccines-13-00126"><label>147.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhang</surname><given-names>B.</given-names></name>
<name><surname>Cavallaro</surname><given-names>A.S.</given-names></name>
<name><surname>Mody</surname><given-names>K.T.</given-names></name>
<name><surname>Zhang</surname><given-names>J.</given-names></name>
<name><surname>Deringer</surname><given-names>J.R.</given-names></name>
<name><surname>Brown</surname><given-names>W.C.</given-names></name>
<name><surname>Mahony</surname><given-names>T.J.</given-names></name>
<name><surname>Yu</surname><given-names>C.</given-names></name>
<name><surname>Mitter</surname><given-names>N.</given-names></name>
</person-group><article-title>Nanoparticle-based delivery of <italic toggle="yes">Anaplasma marginale</italic> membrane proteins; virb9-1 and virb10 produced in the <italic toggle="yes">Pichia pastoris</italic> expression system</article-title><source>Nanomaterials</source><year>2016</year><volume>6</volume><elocation-id>201</elocation-id><pub-id pub-id-type="doi">10.3390/nano6110201</pub-id><pub-id pub-id-type="pmid">28335329</pub-id>
</element-citation></ref><ref id="B148-vaccines-13-00126"><label>148.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rungrojcharoenkit</surname><given-names>K.</given-names></name>
<name><surname>Sunintaboon</surname><given-names>P.</given-names></name>
<name><surname>Ellison</surname><given-names>D.</given-names></name>
<name><surname>Macareo</surname><given-names>L.</given-names></name>
<name><surname>Midoeng</surname><given-names>P.</given-names></name>
<name><surname>Chaisuwirat</surname><given-names>P.</given-names></name>
<name><surname>Fernandez</surname><given-names>S.</given-names></name>
<name><surname>Ubol</surname><given-names>S.</given-names></name>
</person-group><article-title>Development of an adjuvanted nanoparticle vaccine against influenza virus, an in vitro study</article-title><source>PLoS ONE</source><year>2020</year><volume>15</volume><elocation-id>e0237218</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0237218</pub-id><pub-id pub-id-type="pmid">32760143</pub-id>
</element-citation></ref><ref id="B149-vaccines-13-00126"><label>149.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Riehemann</surname><given-names>K.</given-names></name>
<name><surname>Schneider</surname><given-names>S.W.</given-names></name>
<name><surname>Luger</surname><given-names>T.A.</given-names></name>
<name><surname>Godin</surname><given-names>B.</given-names></name>
<name><surname>Ferrari</surname><given-names>M.</given-names></name>
<name><surname>Fuchs</surname><given-names>H.</given-names></name>
</person-group><article-title>Nanomedicine&#x02014;Challenge and perspectives</article-title><source>Angew. Chem. Int. Ed.</source><year>2009</year><volume>48</volume><fpage>872</fpage><lpage>897</lpage><pub-id pub-id-type="doi">10.1002/anie.200802585</pub-id><pub-id pub-id-type="pmid">19142939</pub-id>
</element-citation></ref><ref id="B150-vaccines-13-00126"><label>150.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lung</surname><given-names>P.</given-names></name>
<name><surname>Yang</surname><given-names>J.</given-names></name>
<name><surname>Li</surname><given-names>Q.</given-names></name>
</person-group><article-title>Nanoparticle formulated vaccines: Opportunities and challenges</article-title><source>Nanoscale</source><year>2020</year><volume>12</volume><fpage>5746</fpage><lpage>5763</lpage><pub-id pub-id-type="doi">10.1039/C9NR08958F</pub-id><pub-id pub-id-type="pmid">32124894</pub-id>
</element-citation></ref><ref id="B151-vaccines-13-00126"><label>151.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Verma</surname><given-names>M.</given-names></name>
<name><surname>Ozer</surname><given-names>I.</given-names></name>
<name><surname>Xie</surname><given-names>W.</given-names></name>
<name><surname>Gallagher</surname><given-names>R.</given-names></name>
<name><surname>Teixeira</surname><given-names>A.</given-names></name>
<name><surname>Choy</surname><given-names>M.</given-names></name>
</person-group><article-title>The landscape for lipid-nanoparticle-based genomic medicines</article-title><source>Nat. Rev. Drug Discov.</source><year>2023</year><volume>22</volume><fpage>349</fpage><lpage>350</lpage><pub-id pub-id-type="doi">10.1038/d41573-023-00002-2</pub-id><pub-id pub-id-type="pmid">36627441</pub-id>
</element-citation></ref><ref id="B152-vaccines-13-00126"><label>152.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Uddin</surname><given-names>M.N.</given-names></name>
<name><surname>Roni</surname><given-names>M.A.</given-names></name>
</person-group><article-title>Challenges of storage and stability of mRNA-based COVID-19 vaccines</article-title><source>Vaccines</source><year>2021</year><volume>9</volume><elocation-id>1033</elocation-id><pub-id pub-id-type="doi">10.3390/vaccines9091033</pub-id><pub-id pub-id-type="pmid">34579270</pub-id>
</element-citation></ref><ref id="B153-vaccines-13-00126"><label>153.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pal</surname><given-names>K.</given-names></name>
<name><surname>Chakroborty</surname><given-names>S.</given-names></name>
<name><surname>Nath</surname><given-names>N.</given-names></name>
</person-group><article-title>Limitations of nanomaterials insights in green chemistry sustainable route: Review on novel applications</article-title><source>Green Process. Synth.</source><year>2022</year><volume>11</volume><fpage>951</fpage><lpage>964</lpage><pub-id pub-id-type="doi">10.1515/gps-2022-0081</pub-id></element-citation></ref><ref id="B154-vaccines-13-00126"><label>154.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chen</surname><given-names>S.</given-names></name>
<name><surname>Huang</surname><given-names>X.</given-names></name>
<name><surname>Xue</surname><given-names>Y.</given-names></name>
<name><surname>&#x000c1;lvarez-Benedicto</surname><given-names>E.</given-names></name>
<name><surname>Shi</surname><given-names>Y.</given-names></name>
<name><surname>Chen</surname><given-names>W.</given-names></name>
<name><surname>Koo</surname><given-names>S.</given-names></name>
<name><surname>Siegwart</surname><given-names>D.J.</given-names></name>
<name><surname>Dong</surname><given-names>Y.</given-names></name>
<name><surname>Tao</surname><given-names>W.</given-names></name>
</person-group><article-title>Nanotechnology-based mRNA vaccines</article-title><source>Nat. Rev. Methods Primers</source><year>2023</year><volume>3</volume><fpage>63</fpage><pub-id pub-id-type="doi">10.1038/s43586-023-00246-7</pub-id></element-citation></ref><ref id="B155-vaccines-13-00126"><label>155.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Look</surname><given-names>M.</given-names></name>
<name><surname>Bandyopadhyay</surname><given-names>A.</given-names></name>
<name><surname>Blum</surname><given-names>J.S.</given-names></name>
<name><surname>Fahmy</surname><given-names>T.M.</given-names></name>
</person-group><article-title>Application of nanotechnologies for improved immune response against infectious diseases in the developing world</article-title><source>Adv. Drug Deliv. Rev.</source><year>2010</year><volume>62</volume><fpage>378</fpage><lpage>393</lpage><pub-id pub-id-type="doi">10.1016/j.addr.2009.11.011</pub-id><pub-id pub-id-type="pmid">19922750</pub-id>
</element-citation></ref><ref id="B156-vaccines-13-00126"><label>156.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Khan</surname><given-names>I.</given-names></name>
<name><surname>Saeed</surname><given-names>K.</given-names></name>
<name><surname>Khan</surname><given-names>I.</given-names></name>
</person-group><article-title>Nanoparticles: Properties, applications and toxicities</article-title><source>Arab. J. Chem.</source><year>2019</year><volume>12</volume><fpage>908</fpage><lpage>931</lpage><pub-id pub-id-type="doi">10.1016/j.arabjc.2017.05.011</pub-id></element-citation></ref><ref id="B157-vaccines-13-00126"><label>157.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Torchilin</surname><given-names>V.P.</given-names></name>
</person-group><article-title>Recent advances with liposomes as pharmaceutical carriers</article-title><source>Nat. Rev. Drug Discov.</source><year>2005</year><volume>4</volume><fpage>145</fpage><lpage>160</lpage><pub-id pub-id-type="doi">10.1038/nrd1632</pub-id><pub-id pub-id-type="pmid">15688077</pub-id>
</element-citation></ref><ref id="B158-vaccines-13-00126"><label>158.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Helmy</surname><given-names>Y.A.</given-names></name>
<name><surname>Fawzy</surname><given-names>M.</given-names></name>
<name><surname>Elaswad</surname><given-names>A.</given-names></name>
<name><surname>Sobieh</surname><given-names>A.</given-names></name>
<name><surname>Kenney</surname><given-names>S.P.</given-names></name>
<name><surname>Shehata</surname><given-names>A.A.</given-names></name>
</person-group><article-title>The COVID-19 Pandemic: A Comprehensive Review of Taxonomy, Genetics, Epidemiology, Diagnosis, Treatment, and Control</article-title><source>J. Clin. Med.</source><year>2020</year><volume>9</volume><elocation-id>1225</elocation-id><pub-id pub-id-type="doi">10.3390/jcm9041225</pub-id><pub-id pub-id-type="pmid">32344679</pub-id>
</element-citation></ref><ref id="B159-vaccines-13-00126"><label>159.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Heath</surname><given-names>P.T.</given-names></name>
<name><surname>Galiza</surname><given-names>E.P.</given-names></name>
<name><surname>Baxter</surname><given-names>D.N.</given-names></name>
<name><surname>Boffito</surname><given-names>M.</given-names></name>
<name><surname>Browne</surname><given-names>D.</given-names></name>
<name><surname>Burns</surname><given-names>F.</given-names></name>
<name><surname>Chadwick</surname><given-names>D.R.</given-names></name>
<name><surname>Clark</surname><given-names>R.</given-names></name>
<name><surname>Cosgrove</surname><given-names>C.</given-names></name>
<name><surname>Galloway</surname><given-names>J.</given-names></name>
</person-group><article-title>Safety and efficacy of NVX-CoV2373 COVID-19 vaccine</article-title><source>N. Engl. J. Med.</source><year>2021</year><volume>385</volume><fpage>1172</fpage><lpage>1183</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2107659</pub-id><pub-id pub-id-type="pmid">34192426</pub-id>
</element-citation></ref><ref id="B160-vaccines-13-00126"><label>160.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wang</surname><given-names>F.</given-names></name>
<name><surname>Porter</surname><given-names>M.</given-names></name>
<name><surname>Konstantopoulos</surname><given-names>A.</given-names></name>
<name><surname>Zhang</surname><given-names>P.</given-names></name>
<name><surname>Cui</surname><given-names>H.</given-names></name>
</person-group><article-title>Preclinical development of drug delivery systems for paclitaxel-based cancer chemotherapy</article-title><source>J. Control. Release</source><year>2017</year><volume>267</volume><fpage>100</fpage><lpage>118</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2017.09.026</pub-id><pub-id pub-id-type="pmid">28958854</pub-id>
</element-citation></ref><ref id="B161-vaccines-13-00126"><label>161.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Smith</surname><given-names>J.F.</given-names></name>
<name><surname>Brownlow</surname><given-names>M.</given-names></name>
<name><surname>Brown</surname><given-names>M.</given-names></name>
<name><surname>Kowalski</surname><given-names>R.</given-names></name>
<name><surname>Esser</surname><given-names>M.T.</given-names></name>
<name><surname>Ruiz</surname><given-names>W.</given-names></name>
<name><surname>Barr</surname><given-names>E.</given-names></name>
<name><surname>Brown</surname><given-names>D.R.</given-names></name>
<name><surname>Bryan</surname><given-names>J.T.</given-names></name>
</person-group><article-title>Antibodies from women immunized with Gardasil<sup>&#x000ae;</sup> cross-neutralize HPV 45 pseudovirions</article-title><source>Hum. Vaccines</source><year>2007</year><volume>3</volume><fpage>109</fpage><lpage>115</lpage><pub-id pub-id-type="doi">10.4161/hv.3.4.4058</pub-id></element-citation></ref><ref id="B162-vaccines-13-00126"><label>162.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Passero Jr</surname><given-names>F.C.</given-names></name>
<name><surname>Grapsa</surname><given-names>D.</given-names></name>
<name><surname>Syrigos</surname><given-names>K.N.</given-names></name>
<name><surname>Saif</surname><given-names>M.W.</given-names></name>
</person-group><article-title>The safety and efficacy of Onivyde (irinotecan liposome injection) for the treatment of metastatic pancreatic cancer following gemcitabine-based therapy</article-title><source>Expert Rev. Anticancer. Ther.</source><year>2016</year><volume>16</volume><fpage>697</fpage><lpage>703</lpage><pub-id pub-id-type="doi">10.1080/14737140.2016.1192471</pub-id><pub-id pub-id-type="pmid">27219482</pub-id>
</element-citation></ref><ref id="B163-vaccines-13-00126"><label>163.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kantoff</surname><given-names>P.W.</given-names></name>
<name><surname>Higano</surname><given-names>C.S.</given-names></name>
<name><surname>Shore</surname><given-names>N.D.</given-names></name>
<name><surname>Berger</surname><given-names>E.R.</given-names></name>
<name><surname>Small</surname><given-names>E.J.</given-names></name>
<name><surname>Penson</surname><given-names>D.F.</given-names></name>
<name><surname>Redfern</surname><given-names>C.H.</given-names></name>
<name><surname>Ferrari</surname><given-names>A.C.</given-names></name>
<name><surname>Dreicer</surname><given-names>R.</given-names></name>
<name><surname>Sims</surname><given-names>R.B.</given-names></name>
</person-group><article-title>Sipuleucel-T immunotherapy for castration-resistant prostate cancer</article-title><source>N. Engl. J. Med.</source><year>2010</year><volume>363</volume><fpage>411</fpage><lpage>422</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1001294</pub-id><pub-id pub-id-type="pmid">20818862</pub-id>
</element-citation></ref><ref id="B164-vaccines-13-00126"><label>164.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nordquist</surname><given-names>L.T.</given-names></name>
<name><surname>Shore</surname><given-names>N.D.</given-names></name>
<name><surname>Elist</surname><given-names>J.J.</given-names></name>
<name><surname>Oliver</surname><given-names>J.C.</given-names></name>
<name><surname>Gannon</surname><given-names>W.</given-names></name>
<name><surname>Shahlaee</surname><given-names>A.H.</given-names></name>
<name><surname>Fuller</surname><given-names>S.A.</given-names></name>
<name><surname>Ghanbari</surname><given-names>H.A.</given-names></name>
</person-group><article-title>Phase 1 open-label trial to evaluate the safety and immunogenicity of PAN-301-1, a novel nanoparticle therapeutic vaccine, in patients with biochemically relapsed prostate cancer</article-title><source>J. Clin. Oncol.</source><year>2018</year><volume>29</volume><issue>(Suppl. S15)</issue><fpage>e15166</fpage><pub-id pub-id-type="doi">10.1200/JCO.2018.36.15_suppl.e15166</pub-id></element-citation></ref><ref id="B165-vaccines-13-00126"><label>165.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lee</surname><given-names>D.-H.</given-names></name>
<name><surname>Choi</surname><given-names>S.</given-names></name>
<name><surname>Park</surname><given-names>Y.</given-names></name>
<name><surname>Jin</surname><given-names>H.-s.</given-names></name>
</person-group><article-title>Mucin1 and Mucin16: Therapeutic targets for cancer therapy</article-title><source>Pharmaceuticals</source><year>2021</year><volume>14</volume><elocation-id>1053</elocation-id><pub-id pub-id-type="doi">10.3390/ph14101053</pub-id><pub-id pub-id-type="pmid">34681277</pub-id>
</element-citation></ref><ref id="B166-vaccines-13-00126"><label>166.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wicki</surname><given-names>A.</given-names></name>
<name><surname>Witzigmann</surname><given-names>D.</given-names></name>
<name><surname>Balasubramanian</surname><given-names>V.</given-names></name>
<name><surname>Huwyler</surname><given-names>J.</given-names></name>
</person-group><article-title>Nanomedicine in cancer therapy: Challenges, opportunities, and clinical applications</article-title><source>J. Control. Release</source><year>2015</year><volume>200</volume><fpage>138</fpage><lpage>157</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2014.12.030</pub-id><pub-id pub-id-type="pmid">25545217</pub-id>
</element-citation></ref><ref id="B167-vaccines-13-00126"><label>167.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rodr&#x000ed;guez</surname><given-names>F.</given-names></name>
<name><surname>Caruana</surname><given-names>P.</given-names></name>
<name><surname>De la Fuente</surname><given-names>N.</given-names></name>
<name><surname>Espa&#x000f1;ol</surname><given-names>P.</given-names></name>
<name><surname>G&#x000e1;mez</surname><given-names>M.</given-names></name>
<name><surname>Balart</surname><given-names>J.</given-names></name>
<name><surname>Llurba</surname><given-names>E.</given-names></name>
<name><surname>Rovira</surname><given-names>R.</given-names></name>
<name><surname>Ruiz</surname><given-names>R.</given-names></name>
<name><surname>Mart&#x000ed;n-Lorente</surname><given-names>C.</given-names></name>
</person-group><article-title>Nano-based approved pharmaceuticals for cancer treatment: Present and future challenges</article-title><source>Biomolecules</source><year>2022</year><volume>12</volume><elocation-id>784</elocation-id><pub-id pub-id-type="doi">10.3390/biom12060784</pub-id><pub-id pub-id-type="pmid">35740909</pub-id>
</element-citation></ref><ref id="B168-vaccines-13-00126"><label>168.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cech</surname><given-names>P.G.</given-names></name>
<name><surname>Aebi</surname><given-names>T.</given-names></name>
<name><surname>Abdallah</surname><given-names>M.S.</given-names></name>
<name><surname>Mpina</surname><given-names>M.</given-names></name>
<name><surname>Machunda</surname><given-names>E.B.</given-names></name>
<name><surname>Westerfeld</surname><given-names>N.</given-names></name>
<name><surname>Stoffel</surname><given-names>S.A.</given-names></name>
<name><surname>Zurbriggen</surname><given-names>R.</given-names></name>
<name><surname>Pluschke</surname><given-names>G.</given-names></name>
<name><surname>Tanner</surname><given-names>M.</given-names></name>
</person-group><article-title>Virosome-formulated <italic toggle="yes">Plasmodium falciparum</italic> AMA-1 &#x00026; CSP derived peptides as malaria vaccine: Randomized phase 1b trial in semi-immune adults &#x00026; children</article-title><source>PLoS ONE</source><year>2011</year><volume>6</volume><elocation-id>e22273</elocation-id><pub-id pub-id-type="pmid">21799810</pub-id>
</element-citation></ref><ref id="B169-vaccines-13-00126"><label>169.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Porras</surname><given-names>C.</given-names></name>
<name><surname>Sampson</surname><given-names>J.N.</given-names></name>
<name><surname>Herrero</surname><given-names>R.</given-names></name>
<name><surname>Gail</surname><given-names>M.H.</given-names></name>
<name><surname>Cort&#x000e9;s</surname><given-names>B.</given-names></name>
<name><surname>Hildesheim</surname><given-names>A.</given-names></name>
<name><surname>Cyr</surname><given-names>J.</given-names></name>
<name><surname>Romero</surname><given-names>B.</given-names></name>
<name><surname>Schiller</surname><given-names>J.T.</given-names></name>
<name><surname>Montero</surname><given-names>C.</given-names></name>
</person-group><article-title>Rationale and design of a double-blind randomized non-inferiority clinical trial to evaluate one or two doses of vaccine against human papillomavirus including an epidemiologic survey to estimate vaccine efficacy: The Costa Rica ESCUDDO trial</article-title><source>Vaccine</source><year>2022</year><volume>40</volume><fpage>76</fpage><lpage>88</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2021.11.041</pub-id><pub-id pub-id-type="pmid">34857420</pub-id>
</element-citation></ref><ref id="B170-vaccines-13-00126"><label>170.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Topalidou</surname><given-names>X.</given-names></name>
<name><surname>Kalergis</surname><given-names>A.M.</given-names></name>
<name><surname>Papazisis</surname><given-names>G.</given-names></name>
</person-group><article-title>Respiratory syncytial virus vaccines: A review of the candidates and the approved vaccines</article-title><source>Pathogens</source><year>2023</year><volume>12</volume><elocation-id>1259</elocation-id><pub-id pub-id-type="doi">10.3390/pathogens12101259</pub-id><pub-id pub-id-type="pmid">37887775</pub-id>
</element-citation></ref><ref id="B171-vaccines-13-00126"><label>171.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lamb</surname><given-names>Y.N.</given-names></name>
</person-group><article-title>BNT162b2 mRNA COVID-19 vaccine: First approval</article-title><source>Drugs</source><year>2021</year><volume>81</volume><fpage>495</fpage><lpage>501</lpage><pub-id pub-id-type="doi">10.1007/s40265-021-01480-7</pub-id><pub-id pub-id-type="pmid">33683637</pub-id>
</element-citation></ref><ref id="B172-vaccines-13-00126"><label>172.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Bhangde</surname><given-names>S.</given-names></name>
<name><surname>Lodaya</surname><given-names>R.N.</given-names></name>
<name><surname>Amiji</surname><given-names>M.M.</given-names></name>
</person-group><article-title>Nanoscale Vaccines for Influenza</article-title><source>Nanomedicines for the Prevention and Treatment of Infectious Diseases</source><publisher-name>Springer</publisher-name><publisher-loc>Berlin/Heidelberg, Germany</publisher-loc><year>2023</year><fpage>331</fpage><lpage>347</lpage></element-citation></ref><ref id="B173-vaccines-13-00126"><label>173.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Low</surname><given-names>J.G.</given-names></name>
<name><surname>De Alwis</surname><given-names>R.</given-names></name>
<name><surname>Chen</surname><given-names>S.</given-names></name>
<name><surname>Kalimuddin</surname><given-names>S.</given-names></name>
<name><surname>Leong</surname><given-names>Y.S.</given-names></name>
<name><surname>Mah</surname><given-names>T.K.L.</given-names></name>
<name><surname>Yuen</surname><given-names>N.</given-names></name>
<name><surname>Tan</surname><given-names>H.C.</given-names></name>
<name><surname>Zhang</surname><given-names>S.L.</given-names></name>
<name><surname>Sim</surname><given-names>J.X.</given-names></name>
</person-group><article-title>A phase I/II randomized, double-blinded, placebo-controlled trial of a self-amplifying COVID-19 mRNA vaccine</article-title><source>npj Vaccines</source><year>2022</year><volume>7</volume><fpage>161</fpage><pub-id pub-id-type="doi">10.1038/s41541-022-00590-x</pub-id><pub-id pub-id-type="pmid">36513697</pub-id>
</element-citation></ref><ref id="B174-vaccines-13-00126"><label>174.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Al</surname><given-names>L.I.R.</given-names></name>
<name><surname>S&#x000f6;nmezer</surname><given-names>M.&#x000c7;.</given-names></name>
<name><surname>&#x000dc;nal</surname><given-names>S.</given-names></name>
</person-group><article-title>RNA-Based COVID-19 vaccine candidates with clinical phase trials in progress</article-title><source>Turk. J. Med. Sci.</source><year>2021</year><volume>51</volume><fpage>3246</fpage><lpage>3252</lpage><pub-id pub-id-type="pmid">34365779</pub-id>
</element-citation></ref><ref id="B175-vaccines-13-00126"><label>175.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kalnin</surname><given-names>K.V.</given-names></name>
<name><surname>Plitnik</surname><given-names>T.</given-names></name>
<name><surname>Kishko</surname><given-names>M.</given-names></name>
<name><surname>Zhang</surname><given-names>J.</given-names></name>
<name><surname>Zhang</surname><given-names>D.</given-names></name>
<name><surname>Beauvais</surname><given-names>A.</given-names></name>
<name><surname>Anosova</surname><given-names>N.G.</given-names></name>
<name><surname>Tibbitts</surname><given-names>T.</given-names></name>
<name><surname>DiNapoli</surname><given-names>J.</given-names></name>
<name><surname>Ulinski</surname><given-names>G.</given-names></name>
</person-group><article-title>Immunogenicity and efficacy of mRNA COVID-19 vaccine MRT5500 in preclinical animal models</article-title><source>NPJ Vaccines</source><year>2021</year><volume>6</volume><fpage>61</fpage><pub-id pub-id-type="doi">10.1038/s41541-021-00324-5</pub-id><pub-id pub-id-type="pmid">33875658</pub-id>
</element-citation></ref><ref id="B176-vaccines-13-00126"><label>176.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Prompetchara</surname><given-names>E.</given-names></name>
<name><surname>Ketloy</surname><given-names>C.</given-names></name>
<name><surname>Alameh</surname><given-names>M.-G.</given-names></name>
<name><surname>Tharakhet</surname><given-names>K.</given-names></name>
<name><surname>Kaewpang</surname><given-names>P.</given-names></name>
<name><surname>Yostrerat</surname><given-names>N.</given-names></name>
<name><surname>Pitakpolrat</surname><given-names>P.</given-names></name>
<name><surname>Buranapraditkun</surname><given-names>S.</given-names></name>
<name><surname>Manopwisedjaroen</surname><given-names>S.</given-names></name>
<name><surname>Thitithanyanont</surname><given-names>A.</given-names></name>
</person-group><article-title>Immunogenicity and protective efficacy of SARS-CoV-2 mRNA vaccine encoding secreted non-stabilized spike in female mice</article-title><source>Nat. Commun.</source><year>2023</year><volume>14</volume><fpage>2309</fpage><pub-id pub-id-type="doi">10.1038/s41467-023-37795-0</pub-id><pub-id pub-id-type="pmid">37085495</pub-id>
</element-citation></ref><ref id="B177-vaccines-13-00126"><label>177.</label><element-citation publication-type="book"><person-group person-group-type="author">
<collab>World Health Organization</collab>
</person-group><article-title>Emergency use designation of COVID-19 candidate vaccines: Ethical considerations for current and future COVID-19 placebo-controlled vaccine trials and trial unblinding: Policy brief, 18 December 2020</article-title><source>Emergency Use Designation of COVID-19 Candidate Vaccines: Ethical Considerations for Current and Future COVID-19 Placebo-Controlled Vaccine Trials and Trial Unblinding: Policy Brief, 18 December 2020</source><publisher-name>WHO</publisher-name><publisher-loc>Geneva, Switzerland</publisher-loc><year>2020</year></element-citation></ref><ref id="B178-vaccines-13-00126"><label>178.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Shin</surname><given-names>M.D.</given-names></name>
<name><surname>Shukla</surname><given-names>S.</given-names></name>
<name><surname>Chung</surname><given-names>Y.H.</given-names></name>
<name><surname>Beiss</surname><given-names>V.</given-names></name>
<name><surname>Chan</surname><given-names>S.K.</given-names></name>
<name><surname>Ortega-Rivera</surname><given-names>O.A.</given-names></name>
<name><surname>Wirth</surname><given-names>D.M.</given-names></name>
<name><surname>Chen</surname><given-names>A.</given-names></name>
<name><surname>Sack</surname><given-names>M.</given-names></name>
<name><surname>Pokorski</surname><given-names>J.K.</given-names></name>
</person-group><article-title>COVID-19 vaccine development and a potential nanomaterial path forward</article-title><source>Nat. Nanotechnol.</source><year>2020</year><volume>15</volume><fpage>646</fpage><lpage>655</lpage><pub-id pub-id-type="doi">10.1038/s41565-020-0737-y</pub-id><pub-id pub-id-type="pmid">32669664</pub-id>
</element-citation></ref><ref id="B179-vaccines-13-00126"><label>179.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Silva-Pilipich</surname><given-names>N.</given-names></name>
<name><surname>Beloki</surname><given-names>U.</given-names></name>
<name><surname>Salaberry</surname><given-names>L.</given-names></name>
<name><surname>Smerdou</surname><given-names>C.</given-names></name>
</person-group><article-title>Self-Amplifying RNA: A Second Revolution of mRNA Vaccines against COVID-19</article-title><source>Vaccines</source><year>2024</year><volume>12</volume><elocation-id>318</elocation-id><pub-id pub-id-type="doi">10.3390/vaccines12030318</pub-id><pub-id pub-id-type="pmid">38543952</pub-id>
</element-citation></ref><ref id="B180-vaccines-13-00126"><label>180.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rauch</surname><given-names>S.</given-names></name>
<name><surname>Roth</surname><given-names>N.</given-names></name>
<name><surname>Schwendt</surname><given-names>K.</given-names></name>
<name><surname>Fotin-Mleczek</surname><given-names>M.</given-names></name>
<name><surname>Mueller</surname><given-names>S.O.</given-names></name>
<name><surname>Petsch</surname><given-names>B.</given-names></name>
</person-group><article-title>mRNA-based SARS-CoV-2 vaccine candidate CVnCoV induces high levels of virus-neutralising antibodies and mediates protection in rodents</article-title><source>npj Vaccines</source><year>2021</year><volume>6</volume><fpage>57</fpage><pub-id pub-id-type="doi">10.1038/s41541-021-00311-w</pub-id><pub-id pub-id-type="pmid">33863911</pub-id>
</element-citation></ref><ref id="B181-vaccines-13-00126"><label>181.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Moon</surname><given-names>J.J.</given-names></name>
<name><surname>Suh</surname><given-names>H.</given-names></name>
<name><surname>Bershteyn</surname><given-names>A.</given-names></name>
<name><surname>Stephan</surname><given-names>M.T.</given-names></name>
<name><surname>Liu</surname><given-names>H.</given-names></name>
<name><surname>Huang</surname><given-names>B.</given-names></name>
<name><surname>Sohail</surname><given-names>M.</given-names></name>
<name><surname>Luo</surname><given-names>S.</given-names></name>
<name><surname>Ho Um</surname><given-names>S.</given-names></name>
<name><surname>Khant</surname><given-names>H.</given-names></name>
</person-group><article-title>Interbilayer-crosslinked multilamellar vesicles as synthetic vaccines for potent humoral and cellular immune responses</article-title><source>Nat. Mater.</source><year>2011</year><volume>10</volume><fpage>243</fpage><lpage>251</lpage><pub-id pub-id-type="doi">10.1038/nmat2960</pub-id><pub-id pub-id-type="pmid">21336265</pub-id>
</element-citation></ref><ref id="B182-vaccines-13-00126"><label>182.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Moon</surname><given-names>J.J.</given-names></name>
<name><surname>Suh</surname><given-names>H.</given-names></name>
<name><surname>Li</surname><given-names>A.V.</given-names></name>
<name><surname>Ockenhouse</surname><given-names>C.F.</given-names></name>
<name><surname>Yadava</surname><given-names>A.</given-names></name>
<name><surname>Irvine</surname><given-names>D.J.</given-names></name>
</person-group><article-title>Enhancing humoral responses to a malaria antigen with nanoparticle vaccines that expand Tfh cells and promote germinal center induction</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2012</year><volume>109</volume><fpage>1080</fpage><lpage>1085</lpage><pub-id pub-id-type="doi">10.1073/pnas.1112648109</pub-id><pub-id pub-id-type="pmid">22247289</pub-id>
</element-citation></ref><ref id="B183-vaccines-13-00126"><label>183.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Vickers</surname><given-names>K.C.</given-names></name>
<name><surname>Palmisano</surname><given-names>B.T.</given-names></name>
<name><surname>Shoucri</surname><given-names>B.M.</given-names></name>
<name><surname>Shamburek</surname><given-names>R.D.</given-names></name>
<name><surname>Remaley</surname><given-names>A.T.</given-names></name>
</person-group><article-title>MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins</article-title><source>Nat. Cell Biol.</source><year>2011</year><volume>13</volume><fpage>423</fpage><lpage>433</lpage><pub-id pub-id-type="doi">10.1038/ncb2210</pub-id><pub-id pub-id-type="pmid">21423178</pub-id>
</element-citation></ref><ref id="B184-vaccines-13-00126"><label>184.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Moon</surname><given-names>J.J.</given-names></name>
<name><surname>Huang</surname><given-names>B.</given-names></name>
<name><surname>Irvine</surname><given-names>D.J.</given-names></name>
</person-group><article-title>Engineering nano- and microparticles to tune immunity</article-title><source>Adv. Mater.</source><year>2012</year><volume>24</volume><fpage>3724</fpage><lpage>3746</lpage><pub-id pub-id-type="doi">10.1002/adma.201200446</pub-id><pub-id pub-id-type="pmid">22641380</pub-id>
</element-citation></ref><ref id="B185-vaccines-13-00126"><label>185.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chong</surname><given-names>P.</given-names></name>
<name><surname>Huang</surname><given-names>J.-H.</given-names></name>
<name><surname>Leng</surname><given-names>C.-H.</given-names></name>
<name><surname>Liu</surname><given-names>S.-J.</given-names></name>
<name><surname>Chen</surname><given-names>H.-W.</given-names></name>
</person-group><article-title>Recombinant lipoproteins as novel vaccines with intrinsic adjuvant</article-title><source>Adv. Protein Chem. Struct. Biol.</source><year>2015</year><volume>99</volume><fpage>55</fpage><lpage>74</lpage><pub-id pub-id-type="pmid">26067816</pub-id>
</element-citation></ref><ref id="B186-vaccines-13-00126"><label>186.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Waheed</surname><given-names>I.</given-names></name>
<name><surname>Ali</surname><given-names>A.</given-names></name>
<name><surname>Tabassum</surname><given-names>H.</given-names></name>
<name><surname>Khatoon</surname><given-names>N.</given-names></name>
<name><surname>Lai</surname><given-names>W.-F.</given-names></name>
<name><surname>Zhou</surname><given-names>X.</given-names></name>
</person-group><article-title>Lipid-based nanoparticles as drug delivery carriers for cancer therapy</article-title><source>Front. Oncol.</source><year>2024</year><volume>14</volume><elocation-id>1296091</elocation-id><pub-id pub-id-type="doi">10.3389/fonc.2024.1296091</pub-id><pub-id pub-id-type="pmid">38660132</pub-id>
</element-citation></ref><ref id="B187-vaccines-13-00126"><label>187.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>John</surname><given-names>R.</given-names></name>
<name><surname>Monpara</surname><given-names>J.</given-names></name>
<name><surname>Swaminathan</surname><given-names>S.</given-names></name>
<name><surname>Kalhapure</surname><given-names>R.</given-names></name>
</person-group><article-title>Chemistry and art of developing lipid nanoparticles for biologics delivery: Focus on development and scale-up</article-title><source>Pharmaceutics</source><year>2024</year><volume>16</volume><elocation-id>131</elocation-id><pub-id pub-id-type="doi">10.3390/pharmaceutics16010131</pub-id><pub-id pub-id-type="pmid">38276502</pub-id>
</element-citation></ref><ref id="B188-vaccines-13-00126"><label>188.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ndeupen</surname><given-names>S.</given-names></name>
<name><surname>Qin</surname><given-names>Z.</given-names></name>
<name><surname>Jacobsen</surname><given-names>S.</given-names></name>
<name><surname>Bouteau</surname><given-names>A.</given-names></name>
<name><surname>Estanbouli</surname><given-names>H.</given-names></name>
<name><surname>Igy&#x000e1;rt&#x000f3;</surname><given-names>B.Z.</given-names></name>
</person-group><article-title>The mRNA-LNP platform&#x02019;s lipid nanoparticle component used in preclinical vaccine studies is highly inflammatory</article-title><source>iScience</source><year>2021</year><volume>24</volume><fpage>103479</fpage><pub-id pub-id-type="doi">10.1016/j.isci.2021.103479</pub-id><pub-id pub-id-type="pmid">34841223</pub-id>
</element-citation></ref><ref id="B189-vaccines-13-00126"><label>189.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hou</surname><given-names>X.</given-names></name>
<name><surname>Zaks</surname><given-names>T.</given-names></name>
<name><surname>Langer</surname><given-names>R.</given-names></name>
<name><surname>Dong</surname><given-names>Y.</given-names></name>
</person-group><article-title>Lipid nanoparticles for mRNA delivery</article-title><source>Nat. Rev. Mater.</source><year>2021</year><volume>6</volume><fpage>1078</fpage><lpage>1094</lpage><pub-id pub-id-type="doi">10.1038/s41578-021-00358-0</pub-id><pub-id pub-id-type="pmid">34394960</pub-id>
</element-citation></ref><ref id="B190-vaccines-13-00126"><label>190.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Xu</surname><given-names>F.</given-names></name>
<name><surname>Yuan</surname><given-names>Y.</given-names></name>
<name><surname>Wang</surname><given-names>Y.</given-names></name>
<name><surname>Yin</surname><given-names>Q.</given-names></name>
</person-group><article-title>Emerging peptide-based nanovaccines: From design synthesis to defense against cancer and infection</article-title><source>Biomed. Pharmacother.</source><year>2023</year><volume>158</volume><elocation-id>114117</elocation-id><pub-id pub-id-type="doi">10.1016/j.biopha.2022.114117</pub-id><pub-id pub-id-type="pmid">36528914</pub-id>
</element-citation></ref><ref id="B191-vaccines-13-00126"><label>191.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Abdul Ghaffar</surname><given-names>K.</given-names></name>
<name><surname>Kumar Giddam</surname><given-names>A.</given-names></name>
<name><surname>Zaman</surname><given-names>M.</given-names></name>
<name><surname>Skwarczynski</surname><given-names>M.</given-names></name>
<name><surname>Toth</surname><given-names>I.</given-names></name>
</person-group><article-title>Liposomes as nanovaccine delivery systems</article-title><source>Curr. Top. Med. Chem.</source><year>2014</year><volume>14</volume><fpage>1194</fpage><lpage>1208</lpage><pub-id pub-id-type="doi">10.2174/1568026614666140329232757</pub-id><pub-id pub-id-type="pmid">24678703</pub-id>
</element-citation></ref><ref id="B192-vaccines-13-00126"><label>192.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tretiakova</surname><given-names>D.</given-names></name>
<name><surname>Vodovozova</surname><given-names>E.</given-names></name>
</person-group><article-title>Liposomes as adjuvants and vaccine delivery systems</article-title><source>Biochem. (Mosc.) Suppl. Ser. A Membr. Cell Biol.</source><year>2022</year><volume>16</volume><fpage>1</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.1134/S1990747822020076</pub-id><pub-id pub-id-type="pmid">35194485</pub-id>
</element-citation></ref><ref id="B193-vaccines-13-00126"><label>193.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Allison</surname><given-names>A.</given-names></name>
<name><surname>Gregoriadis</surname><given-names>G.</given-names></name>
</person-group><article-title>Liposomes as immunological adjuvants</article-title><source>Nature</source><year>1974</year><volume>252</volume><fpage>252</fpage><pub-id pub-id-type="doi">10.1038/252252a0</pub-id><pub-id pub-id-type="pmid">4424229</pub-id>
</element-citation></ref><ref id="B194-vaccines-13-00126"><label>194.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yanasarn</surname><given-names>N.</given-names></name>
<name><surname>Sloat</surname><given-names>B.R.</given-names></name>
<name><surname>Cui</surname><given-names>Z.</given-names></name>
</person-group><article-title>Negatively charged liposomes show potent adjuvant activity when simply admixed with protein antigens</article-title><source>Mol. Pharm.</source><year>2011</year><volume>8</volume><fpage>1174</fpage><lpage>1185</lpage><pub-id pub-id-type="doi">10.1021/mp200016d</pub-id><pub-id pub-id-type="pmid">21615153</pub-id>
</element-citation></ref><ref id="B195-vaccines-13-00126"><label>195.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hatakeyama</surname><given-names>H.</given-names></name>
<name><surname>Akita</surname><given-names>H.</given-names></name>
<name><surname>Harashima</surname><given-names>H.</given-names></name>
</person-group><article-title>The polyethyleneglycol dilemma: Advantage and disadvantage of PEGylation of liposomes for systemic genes and nucleic acids delivery to tumors</article-title><source>Biol. Pharm. Bull.</source><year>2013</year><volume>36</volume><fpage>892</fpage><lpage>899</lpage><pub-id pub-id-type="doi">10.1248/bpb.b13-00059</pub-id><pub-id pub-id-type="pmid">23727912</pub-id>
</element-citation></ref><ref id="B196-vaccines-13-00126"><label>196.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Shetye</surname><given-names>L.</given-names></name>
<name><surname>Sherlekar</surname><given-names>A.</given-names></name>
<name><surname>Mendhulkar</surname><given-names>V.</given-names></name>
</person-group><article-title>Liposome-Based Drug Delivery&#x02014;A New Therapeutic Paradigm</article-title><source>Advanced Drug Delivery: Methods and Applications</source><publisher-name>Springer</publisher-name><publisher-loc>Berlin/Heidelberg, Germany</publisher-loc><year>2023</year><fpage>21</fpage><lpage>48</lpage></element-citation></ref><ref id="B197-vaccines-13-00126"><label>197.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gordillo-Galeano</surname><given-names>A.</given-names></name>
<name><surname>Mora-Huertas</surname><given-names>C.E.</given-names></name>
</person-group><article-title>Solid lipid nanoparticles and nanostructured lipid carriers: A review emphasizing on particle structure and drug release</article-title><source>Eur. J. Pharm. Biopharm.</source><year>2018</year><volume>133</volume><fpage>285</fpage><lpage>308</lpage><pub-id pub-id-type="doi">10.1016/j.ejpb.2018.10.017</pub-id><pub-id pub-id-type="pmid">30463794</pub-id>
</element-citation></ref><ref id="B198-vaccines-13-00126"><label>198.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pensado</surname><given-names>A.</given-names></name>
<name><surname>Seijo</surname><given-names>B.</given-names></name>
<name><surname>Sanchez</surname><given-names>A.</given-names></name>
</person-group><article-title>Current strategies for DNA therapy based on lipid nanocarriers</article-title><source>Expert Opin. Drug Deliv.</source><year>2014</year><volume>11</volume><fpage>1721</fpage><lpage>1731</lpage><pub-id pub-id-type="doi">10.1517/17425247.2014.935337</pub-id><pub-id pub-id-type="pmid">25046195</pub-id>
</element-citation></ref><ref id="B199-vaccines-13-00126"><label>199.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Peres</surname><given-names>L.B.</given-names></name>
<name><surname>Peres</surname><given-names>L.B.</given-names></name>
<name><surname>de Ara&#x000fa;jo</surname><given-names>P.H.H.</given-names></name>
<name><surname>Sayer</surname><given-names>C.</given-names></name>
</person-group><article-title>Solid lipid nanoparticles for encapsulation of hydrophilic drugs by an organic solvent free double emulsion technique</article-title><source>Colloids Surf. B Biointerfaces</source><year>2016</year><volume>140</volume><fpage>317</fpage><lpage>323</lpage><pub-id pub-id-type="doi">10.1016/j.colsurfb.2015.12.033</pub-id><pub-id pub-id-type="pmid">26764112</pub-id>
</element-citation></ref><ref id="B200-vaccines-13-00126"><label>200.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pandey</surname><given-names>S.</given-names></name>
<name><surname>Shaikh</surname><given-names>F.</given-names></name>
<name><surname>Gupta</surname><given-names>A.</given-names></name>
<name><surname>Tripathi</surname><given-names>P.</given-names></name>
<name><surname>Yadav</surname><given-names>J.S.</given-names></name>
</person-group><article-title>A recent update: Solid lipid nanoparticles for effective drug delivery</article-title><source>Adv. Pharm. Bull.</source><year>2022</year><volume>12</volume><fpage>17</fpage><pub-id pub-id-type="doi">10.34172/apb.2022.007</pub-id><pub-id pub-id-type="pmid">35517874</pub-id>
</element-citation></ref><ref id="B201-vaccines-13-00126"><label>201.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ghasemiyeh</surname><given-names>P.</given-names></name>
<name><surname>Mohammadi-Samani</surname><given-names>S.</given-names></name>
</person-group><article-title>Solid lipid nanoparticles and nanostructured lipid carriers as novel drug delivery systems: Applications, advantages and disadvantages</article-title><source>Res. Pharm. Sci.</source><year>2018</year><volume>13</volume><fpage>288</fpage><lpage>303</lpage><pub-id pub-id-type="pmid">30065762</pub-id>
</element-citation></ref><ref id="B202-vaccines-13-00126"><label>202.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Santos</surname><given-names>P.</given-names></name>
<name><surname>Almeida</surname><given-names>F.</given-names></name>
</person-group><article-title>Exosome-based vaccines: History, current state, and clinical trials</article-title><source>Front. Immunol.</source><year>2021</year><volume>12</volume><elocation-id>711565</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2021.711565</pub-id><pub-id pub-id-type="pmid">34335627</pub-id>
</element-citation></ref><ref id="B203-vaccines-13-00126"><label>203.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hazrati</surname><given-names>A.</given-names></name>
<name><surname>Soudi</surname><given-names>S.</given-names></name>
<name><surname>Malekpour</surname><given-names>K.</given-names></name>
<name><surname>Mahmoudi</surname><given-names>M.</given-names></name>
<name><surname>Rahimi</surname><given-names>A.</given-names></name>
<name><surname>Hashemi</surname><given-names>S.M.</given-names></name>
<name><surname>Varma</surname><given-names>R.S.</given-names></name>
</person-group><article-title>Immune cells-derived exosomes function as a double-edged sword: Role in disease progression and their therapeutic applications</article-title><source>Biomark. Res.</source><year>2022</year><volume>10</volume><elocation-id>30</elocation-id><pub-id pub-id-type="doi">10.1186/s40364-022-00374-4</pub-id><pub-id pub-id-type="pmid">35550636</pub-id>
</element-citation></ref><ref id="B204-vaccines-13-00126"><label>204.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dai</surname><given-names>J.</given-names></name>
<name><surname>Su</surname><given-names>Y.</given-names></name>
<name><surname>Zhong</surname><given-names>S.</given-names></name>
<name><surname>Cong</surname><given-names>L.</given-names></name>
<name><surname>Liu</surname><given-names>B.</given-names></name>
<name><surname>Yang</surname><given-names>J.</given-names></name>
<name><surname>Tao</surname><given-names>Y.</given-names></name>
<name><surname>He</surname><given-names>Z.</given-names></name>
<name><surname>Chen</surname><given-names>C.</given-names></name>
<name><surname>Jiang</surname><given-names>Y.</given-names></name>
</person-group><article-title>Exosomes: Key players in cancer and potential therapeutic strategy</article-title><source>Signal Transduct. Target. Ther.</source><year>2020</year><volume>5</volume><fpage>145</fpage><pub-id pub-id-type="doi">10.1038/s41392-020-00261-0</pub-id><pub-id pub-id-type="pmid">32759948</pub-id>
</element-citation></ref><ref id="B205-vaccines-13-00126"><label>205.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rezabakhsh</surname><given-names>A.</given-names></name>
<name><surname>Mahdipour</surname><given-names>M.</given-names></name>
<name><surname>Nourazarian</surname><given-names>A.</given-names></name>
<name><surname>Habibollahi</surname><given-names>P.</given-names></name>
<name><surname>Sokullu</surname><given-names>E.</given-names></name>
<name><surname>Avci</surname><given-names>&#x000c7;.B.</given-names></name>
<name><surname>Rahbarghazi</surname><given-names>R.</given-names></name>
</person-group><article-title>Application of exosomes for the alleviation of COVID-19-related pathologies</article-title><source>Cell Biochem. Funct.</source><year>2022</year><volume>40</volume><fpage>430</fpage><lpage>438</lpage><pub-id pub-id-type="doi">10.1002/cbf.3720</pub-id><pub-id pub-id-type="pmid">35647674</pub-id>
</element-citation></ref><ref id="B206-vaccines-13-00126"><label>206.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wallis</surname><given-names>J.</given-names></name>
<name><surname>Shenton</surname><given-names>D.</given-names></name>
<name><surname>Carlisle</surname><given-names>R.</given-names></name>
</person-group><article-title>Novel approaches for the design, delivery and administration of vaccine technologies</article-title><source>Clin. Exp. Immunol.</source><year>2019</year><volume>196</volume><fpage>189</fpage><lpage>204</lpage><pub-id pub-id-type="doi">10.1111/cei.13287</pub-id><pub-id pub-id-type="pmid">30963549</pub-id>
</element-citation></ref><ref id="B207-vaccines-13-00126"><label>207.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gl&#x000fc;ck</surname><given-names>R.</given-names></name>
<name><surname>Metcalfe</surname><given-names>I.</given-names></name>
</person-group><article-title>New technology platforms in the development of vaccines for the future</article-title><source>Vaccine</source><year>2002</year><volume>20</volume><fpage>B10</fpage><lpage>B16</lpage><pub-id pub-id-type="doi">10.1016/S0264-410X(02)00513-3</pub-id><pub-id pub-id-type="pmid">12477412</pub-id>
</element-citation></ref><ref id="B208-vaccines-13-00126"><label>208.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>O&#x02019;Hagan</surname><given-names>D.T.</given-names></name>
</person-group><article-title>MF59 is a safe and potent vaccine adjuvant that enhances protection against influenza virus infection</article-title><source>Expert Rev. Vaccines</source><year>2007</year><volume>6</volume><fpage>699</fpage><lpage>710</lpage><pub-id pub-id-type="doi">10.1586/14760584.6.5.699</pub-id><pub-id pub-id-type="pmid">17931151</pub-id>
</element-citation></ref><ref id="B209-vaccines-13-00126"><label>209.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tang</surname><given-names>J.-l.</given-names></name>
<name><surname>Sun</surname><given-names>J.</given-names></name>
<name><surname>He</surname><given-names>Z.-G.</given-names></name>
</person-group><article-title>Self-emulsifying drug delivery systems: Strategy for improving oral delivery of poorly soluble drugs</article-title><source>Curr. Drug Ther.</source><year>2007</year><volume>2</volume><fpage>85</fpage><lpage>93</lpage><pub-id pub-id-type="doi">10.2174/157488507779422400</pub-id></element-citation></ref><ref id="B210-vaccines-13-00126"><label>210.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Akagi</surname><given-names>T.</given-names></name>
<name><surname>Baba</surname><given-names>M.</given-names></name>
<name><surname>Akashi</surname><given-names>M.</given-names></name>
</person-group><article-title>Biodegradable nanoparticles as vaccine adjuvants and delivery systems: Regulation of immune responses by nanoparticle-based vaccine</article-title><source>Polym. Nanomed.</source><year>2012</year><volume>247</volume><fpage>31</fpage><lpage>64</lpage></element-citation></ref><ref id="B211-vaccines-13-00126"><label>211.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Liu</surname><given-names>B.</given-names></name>
<name><surname>Wu</surname><given-names>Z.</given-names></name>
<name><surname>Liu</surname><given-names>T.</given-names></name>
<name><surname>Qian</surname><given-names>R.</given-names></name>
<name><surname>Wu</surname><given-names>T.</given-names></name>
<name><surname>Liu</surname><given-names>Q.</given-names></name>
<name><surname>Shen</surname><given-names>A.</given-names></name>
</person-group><article-title>Polymeric nanoparticles engineered as a vaccine adjuvant-delivery system</article-title><source>Immunization-Vaccine Adjuvant Delivery System and Strategies</source><publisher-name>IntechOpen</publisher-name><publisher-loc>London, UK</publisher-loc><year>2018</year></element-citation></ref><ref id="B212-vaccines-13-00126"><label>212.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Danhier</surname><given-names>F.</given-names></name>
<name><surname>Ansorena</surname><given-names>E.</given-names></name>
<name><surname>Silva</surname><given-names>J.M.</given-names></name>
<name><surname>Coco</surname><given-names>R.</given-names></name>
<name><surname>Le Breton</surname><given-names>A.</given-names></name>
<name><surname>Pr&#x000e9;at</surname><given-names>V.</given-names></name>
</person-group><article-title>PLGA-based nanoparticles: An overview of biomedical applications</article-title><source>J. Control. Release</source><year>2012</year><volume>161</volume><fpage>505</fpage><lpage>522</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2012.01.043</pub-id><pub-id pub-id-type="pmid">22353619</pub-id>
</element-citation></ref><ref id="B213-vaccines-13-00126"><label>213.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Reis</surname><given-names>C.P.</given-names></name>
<name><surname>Neufeld</surname><given-names>R.J.</given-names></name>
<name><surname>Veiga</surname><given-names>F.</given-names></name>
<name><surname>Ribeiro</surname><given-names>A.J.</given-names></name>
</person-group><article-title>Preparation of drug-loaded polymeric nanoparticles</article-title><source>Nanomedicine in Cancer</source><publisher-name>Jenny Stanford Publishing</publisher-name><publisher-loc>Oxon, UK</publisher-loc><year>2017</year><fpage>171</fpage><lpage>214</lpage></element-citation></ref><ref id="B214-vaccines-13-00126"><label>214.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Maji</surname><given-names>I.</given-names></name>
<name><surname>Mahajan</surname><given-names>S.</given-names></name>
<name><surname>Sriram</surname><given-names>A.</given-names></name>
<name><surname>Mehra</surname><given-names>N.K.</given-names></name>
<name><surname>Singh</surname><given-names>P.K.</given-names></name>
</person-group><article-title>Polymeric nanomaterials: Fundamentals and therapeutic applications</article-title><source>Nanomaterial-Based Drug Delivery Systems: Therapeutic and Theranostic Applications</source><publisher-name>Springer</publisher-name><publisher-loc>Berlin/Heidelberg, Germany</publisher-loc><year>2023</year><fpage>33</fpage><lpage>64</lpage></element-citation></ref><ref id="B215-vaccines-13-00126"><label>215.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cano</surname><given-names>A.</given-names></name>
<name><surname>Ettcheto</surname><given-names>M.</given-names></name>
<name><surname>Espina</surname><given-names>M.</given-names></name>
<name><surname>L&#x000f3;pez-Machado</surname><given-names>A.</given-names></name>
<name><surname>Cajal</surname><given-names>Y.</given-names></name>
<name><surname>Rabanal</surname><given-names>F.</given-names></name>
<name><surname>S&#x000e1;nchez-L&#x000f3;pez</surname><given-names>E.</given-names></name>
<name><surname>Camins</surname><given-names>A.</given-names></name>
<name><surname>Garc&#x000ed;a</surname><given-names>M.L.</given-names></name>
<name><surname>Souto</surname><given-names>E.B.</given-names></name>
</person-group><article-title>State-of-the-art polymeric nanoparticles as promising therapeutic tools against human bacterial infections</article-title><source>J. Nanobiotechnology</source><year>2020</year><volume>18</volume><fpage>1</fpage><lpage>24</lpage><pub-id pub-id-type="doi">10.1186/s12951-020-00714-2</pub-id><pub-id pub-id-type="pmid">31898555</pub-id>
</element-citation></ref><ref id="B216-vaccines-13-00126"><label>216.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jin</surname><given-names>Z.</given-names></name>
<name><surname>Gao</surname><given-names>S.</given-names></name>
<name><surname>Cui</surname><given-names>X.</given-names></name>
<name><surname>Sun</surname><given-names>D.</given-names></name>
<name><surname>Zhao</surname><given-names>K.</given-names></name>
</person-group><article-title>Adjuvants and delivery systems based on polymeric nanoparticles for mucosal vaccines</article-title><source>Int. J. Pharm.</source><year>2019</year><volume>572</volume><fpage>118731</fpage><pub-id pub-id-type="doi">10.1016/j.ijpharm.2019.118731</pub-id><pub-id pub-id-type="pmid">31669213</pub-id>
</element-citation></ref><ref id="B217-vaccines-13-00126"><label>217.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Elsabahy</surname><given-names>M.</given-names></name>
<name><surname>Wooley</surname><given-names>K.L.</given-names></name>
</person-group><article-title>Design of polymeric nanoparticles for biomedical delivery applications</article-title><source>Chem. Soc. Rev.</source><year>2012</year><volume>41</volume><fpage>2545</fpage><lpage>2561</lpage><pub-id pub-id-type="doi">10.1039/c2cs15327k</pub-id><pub-id pub-id-type="pmid">22334259</pub-id>
</element-citation></ref><ref id="B218-vaccines-13-00126"><label>218.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cohn</surname><given-names>D.</given-names></name>
<name><surname>Stern</surname><given-names>T.</given-names></name>
<name><surname>Gonz&#x000e1;lez</surname><given-names>M.F.</given-names></name>
<name><surname>Epstein</surname><given-names>J.</given-names></name>
</person-group><article-title>Biodegradable poly(ethylene oxide)/poly(&#x003f5;-caprolactone) multiblock copolymers</article-title><source>J. Biomed. Mater. Res.</source><year>2002</year><volume>59</volume><fpage>273</fpage><lpage>281</lpage><pub-id pub-id-type="doi">10.1002/jbm.1242</pub-id><pub-id pub-id-type="pmid">11745563</pub-id>
</element-citation></ref><ref id="B219-vaccines-13-00126"><label>219.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Khodaverdi</surname><given-names>E.</given-names></name>
<name><surname>Tayarani-Najaran</surname><given-names>Z.</given-names></name>
<name><surname>Minbashi</surname><given-names>E.</given-names></name>
<name><surname>Alibolandi</surname><given-names>M.</given-names></name>
<name><surname>Hosseini</surname><given-names>J.</given-names></name>
<name><surname>Sepahi</surname><given-names>S.</given-names></name>
<name><surname>Kamali</surname><given-names>H.</given-names></name>
<name><surname>Hadizadeh</surname><given-names>F.</given-names></name>
</person-group><article-title>Docetaxel-loaded mixed micelles and polymersomes composed of poly (caprolactone)-poly(ethylene glycol)(PEG-PCL) and poly (lactic acid)-poly (ethylene glycol)(PEG-PLA): Preparation and in-vitro characterization</article-title><source>Iran. J. Pharm. Res. IJPR</source><year>2019</year><volume>18</volume><fpage>142</fpage><pub-id pub-id-type="pmid">31089351</pub-id>
</element-citation></ref><ref id="B220-vaccines-13-00126"><label>220.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tian</surname><given-names>J.-H.</given-names></name>
<name><surname>Patel</surname><given-names>N.</given-names></name>
<name><surname>Haupt</surname><given-names>R.</given-names></name>
<name><surname>Zhou</surname><given-names>H.</given-names></name>
<name><surname>Weston</surname><given-names>S.</given-names></name>
<name><surname>Hammond</surname><given-names>H.</given-names></name>
<name><surname>Logue</surname><given-names>J.</given-names></name>
<name><surname>Portnoff</surname><given-names>A.D.</given-names></name>
<name><surname>Norton</surname><given-names>J.</given-names></name>
<name><surname>Guebre-Xabier</surname><given-names>M.</given-names></name>
</person-group><article-title>SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 immunogenicity in baboons and protection in mice</article-title><source>Nat. Commun.</source><year>2021</year><volume>12</volume><fpage>372</fpage><pub-id pub-id-type="doi">10.1038/s41467-020-20653-8</pub-id><pub-id pub-id-type="pmid">33446655</pub-id>
</element-citation></ref><ref id="B221-vaccines-13-00126"><label>221.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bangaru</surname><given-names>S.</given-names></name>
<name><surname>Ozorowski</surname><given-names>G.</given-names></name>
<name><surname>Turner</surname><given-names>H.L.</given-names></name>
<name><surname>Antanasijevic</surname><given-names>A.</given-names></name>
<name><surname>Huang</surname><given-names>D.</given-names></name>
<name><surname>Wang</surname><given-names>X.</given-names></name>
<name><surname>Torres</surname><given-names>J.L.</given-names></name>
<name><surname>Diedrich</surname><given-names>J.K.</given-names></name>
<name><surname>Tian</surname><given-names>J.-H.</given-names></name>
<name><surname>Portnoff</surname><given-names>A.D.</given-names></name>
</person-group><article-title>Structural analysis of full-length SARS-CoV-2 spike protein from an advanced vaccine candidate</article-title><source>Science</source><year>2020</year><volume>370</volume><fpage>1089</fpage><lpage>1094</lpage><pub-id pub-id-type="doi">10.1126/science.abe1502</pub-id><pub-id pub-id-type="pmid">33082295</pub-id>
</element-citation></ref><ref id="B222-vaccines-13-00126"><label>222.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bivas-Benita</surname><given-names>M.</given-names></name>
<name><surname>van Meijgaarden</surname><given-names>K.E.</given-names></name>
<name><surname>Franken</surname><given-names>K.L.</given-names></name>
<name><surname>Junginger</surname><given-names>H.E.</given-names></name>
<name><surname>Borchard</surname><given-names>G.</given-names></name>
<name><surname>Ottenhoff</surname><given-names>T.H.</given-names></name>
<name><surname>Geluk</surname><given-names>A.</given-names></name>
</person-group><article-title>Pulmonary delivery of chitosan-DNA nanoparticles enhances the immunogenicity of a DNA vaccine encoding HLA-A* 0201-restricted T-cell epitopes of <italic toggle="yes">Mycobacterium tuberculosis</italic></article-title><source>Vaccine</source><year>2004</year><volume>22</volume><fpage>1609</fpage><lpage>1615</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2003.09.044</pub-id><pub-id pub-id-type="pmid">15068842</pub-id>
</element-citation></ref><ref id="B223-vaccines-13-00126"><label>223.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mitchell</surname><given-names>M.J.</given-names></name>
<name><surname>Billingsley</surname><given-names>M.M.</given-names></name>
<name><surname>Haley</surname><given-names>R.M.</given-names></name>
<name><surname>Wechsler</surname><given-names>M.E.</given-names></name>
<name><surname>Peppas</surname><given-names>N.A.</given-names></name>
<name><surname>Langer</surname><given-names>R.</given-names></name>
</person-group><article-title>Engineering precision nanoparticles for drug delivery</article-title><source>Nat. Rev. Drug Discov.</source><year>2021</year><volume>20</volume><fpage>101</fpage><lpage>124</lpage><pub-id pub-id-type="doi">10.1038/s41573-020-0090-8</pub-id><pub-id pub-id-type="pmid">33277608</pub-id>
</element-citation></ref><ref id="B224-vaccines-13-00126"><label>224.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Rezigue</surname><given-names>M.</given-names></name>
</person-group><source>Lipid and Polymeric Nanoparticles: Drug Delivery Applications</source><publisher-name>Springer</publisher-name><publisher-loc>Cham, Switzerland</publisher-loc><year>2020</year><fpage>167</fpage><lpage>230</lpage></element-citation></ref><ref id="B225-vaccines-13-00126"><label>225.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chenthamara</surname><given-names>D.</given-names></name>
<name><surname>Subramaniam</surname><given-names>S.</given-names></name>
<name><surname>Ramakrishnan</surname><given-names>S.G.</given-names></name>
<name><surname>Krishnaswamy</surname><given-names>S.</given-names></name>
<name><surname>Essa</surname><given-names>M.M.</given-names></name>
<name><surname>Lin</surname><given-names>F.-H.</given-names></name>
<name><surname>Qoronfleh</surname><given-names>M.W.</given-names></name>
</person-group><article-title>Therapeutic efficacy of nanoparticles and routes of administration</article-title><source>Biomater. Res.</source><year>2019</year><volume>23</volume><elocation-id>20</elocation-id><pub-id pub-id-type="doi">10.1186/s40824-019-0166-x</pub-id><pub-id pub-id-type="pmid">31832232</pub-id>
</element-citation></ref><ref id="B226-vaccines-13-00126"><label>226.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Elzoghby</surname><given-names>A.</given-names></name>
<name><surname>M Abd-Elwakil</surname><given-names>M.</given-names></name>
<name><surname>Abd-Elsalam</surname><given-names>K.</given-names></name>
<name><surname>T Elsayed</surname><given-names>M.</given-names></name>
<name><surname>Hashem</surname><given-names>Y.</given-names></name>
<name><surname>Mohamed</surname><given-names>O.</given-names></name>
</person-group><article-title>Natural polymeric nanoparticles for brain-targeting: Implications on drug and gene delivery</article-title><source>Curr. Pharm. Des.</source><year>2016</year><volume>22</volume><fpage>3305</fpage><lpage>3323</lpage><pub-id pub-id-type="doi">10.2174/1381612822666160204120829</pub-id><pub-id pub-id-type="pmid">26845323</pub-id>
</element-citation></ref><ref id="B227-vaccines-13-00126"><label>227.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sun</surname><given-names>Z.</given-names></name>
<name><surname>Zhao</surname><given-names>H.</given-names></name>
<name><surname>Ma</surname><given-names>L.</given-names></name>
<name><surname>Shi</surname><given-names>Y.</given-names></name>
<name><surname>Ji</surname><given-names>M.</given-names></name>
<name><surname>Sun</surname><given-names>X.</given-names></name>
<name><surname>Ma</surname><given-names>D.</given-names></name>
<name><surname>Zhou</surname><given-names>W.</given-names></name>
<name><surname>Huang</surname><given-names>T.</given-names></name>
<name><surname>Zhang</surname><given-names>D.</given-names></name>
</person-group><article-title>The quest for nanoparticle-powered vaccines in cancer immunotherapy</article-title><source>J. Nanobiotechnol.</source><year>2024</year><volume>22</volume><elocation-id>61</elocation-id><pub-id pub-id-type="doi">10.1186/s12951-024-02311-z</pub-id><pub-id pub-id-type="pmid">38355548</pub-id>
</element-citation></ref><ref id="B228-vaccines-13-00126"><label>228.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dunkle</surname><given-names>L.M.</given-names></name>
<name><surname>Kotloff</surname><given-names>K.L.</given-names></name>
<name><surname>Gay</surname><given-names>C.L.</given-names></name>
<name><surname>&#x000c1;&#x000f1;ez</surname><given-names>G.</given-names></name>
<name><surname>Adelglass</surname><given-names>J.M.</given-names></name>
<name><surname>Barrat Hern&#x000e1;ndez</surname><given-names>A.Q.</given-names></name>
<name><surname>Harper</surname><given-names>W.L.</given-names></name>
<name><surname>Duncanson</surname><given-names>D.M.</given-names></name>
<name><surname>McArthur</surname><given-names>M.A.</given-names></name>
<name><surname>Florescu</surname><given-names>D.F.</given-names></name>
</person-group><article-title>Efficacy and safety of NVX-CoV2373 in adults in the United States and Mexico</article-title><source>N. Engl. J. Med.</source><year>2022</year><volume>386</volume><fpage>531</fpage><lpage>543</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2116185</pub-id><pub-id pub-id-type="pmid">34910859</pub-id>
</element-citation></ref><ref id="B229-vaccines-13-00126"><label>229.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Vasudevan</surname><given-names>S.S.</given-names></name>
<name><surname>Kandrikar</surname><given-names>T.Y.</given-names></name>
<name><surname>Sayyed</surname><given-names>A.A.</given-names></name>
<name><surname>Sarker</surname><given-names>P.</given-names></name>
<name><surname>Nasir</surname><given-names>N.S.</given-names></name>
<name><surname>Venugopalan</surname><given-names>S.</given-names></name>
<name><surname>Mariajohn</surname><given-names>R.</given-names></name>
<name><surname>Chavda</surname><given-names>V.P.</given-names></name>
<name><surname>Gondaliya</surname><given-names>P.</given-names></name>
</person-group><article-title>Nanoparticle-based vaccines and future vaccine technologies</article-title><source>Advanced Vaccination Technologies for Infectious and Chronic Diseases</source><publisher-name>Elsevier</publisher-name><publisher-loc>Amsterdam, The Netherlands</publisher-loc><year>2024</year><fpage>477</fpage><lpage>495</lpage></element-citation></ref><ref id="B230-vaccines-13-00126"><label>230.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cable</surname><given-names>J.</given-names></name>
<name><surname>Graham</surname><given-names>B.S.</given-names></name>
<name><surname>Koup</surname><given-names>R.A.</given-names></name>
<name><surname>Seder</surname><given-names>R.A.</given-names></name>
<name><surname>Karik&#x000f3;</surname><given-names>K.</given-names></name>
<name><surname>Pardi</surname><given-names>N.</given-names></name>
<name><surname>Barouch</surname><given-names>D.H.</given-names></name>
<name><surname>Sharma</surname><given-names>B.</given-names></name>
<name><surname>Rauch</surname><given-names>S.</given-names></name>
<name><surname>Nachbagauer</surname><given-names>R.</given-names></name>
</person-group><article-title>Progress in vaccine development for infectious diseases&#x02014;A Keystone Symposia report</article-title><source>Ann. N. Y. Acad. Sci.</source><year>2023</year><volume>1524</volume><fpage>65</fpage><lpage>86</lpage><pub-id pub-id-type="doi">10.1111/nyas.14975</pub-id><pub-id pub-id-type="pmid">37020354</pub-id>
</element-citation></ref><ref id="B231-vaccines-13-00126"><label>231.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kasturi</surname><given-names>S.P.</given-names></name>
<name><surname>Skountzou</surname><given-names>I.</given-names></name>
<name><surname>Albrecht</surname><given-names>R.A.</given-names></name>
<name><surname>Koutsonanos</surname><given-names>D.</given-names></name>
<name><surname>Hua</surname><given-names>T.</given-names></name>
<name><surname>Nakaya</surname><given-names>H.I.</given-names></name>
<name><surname>Ravindran</surname><given-names>R.</given-names></name>
<name><surname>Stewart</surname><given-names>S.</given-names></name>
<name><surname>Alam</surname><given-names>M.</given-names></name>
<name><surname>Kwissa</surname><given-names>M.</given-names></name>
</person-group><article-title>Programming the magnitude and persistence of antibody responses with innate immunity</article-title><source>Nature</source><year>2011</year><volume>470</volume><fpage>543</fpage><lpage>547</lpage><pub-id pub-id-type="doi">10.1038/nature09737</pub-id><pub-id pub-id-type="pmid">21350488</pub-id>
</element-citation></ref><ref id="B232-vaccines-13-00126"><label>232.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hess</surname><given-names>K.L.</given-names></name>
<name><surname>Medintz</surname><given-names>I.L.</given-names></name>
<name><surname>Jewell</surname><given-names>C.M.</given-names></name>
</person-group><article-title>Designing inorganic nanomaterials for vaccines and immunotherapies</article-title><source>Nano Today</source><year>2019</year><volume>27</volume><fpage>73</fpage><lpage>98</lpage><pub-id pub-id-type="doi">10.1016/j.nantod.2019.04.005</pub-id><pub-id pub-id-type="pmid">32292488</pub-id>
</element-citation></ref><ref id="B233-vaccines-13-00126"><label>233.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Joseph</surname><given-names>T.M.</given-names></name>
<name><surname>Kar Mahapatra</surname><given-names>D.</given-names></name>
<name><surname>Esmaeili</surname><given-names>A.</given-names></name>
<name><surname>Piszczyk</surname><given-names>&#x00141;.</given-names></name>
<name><surname>Hasanin</surname><given-names>M.S.</given-names></name>
<name><surname>Kattali</surname><given-names>M.</given-names></name>
<name><surname>Haponiuk</surname><given-names>J.</given-names></name>
<name><surname>Thomas</surname><given-names>S.</given-names></name>
</person-group><article-title>Nanoparticles: Taking a unique position in medicine</article-title><source>Nanomaterials</source><year>2023</year><volume>13</volume><elocation-id>574</elocation-id><pub-id pub-id-type="doi">10.3390/nano13030574</pub-id><pub-id pub-id-type="pmid">36770535</pub-id>
</element-citation></ref><ref id="B234-vaccines-13-00126"><label>234.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bansal</surname><given-names>S.A.</given-names></name>
<name><surname>Kumar</surname><given-names>V.</given-names></name>
<name><surname>Karimi</surname><given-names>J.</given-names></name>
<name><surname>Singh</surname><given-names>A.P.</given-names></name>
<name><surname>Kumar</surname><given-names>S.</given-names></name>
</person-group><article-title>Role of gold nanoparticles in advanced biomedical applications</article-title><source>Nanoscale Adv.</source><year>2020</year><volume>2</volume><fpage>3764</fpage><lpage>3787</lpage><pub-id pub-id-type="doi">10.1039/D0NA00472C</pub-id><pub-id pub-id-type="pmid">36132791</pub-id>
</element-citation></ref><ref id="B235-vaccines-13-00126"><label>235.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Amendola</surname><given-names>V.</given-names></name>
<name><surname>Pilot</surname><given-names>R.</given-names></name>
<name><surname>Frasconi</surname><given-names>M.</given-names></name>
<name><surname>Marag&#x000f2;</surname><given-names>O.M.</given-names></name>
<name><surname>Iat&#x000ec;</surname><given-names>M.A.</given-names></name>
</person-group><article-title>Surface plasmon resonance in gold nanoparticles: A review</article-title><source>J. Phys. Condens. Matter</source><year>2017</year><volume>29</volume><fpage>203002</fpage><pub-id pub-id-type="doi">10.1088/1361-648X/aa60f3</pub-id><pub-id pub-id-type="pmid">28426435</pub-id>
</element-citation></ref><ref id="B236-vaccines-13-00126"><label>236.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Gnanaraj</surname><given-names>M.</given-names></name>
<name><surname>Sisubalan</surname><given-names>N.</given-names></name>
<name><surname>Jebastin</surname><given-names>T.</given-names></name>
<name><surname>Vijayan</surname><given-names>A.</given-names></name>
<name><surname>Muneeshwaran</surname><given-names>T.</given-names></name>
<name><surname>Manikandan</surname><given-names>R.</given-names></name>
</person-group><article-title>Gold Nanoparticles as Antibacterial and Antiviral Agents: Biomedical Applications and Theranostic Potential</article-title><source>Nanoparticles in Modern Antimicrobial and Antiviral Applications</source><publisher-name>Springer</publisher-name><publisher-loc>Berlin/Heidelberg, Germany</publisher-loc><year>2024</year><fpage>19</fpage><lpage>45</lpage></element-citation></ref><ref id="B237-vaccines-13-00126"><label>237.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Chaudhary</surname><given-names>K.</given-names></name>
<name><surname>Masram</surname><given-names>D.T.</given-names></name>
</person-group><article-title>Biological activities of nanoparticles and mechanism of action</article-title><source>Model Organisms to Study Biological Activities and Toxicity of Nanoparticles</source><publisher-name>Springer</publisher-name><publisher-loc>Berlin/Heidelberg, Germany</publisher-loc><year>2020</year><fpage>19</fpage><lpage>34</lpage></element-citation></ref><ref id="B238-vaccines-13-00126"><label>238.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chernykh</surname><given-names>I.</given-names></name>
<name><surname>Kopanitsa</surname><given-names>M.</given-names></name>
<name><surname>Shchul&#x02019;kin</surname><given-names>A.</given-names></name>
<name><surname>Yakusheva</surname><given-names>E.</given-names></name>
<name><surname>Frolova</surname><given-names>M.</given-names></name>
</person-group><article-title>Gold nanoparticles as potential antitumor agents</article-title><source>Pharm. Chem. J.</source><year>2021</year><volume>55</volume><fpage>934</fpage><lpage>941</lpage><pub-id pub-id-type="doi">10.1007/s11094-021-02518-6</pub-id></element-citation></ref><ref id="B239-vaccines-13-00126"><label>239.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>He</surname><given-names>J.-s.</given-names></name>
<name><surname>Liu</surname><given-names>S.-j.</given-names></name>
<name><surname>Zhang</surname><given-names>Y.-r.</given-names></name>
<name><surname>Chu</surname><given-names>X.-d.</given-names></name>
<name><surname>Lin</surname><given-names>Z.-b.</given-names></name>
<name><surname>Zhao</surname><given-names>Z.</given-names></name>
<name><surname>Qiu</surname><given-names>S.-h.</given-names></name>
<name><surname>Guo</surname><given-names>Y.-g.</given-names></name>
<name><surname>Ding</surname><given-names>H.</given-names></name>
<name><surname>Pan</surname><given-names>Y.-l.</given-names></name>
</person-group><article-title>The application of and strategy for gold nanoparticles in cancer immunotherapy</article-title><source>Front. Pharmacol.</source><year>2021</year><volume>12</volume><elocation-id>687399</elocation-id><pub-id pub-id-type="doi">10.3389/fphar.2021.687399</pub-id><pub-id pub-id-type="pmid">34163367</pub-id>
</element-citation></ref><ref id="B240-vaccines-13-00126"><label>240.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Farf&#x000e1;n-Castro</surname><given-names>S.</given-names></name>
<name><surname>Garc&#x000ed;a-Soto</surname><given-names>M.J.</given-names></name>
<name><surname>Aguilar-Aguilar</surname><given-names>A.</given-names></name>
<name><surname>Gonz&#x000e1;lez-Ortega</surname><given-names>O.</given-names></name>
<name><surname>Rosales-Mendoza</surname><given-names>S.</given-names></name>
</person-group><article-title>Application of gold nanoparticles in vaccine development</article-title><source>Gold Nanoparticles for Drug Delivery</source><publisher-name>Elsevier</publisher-name><publisher-loc>Amsterdam, The Netherlands</publisher-loc><year>2024</year><fpage>445</fpage><lpage>493</lpage></element-citation></ref><ref id="B241-vaccines-13-00126"><label>241.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Xu</surname><given-names>L.</given-names></name>
<name><surname>Wang</surname><given-names>X.</given-names></name>
<name><surname>Wang</surname><given-names>W.</given-names></name>
<name><surname>Sun</surname><given-names>M.</given-names></name>
<name><surname>Choi</surname><given-names>W.J.</given-names></name>
<name><surname>Kim</surname><given-names>J.-Y.</given-names></name>
<name><surname>Hao</surname><given-names>C.</given-names></name>
<name><surname>Li</surname><given-names>S.</given-names></name>
<name><surname>Qu</surname><given-names>A.</given-names></name>
<name><surname>Lu</surname><given-names>M.</given-names></name>
</person-group><article-title>Enantiomer-dependent immunological response to chiral nanoparticles</article-title><source>Nature</source><year>2022</year><volume>601</volume><fpage>366</fpage><lpage>373</lpage><pub-id pub-id-type="doi">10.1038/s41586-021-04243-2</pub-id><pub-id pub-id-type="pmid">35046606</pub-id>
</element-citation></ref><ref id="B242-vaccines-13-00126"><label>242.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tapia</surname><given-names>D.</given-names></name>
<name><surname>Sanchez-Villamil</surname><given-names>J.I.</given-names></name>
<name><surname>Torres</surname><given-names>A.G.</given-names></name>
</person-group><article-title>Multicomponent gold nano-glycoconjugate as a highly immunogenic and protective platform against <italic toggle="yes">Burkholderia mallei</italic></article-title><source>npj Vaccines</source><year>2020</year><volume>5</volume><fpage>82</fpage><pub-id pub-id-type="doi">10.1038/s41541-020-00229-9</pub-id><pub-id pub-id-type="pmid">32963813</pub-id>
</element-citation></ref><ref id="B243-vaccines-13-00126"><label>243.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gao</surname><given-names>L.</given-names></name>
<name><surname>Song</surname><given-names>Y.</given-names></name>
<name><surname>Zhong</surname><given-names>J.</given-names></name>
<name><surname>Lin</surname><given-names>X.</given-names></name>
<name><surname>Zhou</surname><given-names>S.-F.</given-names></name>
<name><surname>Zhan</surname><given-names>G.</given-names></name>
</person-group><article-title>Biocompatible 2D Cu-TCPP nanosheets derived from Cu<sub>2</sub>O nanocubes as multifunctional nanoplatforms for combined anticancer therapy</article-title><source>ACS Biomater. Sci. Eng.</source><year>2022</year><volume>8</volume><fpage>1074</fpage><lpage>1086</lpage><pub-id pub-id-type="doi">10.1021/acsbiomaterials.1c01430</pub-id><pub-id pub-id-type="pmid">35129963</pub-id>
</element-citation></ref><ref id="B244-vaccines-13-00126"><label>244.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sztandera</surname><given-names>K.</given-names></name>
<name><surname>Gorzkiewicz</surname><given-names>M.</given-names></name>
<name><surname>Klajnert-Maculewicz</surname><given-names>B.</given-names></name>
</person-group><article-title>Gold nanoparticles in cancer treatment</article-title><source>Mol. Pharm.</source><year>2018</year><volume>16</volume><fpage>1</fpage><lpage>23</lpage><pub-id pub-id-type="doi">10.1021/acs.molpharmaceut.8b00810</pub-id><pub-id pub-id-type="pmid">30452861</pub-id>
</element-citation></ref><ref id="B245-vaccines-13-00126"><label>245.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Vines</surname><given-names>J.B.</given-names></name>
<name><surname>Yoon</surname><given-names>J.-H.</given-names></name>
<name><surname>Ryu</surname><given-names>N.-E.</given-names></name>
<name><surname>Lim</surname><given-names>D.-J.</given-names></name>
<name><surname>Park</surname><given-names>H.</given-names></name>
</person-group><article-title>Gold nanoparticles for photothermal cancer therapy</article-title><source>Front. Chem.</source><year>2019</year><volume>7</volume><elocation-id>167</elocation-id><pub-id pub-id-type="doi">10.3389/fchem.2019.00167</pub-id><pub-id pub-id-type="pmid">31024882</pub-id>
</element-citation></ref><ref id="B246-vaccines-13-00126"><label>246.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Singh</surname><given-names>P.</given-names></name>
<name><surname>Mijakovic</surname><given-names>I.</given-names></name>
</person-group><article-title>Advances in gold nanoparticle technology as a tool for diagnostics and treatment of cancer</article-title><source>Expert Rev. Mol. Diagn.</source><year>2021</year><volume>21</volume><fpage>627</fpage><lpage>630</lpage><pub-id pub-id-type="doi">10.1080/14737159.2021.1933447</pub-id><pub-id pub-id-type="pmid">34014787</pub-id>
</element-citation></ref><ref id="B247-vaccines-13-00126"><label>247.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nandanwar</surname><given-names>R.</given-names></name>
<name><surname>Singh</surname><given-names>P.</given-names></name>
<name><surname>Haque</surname><given-names>F.Z.</given-names></name>
</person-group><article-title>Synthesis and properties of silica nanoparticles by sol-gel method for the application in green chemistry</article-title><source>Mater. Sci. Res. India</source><year>2013</year><volume>10</volume><fpage>85</fpage><lpage>92</lpage></element-citation></ref><ref id="B248-vaccines-13-00126"><label>248.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bharti</surname><given-names>C.</given-names></name>
<name><surname>Nagaich</surname><given-names>U.</given-names></name>
<name><surname>Pal</surname><given-names>A.K.</given-names></name>
<name><surname>Gulati</surname><given-names>N.</given-names></name>
</person-group><article-title>Mesoporous silica nanoparticles in target drug delivery system: A review</article-title><source>Int. J. Pharm. Investig.</source><year>2015</year><volume>5</volume><fpage>124</fpage><pub-id pub-id-type="doi">10.4103/2230-973X.160844</pub-id><pub-id pub-id-type="pmid">26258053</pub-id>
</element-citation></ref><ref id="B249-vaccines-13-00126"><label>249.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tang</surname><given-names>F.</given-names></name>
<name><surname>Li</surname><given-names>L.</given-names></name>
<name><surname>Chen</surname><given-names>D.</given-names></name>
</person-group><article-title>Mesoporous silica nanoparticles: Synthesis, biocompatibility and drug delivery</article-title><source>Adv. Mater.</source><year>2012</year><volume>24</volume><fpage>1504</fpage><lpage>1534</lpage><pub-id pub-id-type="doi">10.1002/adma.201104763</pub-id><pub-id pub-id-type="pmid">22378538</pub-id>
</element-citation></ref><ref id="B250-vaccines-13-00126"><label>250.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Scheiblhofer</surname><given-names>S.</given-names></name>
<name><surname>Machado</surname><given-names>Y.</given-names></name>
<name><surname>Feinle</surname><given-names>A.</given-names></name>
<name><surname>Thalhamer</surname><given-names>J.</given-names></name>
<name><surname>H&#x000fc;sing</surname><given-names>N.</given-names></name>
<name><surname>Weiss</surname><given-names>R.</given-names></name>
</person-group><article-title>Potential of nanoparticles for allergen-specific immunotherapy&#x02013;use of silica nanoparticles as vaccination platform</article-title><source>Expert Opin. Drug Deliv.</source><year>2016</year><volume>13</volume><fpage>1777</fpage><lpage>1788</lpage><pub-id pub-id-type="doi">10.1080/17425247.2016.1203898</pub-id><pub-id pub-id-type="pmid">27321476</pub-id>
</element-citation></ref><ref id="B251-vaccines-13-00126"><label>251.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ser&#x000e9;</surname><given-names>S.</given-names></name>
<name><surname>Vounckx</surname><given-names>U.</given-names></name>
<name><surname>Seo</surname><given-names>J.W.</given-names></name>
<name><surname>Lenaerts</surname><given-names>I.</given-names></name>
<name><surname>Van Gool</surname><given-names>S.</given-names></name>
<name><surname>Locquet</surname><given-names>J.-P.</given-names></name>
</person-group><article-title>Proof of concept study: Mesoporous silica nanoparticles, from synthesis to active specific immunotherapy</article-title><source>Front. Nanotechnol.</source><year>2020</year><volume>2</volume><elocation-id>584233</elocation-id><pub-id pub-id-type="doi">10.3389/fnano.2020.584233</pub-id></element-citation></ref><ref id="B252-vaccines-13-00126"><label>252.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Liu</surname><given-names>J.Y.</given-names></name>
<name><surname>Sayes</surname><given-names>C.M.</given-names></name>
</person-group><article-title>A toxicological profile of silica nanoparticles</article-title><source>Toxicol. Res.</source><year>2022</year><volume>11</volume><fpage>565</fpage><lpage>582</lpage><pub-id pub-id-type="doi">10.1093/toxres/tfac038</pub-id></element-citation></ref><ref id="B253-vaccines-13-00126"><label>253.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pallavi</surname><given-names>P.</given-names></name>
<name><surname>Harini</surname><given-names>K.</given-names></name>
<name><surname>Alshehri</surname><given-names>S.</given-names></name>
<name><surname>Ghoneim</surname><given-names>M.M.</given-names></name>
<name><surname>Alshlowi</surname><given-names>A.</given-names></name>
<name><surname>Gowtham</surname><given-names>P.</given-names></name>
<name><surname>Girigoswami</surname><given-names>K.</given-names></name>
<name><surname>Shakeel</surname><given-names>F.</given-names></name>
<name><surname>Girigoswami</surname><given-names>A.</given-names></name>
</person-group><article-title>From synthetic route of silica nanoparticles to theranostic applications</article-title><source>Processes</source><year>2022</year><volume>10</volume><elocation-id>2595</elocation-id><pub-id pub-id-type="doi">10.3390/pr10122595</pub-id></element-citation></ref><ref id="B254-vaccines-13-00126"><label>254.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Xiao</surname><given-names>D.</given-names></name>
<name><surname>Qi</surname><given-names>H.</given-names></name>
<name><surname>Teng</surname><given-names>Y.</given-names></name>
<name><surname>Pierre</surname><given-names>D.</given-names></name>
<name><surname>Kutoka</surname><given-names>P.T.</given-names></name>
<name><surname>Liu</surname><given-names>D.</given-names></name>
</person-group><article-title>Advances and challenges of fluorescent nanomaterials for synthesis and biomedical applications</article-title><source>Nanoscale Res. Lett.</source><year>2021</year><volume>16</volume><fpage>1</fpage><lpage>23</lpage><pub-id pub-id-type="doi">10.1186/s11671-021-03613-z</pub-id><pub-id pub-id-type="pmid">33387075</pub-id>
</element-citation></ref><ref id="B255-vaccines-13-00126"><label>255.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nooraei</surname><given-names>S.</given-names></name>
<name><surname>Bahrulolum</surname><given-names>H.</given-names></name>
<name><surname>Hoseini</surname><given-names>Z.S.</given-names></name>
<name><surname>Katalani</surname><given-names>C.</given-names></name>
<name><surname>Hajizade</surname><given-names>A.</given-names></name>
<name><surname>Easton</surname><given-names>A.J.</given-names></name>
<name><surname>Ahmadian</surname><given-names>G.</given-names></name>
</person-group><article-title>Virus-like particles: Preparation, immunogenicity and their roles as nanovaccines and drug nanocarriers</article-title><source>J. Nanobiotechnol.</source><year>2021</year><volume>19</volume><fpage>1</fpage><lpage>27</lpage><pub-id pub-id-type="doi">10.1186/s12951-021-00806-7</pub-id></element-citation></ref><ref id="B256-vaccines-13-00126"><label>256.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Liu</surname><given-names>X.</given-names></name>
<name><surname>Liu</surname><given-names>Y.</given-names></name>
<name><surname>Yang</surname><given-names>X.</given-names></name>
<name><surname>Lu</surname><given-names>X.</given-names></name>
<name><surname>Xu</surname><given-names>X.-N.</given-names></name>
<name><surname>Zhang</surname><given-names>J.</given-names></name>
<name><surname>Chen</surname><given-names>R.</given-names></name>
</person-group><article-title>Potentiating the Immune Responses of HBsAg-VLP Vaccine Using a Polyphosphoester-Based Cationic Polymer Adjuvant</article-title><source>ACS Appl. Mater. Interfaces</source><year>2023</year><volume>15</volume><fpage>48871</fpage><lpage>48881</lpage><pub-id pub-id-type="doi">10.1021/acsami.3c07491</pub-id><pub-id pub-id-type="pmid">37816068</pub-id>
</element-citation></ref><ref id="B257-vaccines-13-00126"><label>257.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gupta</surname><given-names>R.</given-names></name>
<name><surname>Arora</surname><given-names>K.</given-names></name>
<name><surname>Roy</surname><given-names>S.S.</given-names></name>
<name><surname>Joseph</surname><given-names>A.</given-names></name>
<name><surname>Rastogi</surname><given-names>R.</given-names></name>
<name><surname>Arora</surname><given-names>N.M.</given-names></name>
<name><surname>Kundu</surname><given-names>P.K.</given-names></name>
</person-group><article-title>Platforms, advances, and technical challenges in virus-like particles-based vaccines</article-title><source>Front. Immunol.</source><year>2023</year><volume>14</volume><elocation-id>1123805</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2023.1123805</pub-id><pub-id pub-id-type="pmid">36845125</pub-id>
</element-citation></ref><ref id="B258-vaccines-13-00126"><label>258.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Chu</surname><given-names>K.-B.</given-names></name>
<name><surname>Quan</surname><given-names>F.-S.</given-names></name>
</person-group><source>Virus-Like Particle Vaccines Against Respiratory Viruses and Protozoan Parasites</source><publisher-name>Springer</publisher-name><publisher-loc>Berlin/Heidelberg, Germany</publisher-loc><year>2021</year></element-citation></ref><ref id="B259-vaccines-13-00126"><label>259.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Patil</surname><given-names>S.</given-names></name>
</person-group><article-title>A review of virus-like particle-based SARS-CoV-2 vaccines in clinical trial phases</article-title><source>Iran. J. Pharm. Res. IJPR</source><year>2021</year><volume>13</volume><fpage>2901</fpage><lpage>2905</lpage></element-citation></ref><ref id="B260-vaccines-13-00126"><label>260.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Aboshi</surname><given-names>M.</given-names></name>
<name><surname>Matsuda</surname><given-names>K.</given-names></name>
<name><surname>Kawakami</surname><given-names>D.</given-names></name>
<name><surname>Kono</surname><given-names>K.</given-names></name>
<name><surname>Kazami</surname><given-names>Y.</given-names></name>
<name><surname>Sekida</surname><given-names>T.</given-names></name>
<name><surname>Komori</surname><given-names>M.</given-names></name>
<name><surname>Morey</surname><given-names>A.L.</given-names></name>
<name><surname>Suga</surname><given-names>S.</given-names></name>
<name><surname>Smith</surname><given-names>J.F.</given-names></name>
</person-group><article-title>Safety and immunogenicity of VLPCOV-02, a SARS-CoV-2 self-amplifying RNA vaccine with a modified base, 5-methylcytosine</article-title><source>iScience</source><year>2024</year><volume>27</volume><fpage>108964</fpage><pub-id pub-id-type="doi">10.1016/j.isci.2024.108964</pub-id><pub-id pub-id-type="pmid">38352232</pub-id>
</element-citation></ref><ref id="B261-vaccines-13-00126"><label>261.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Polack</surname><given-names>F.P.</given-names></name>
<name><surname>Thomas</surname><given-names>S.J.</given-names></name>
<name><surname>Kitchin</surname><given-names>N.</given-names></name>
<name><surname>Absalon</surname><given-names>J.</given-names></name>
<name><surname>Gurtman</surname><given-names>A.</given-names></name>
<name><surname>Lockhart</surname><given-names>S.</given-names></name>
<name><surname>Perez</surname><given-names>J.L.</given-names></name>
<name><surname>P&#x000e9;rez Marc</surname><given-names>G.</given-names></name>
<name><surname>Moreira</surname><given-names>E.D.</given-names></name>
<name><surname>Zerbini</surname><given-names>C.</given-names></name>
</person-group><article-title>Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine</article-title><source>N. Engl. J. Med.</source><year>2020</year><volume>383</volume><fpage>2603</fpage><lpage>2615</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2034577</pub-id><pub-id pub-id-type="pmid">33301246</pub-id>
</element-citation></ref><ref id="B262-vaccines-13-00126"><label>262.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Vandoolaeghe</surname><given-names>P.</given-names></name>
<name><surname>Schuerman</surname><given-names>L.</given-names></name>
</person-group><article-title>The RTS, S/AS01 malaria vaccine in children 5 to 17 months of age at first vaccination</article-title><source>Expert Rev. Vaccines</source><year>2016</year><volume>15</volume><fpage>1481</fpage><lpage>1493</lpage><pub-id pub-id-type="doi">10.1080/14760584.2016.1236689</pub-id><pub-id pub-id-type="pmid">27841689</pub-id>
</element-citation></ref><ref id="B263-vaccines-13-00126"><label>263.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Syomin</surname><given-names>B.</given-names></name>
<name><surname>Ilyin</surname><given-names>Y.</given-names></name>
</person-group><article-title>Virus-like particles as an instrument of vaccine production</article-title><source>Mol. Biol.</source><year>2019</year><volume>53</volume><fpage>323</fpage><lpage>334</lpage><pub-id pub-id-type="doi">10.1134/S0026893319030154</pub-id><pub-id pub-id-type="pmid">32214478</pub-id>
</element-citation></ref><ref id="B264-vaccines-13-00126"><label>264.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Erdmann</surname><given-names>N.B.</given-names></name>
<name><surname>Williams</surname><given-names>W.B.</given-names></name>
<name><surname>Walsh</surname><given-names>S.R.</given-names></name>
<name><surname>Grunenberg</surname><given-names>N.</given-names></name>
<name><surname>Edlefsen</surname><given-names>P.T.</given-names></name>
<name><surname>Goepfert</surname><given-names>P.A.</given-names></name>
<name><surname>Cain</surname><given-names>D.W.</given-names></name>
<name><surname>Cohen</surname><given-names>K.W.</given-names></name>
<name><surname>Maenza</surname><given-names>J.</given-names></name>
<name><surname>Mayer</surname><given-names>K.H.</given-names></name>
</person-group><article-title>A HIV-1 Gp41 peptide-liposome vaccine elicits neutralizing epitope-targeted antibody responses in healthy individuals</article-title><source>medRxiv</source><year>2024</year><pub-id pub-id-type="doi">10.1101/2024.03.15.24304305</pub-id></element-citation></ref><ref id="B265-vaccines-13-00126"><label>265.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zeigler</surname><given-names>D.F.</given-names></name>
<name><surname>Gage</surname><given-names>E.</given-names></name>
<name><surname>Roque</surname><given-names>R.</given-names></name>
<name><surname>Clegg</surname><given-names>C.H.</given-names></name>
</person-group><article-title>Epitope targeting with self-assembled peptide vaccines</article-title><source>NPJ Vaccines</source><year>2019</year><volume>4</volume><fpage>30</fpage><pub-id pub-id-type="doi">10.1038/s41541-019-0125-5</pub-id><pub-id pub-id-type="pmid">31341647</pub-id>
</element-citation></ref><ref id="B266-vaccines-13-00126"><label>266.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Walls</surname><given-names>A.C.</given-names></name>
<name><surname>Fiala</surname><given-names>B.</given-names></name>
<name><surname>Sch&#x000e4;fer</surname><given-names>A.</given-names></name>
<name><surname>Wrenn</surname><given-names>S.</given-names></name>
<name><surname>Pham</surname><given-names>M.N.</given-names></name>
<name><surname>Murphy</surname><given-names>M.</given-names></name>
<name><surname>Longping</surname><given-names>V.T.</given-names></name>
<name><surname>Shehata</surname><given-names>L.</given-names></name>
<name><surname>O&#x02019;Connor</surname><given-names>M.A.</given-names></name>
<name><surname>Chen</surname><given-names>C.</given-names></name>
</person-group><article-title>Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2</article-title><source>Cell</source><year>2020</year><volume>183</volume><fpage>1367</fpage><lpage>1382.e17</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2020.10.043</pub-id><pub-id pub-id-type="pmid">33160446</pub-id>
</element-citation></ref><ref id="B267-vaccines-13-00126"><label>267.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yang</surname><given-names>J.</given-names></name>
<name><surname>Wang</surname><given-names>W.</given-names></name>
<name><surname>Chen</surname><given-names>Z.</given-names></name>
<name><surname>Lu</surname><given-names>S.</given-names></name>
<name><surname>Yang</surname><given-names>F.</given-names></name>
<name><surname>Bi</surname><given-names>Z.</given-names></name>
<name><surname>Bao</surname><given-names>L.</given-names></name>
<name><surname>Mo</surname><given-names>F.</given-names></name>
<name><surname>Li</surname><given-names>X.</given-names></name>
<name><surname>Huang</surname><given-names>Y.</given-names></name>
</person-group><article-title>A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity</article-title><source>Nature</source><year>2020</year><volume>586</volume><fpage>572</fpage><lpage>577</lpage><pub-id pub-id-type="doi">10.1038/s41586-020-2599-8</pub-id><pub-id pub-id-type="pmid">32726802</pub-id>
</element-citation></ref><ref id="B268-vaccines-13-00126"><label>268.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>L&#x000f3;pez-Sagaseta</surname><given-names>J.</given-names></name>
<name><surname>Malito</surname><given-names>E.</given-names></name>
<name><surname>Rappuoli</surname><given-names>R.</given-names></name>
<name><surname>Bottomley</surname><given-names>M.J.</given-names></name>
</person-group><article-title>Self-assembling protein nanoparticles in the design of vaccines</article-title><source>Comput. Struct. Biotechnol. J.</source><year>2016</year><volume>14</volume><fpage>58</fpage><lpage>68</lpage><pub-id pub-id-type="doi">10.1016/j.csbj.2015.11.001</pub-id><pub-id pub-id-type="pmid">26862374</pub-id>
</element-citation></ref><ref id="B269-vaccines-13-00126"><label>269.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhao</surname><given-names>L.</given-names></name>
<name><surname>Seth</surname><given-names>A.</given-names></name>
<name><surname>Wibowo</surname><given-names>N.</given-names></name>
<name><surname>Zhao</surname><given-names>C.-X.</given-names></name>
<name><surname>Mitter</surname><given-names>N.</given-names></name>
<name><surname>Yu</surname><given-names>C.</given-names></name>
<name><surname>Middelberg</surname><given-names>A.P.</given-names></name>
</person-group><article-title>Nanoparticle vaccines</article-title><source>Vaccine</source><year>2014</year><volume>32</volume><fpage>327</fpage><lpage>337</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2013.11.069</pub-id><pub-id pub-id-type="pmid">24295808</pub-id>
</element-citation></ref><ref id="B270-vaccines-13-00126"><label>270.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bagheri-Josheghani</surname><given-names>S.</given-names></name>
<name><surname>Bakhshi</surname><given-names>B.</given-names></name>
<name><surname>Najar-peerayeh</surname><given-names>S.</given-names></name>
</person-group><article-title>The influence of nanoparticle on vaccine responses against bacterial infection</article-title><source>J. Nanotechnol.</source><year>2022</year><volume>2022</volume><fpage>6856982</fpage><pub-id pub-id-type="doi">10.1155/2022/6856982</pub-id></element-citation></ref><ref id="B271-vaccines-13-00126"><label>271.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chang</surname><given-names>H.C.</given-names></name>
<name><surname>Zou</surname><given-names>Z.Z.</given-names></name>
<name><surname>Wang</surname><given-names>Q.H.</given-names></name>
<name><surname>Li</surname><given-names>J.</given-names></name>
<name><surname>Jin</surname><given-names>H.</given-names></name>
<name><surname>Yin</surname><given-names>Q.X.</given-names></name>
<name><surname>Xing</surname><given-names>D.</given-names></name>
</person-group><article-title>Targeting and specific activation of antigen--presenting cells by endogenous antigen-loaded nanoparticles elicits tumor-specific immunity</article-title><source>Adv. Sci.</source><year>2020</year><volume>7</volume><fpage>1900069</fpage><pub-id pub-id-type="doi">10.1002/advs.201900069</pub-id><pub-id pub-id-type="pmid">31921548</pub-id>
</element-citation></ref><ref id="B272-vaccines-13-00126"><label>272.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gamucci</surname><given-names>O.</given-names></name>
<name><surname>Bertero</surname><given-names>A.</given-names></name>
<name><surname>Gagliardi</surname><given-names>M.</given-names></name>
<name><surname>Bardi</surname><given-names>G.</given-names></name>
</person-group><article-title>Biomedical nanoparticles: Overview of their surface immune-compatibility</article-title><source>Coatings</source><year>2014</year><volume>4</volume><fpage>139</fpage><lpage>159</lpage><pub-id pub-id-type="doi">10.3390/coatings4010139</pub-id></element-citation></ref><ref id="B273-vaccines-13-00126"><label>273.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zaman</surname><given-names>M.</given-names></name>
<name><surname>Good</surname><given-names>M.F.</given-names></name>
<name><surname>Toth</surname><given-names>I.</given-names></name>
</person-group><article-title>Nanovaccines and their mode of action</article-title><source>Methods</source><year>2013</year><volume>60</volume><fpage>226</fpage><lpage>231</lpage><pub-id pub-id-type="doi">10.1016/j.ymeth.2013.04.014</pub-id><pub-id pub-id-type="pmid">23623821</pub-id>
</element-citation></ref><ref id="B274-vaccines-13-00126"><label>274.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lin</surname><given-names>Y.</given-names></name>
<name><surname>Chen</surname><given-names>X.</given-names></name>
<name><surname>Wang</surname><given-names>K.</given-names></name>
<name><surname>Liang</surname><given-names>L.</given-names></name>
<name><surname>Zhang</surname><given-names>H.</given-names></name>
</person-group><article-title>An Overview of Nanoparticle-Based Delivery Platforms for mRNA Vaccines for Treating Cancer</article-title><source>Vaccines</source><year>2024</year><volume>12</volume><elocation-id>727</elocation-id><pub-id pub-id-type="doi">10.3390/vaccines12070727</pub-id><pub-id pub-id-type="pmid">39066365</pub-id>
</element-citation></ref><ref id="B275-vaccines-13-00126"><label>275.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Oberli</surname><given-names>M.A.</given-names></name>
<name><surname>Reichmuth</surname><given-names>A.M.</given-names></name>
<name><surname>Dorkin</surname><given-names>J.R.</given-names></name>
<name><surname>Mitchell</surname><given-names>M.J.</given-names></name>
<name><surname>Fenton</surname><given-names>O.S.</given-names></name>
<name><surname>Jaklenec</surname><given-names>A.</given-names></name>
<name><surname>Anderson</surname><given-names>D.G.</given-names></name>
<name><surname>Langer</surname><given-names>R.</given-names></name>
<name><surname>Blankschtein</surname><given-names>D.</given-names></name>
</person-group><article-title>Lipid nanoparticle assisted mRNA delivery for potent cancer immunotherapy</article-title><source>Nano Lett.</source><year>2017</year><volume>17</volume><fpage>1326</fpage><lpage>1335</lpage><pub-id pub-id-type="doi">10.1021/acs.nanolett.6b03329</pub-id><pub-id pub-id-type="pmid">28273716</pub-id>
</element-citation></ref><ref id="B276-vaccines-13-00126"><label>276.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pardi</surname><given-names>N.</given-names></name>
<name><surname>Hogan</surname><given-names>M.J.</given-names></name>
<name><surname>Porter</surname><given-names>F.W.</given-names></name>
<name><surname>Weissman</surname><given-names>D.</given-names></name>
</person-group><article-title>mRNA vaccines&#x02014;A new era in vaccinology</article-title><source>Nat. Rev. Drug Discov.</source><year>2018</year><volume>17</volume><fpage>261</fpage><lpage>279</lpage><pub-id pub-id-type="doi">10.1038/nrd.2017.243</pub-id><pub-id pub-id-type="pmid">29326426</pub-id>
</element-citation></ref><ref id="B277-vaccines-13-00126"><label>277.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Han</surname><given-names>Y.</given-names></name>
<name><surname>Renu</surname><given-names>S.</given-names></name>
<name><surname>Patil</surname><given-names>V.</given-names></name>
<name><surname>Schrock</surname><given-names>J.</given-names></name>
<name><surname>Feliciano-Ruiz</surname><given-names>N.</given-names></name>
<name><surname>Selvaraj</surname><given-names>R.</given-names></name>
<name><surname>Renukaradhya</surname><given-names>G.J.</given-names></name>
</person-group><article-title>Mannose-modified chitosan-nanoparticle-based <italic toggle="yes">Salmonella</italic> subunit oralvaccine-induced immune response and efficacy in a challenge trial in broilers</article-title><source>Vaccines</source><year>2020</year><volume>8</volume><elocation-id>299</elocation-id><pub-id pub-id-type="doi">10.3390/vaccines8020299</pub-id><pub-id pub-id-type="pmid">32545295</pub-id>
</element-citation></ref><ref id="B278-vaccines-13-00126"><label>278.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dolatyabi</surname><given-names>S.</given-names></name>
<name><surname>Renu</surname><given-names>S.</given-names></name>
<name><surname>Schrock</surname><given-names>J.</given-names></name>
<name><surname>Renukaradhya</surname><given-names>G.J.</given-names></name>
</person-group><article-title>Chitosan-nanoparticle-based oral <italic toggle="yes">Salmonella</italic> enteritidis subunit vaccine elicits cross-protection against <italic toggle="yes">Salmonella</italic> typhimurium in broilers</article-title><source>Poult. Sci.</source><year>2024</year><volume>103</volume><fpage>103569</fpage><pub-id pub-id-type="doi">10.1016/j.psj.2024.103569</pub-id><pub-id pub-id-type="pmid">38447310</pub-id>
</element-citation></ref><ref id="B279-vaccines-13-00126"><label>279.</label><element-citation publication-type="webpage"><person-group person-group-type="author">
<name><surname>Tapia</surname><given-names>D.</given-names></name>
</person-group><article-title>Evaluation of a Gold Nanoparticle Platform as Highly Immunogenic and Protective Therapy Against <italic toggle="yes">Burkholderia Mallei</italic>, <italic toggle="yes">B. pseudomallei</italic>, and Enterohemorrhagic <italic toggle="yes">Escherichia coli</italic> O157: H7. Ph.D. Published ETD Collection 2022</article-title><comment>Available online: <ext-link xlink:href="https://hdl.handle.net/2152.3/11436" ext-link-type="uri">https://hdl.handle.net/2152.3/11436</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2025-01-13">(accessed on 13 January 2025)</date-in-citation></element-citation></ref><ref id="B280-vaccines-13-00126"><label>280.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zagaglia</surname><given-names>C.</given-names></name>
<name><surname>Ammendolia</surname><given-names>M.G.</given-names></name>
<name><surname>Maurizi</surname><given-names>L.</given-names></name>
<name><surname>Nicoletti</surname><given-names>M.</given-names></name>
<name><surname>Longhi</surname><given-names>C.</given-names></name>
</person-group><article-title>Urinary tract infections caused by uropathogenic <italic toggle="yes">Escherichia coli</italic> strains&#x02014;New strategies for an old pathogen</article-title><source>Microorganisms</source><year>2022</year><volume>10</volume><elocation-id>1425</elocation-id><pub-id pub-id-type="doi">10.3390/microorganisms10071425</pub-id><pub-id pub-id-type="pmid">35889146</pub-id>
</element-citation></ref><ref id="B281-vaccines-13-00126"><label>281.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wang</surname><given-names>X.</given-names></name>
<name><surname>Gao</surname><given-names>X.</given-names></name>
<name><surname>Wang</surname><given-names>L.</given-names></name>
<name><surname>Lin</surname><given-names>J.</given-names></name>
<name><surname>Liu</surname><given-names>Y.</given-names></name>
</person-group><article-title>Advances of Nanotechnology Toward Vaccine Development Against Animal Infectious Diseases</article-title><source>Adv. Funct. Mater.</source><year>2023</year><volume>33</volume><fpage>2305061</fpage><pub-id pub-id-type="doi">10.1002/adfm.202305061</pub-id></element-citation></ref><ref id="B282-vaccines-13-00126"><label>282.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mat Rani</surname><given-names>N.N.I.</given-names></name>
<name><surname>Alzubaidi</surname><given-names>Z.M.</given-names></name>
<name><surname>Butt</surname><given-names>A.M.</given-names></name>
<name><surname>Mohammad Faizal</surname><given-names>N.D.F.</given-names></name>
<name><surname>Sekar</surname><given-names>M.</given-names></name>
<name><surname>Azhari</surname><given-names>H.</given-names></name>
<name><surname>Mohd Amin</surname><given-names>M.C.I.</given-names></name>
</person-group><article-title>Outer membrane vesicles as biomimetic vaccine carriers against infections and cancers</article-title><source>Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol.</source><year>2022</year><volume>14</volume><elocation-id>e1784</elocation-id><pub-id pub-id-type="doi">10.1002/wnan.1784</pub-id><pub-id pub-id-type="pmid">35194964</pub-id>
</element-citation></ref><ref id="B283-vaccines-13-00126"><label>283.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mawad</surname><given-names>A.</given-names></name>
<name><surname>Helmy</surname><given-names>Y.A.</given-names></name>
<name><surname>Shalkami</surname><given-names>A.-G.</given-names></name>
<name><surname>Kathayat</surname><given-names>D.</given-names></name>
<name><surname>Rajashekara</surname><given-names>G.E.</given-names></name>
</person-group><article-title><italic toggle="yes">coli</italic> Nissle microencapsulation in alginate-chitosan nanoparticles and its effect on <italic toggle="yes">Campylobacter jejuni</italic> in vitro</article-title><source>Appl. Microbiol. Biotechnol.</source><year>2018</year><volume>102</volume><fpage>10675</fpage><lpage>10690</lpage><pub-id pub-id-type="doi">10.1007/s00253-018-9417-3</pub-id><pub-id pub-id-type="pmid">30302522</pub-id>
</element-citation></ref><ref id="B284-vaccines-13-00126"><label>284.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Helmy Yosra</surname><given-names>A.</given-names></name>
<name><surname>Closs</surname><given-names>G.</given-names></name>
<name><surname>Jung</surname><given-names>K.</given-names></name>
<name><surname>Kathayat</surname><given-names>D.</given-names></name>
<name><surname>Vlasova</surname><given-names>A.</given-names></name>
<name><surname>Rajashekara</surname><given-names>G.</given-names></name>
</person-group><article-title>Effect of Probiotic <italic toggle="yes">E. coli</italic> Nissle 1917 Supplementation on the Growth Performance, Immune Responses, Intestinal Morphology, and Gut Microbes of Campylobacter jejuni Infected Chickens</article-title><source>Infect. Immun.</source><year>2022</year><volume>90</volume><fpage>e0033722</fpage><pub-id pub-id-type="doi">10.1128/iai.00337-22</pub-id><pub-id pub-id-type="pmid">36135600</pub-id>
</element-citation></ref><ref id="B285-vaccines-13-00126"><label>285.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Oladejo</surname><given-names>M.</given-names></name>
<name><surname>Paterson</surname><given-names>Y.</given-names></name>
<name><surname>Wood</surname><given-names>L.M.</given-names></name>
</person-group><article-title>Clinical experience and recent advances in the development of listeria-based tumor immunotherapies</article-title><source>Front. Immunol.</source><year>2021</year><volume>12</volume><elocation-id>642316</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2021.642316</pub-id><pub-id pub-id-type="pmid">33936058</pub-id>
</element-citation></ref><ref id="B286-vaccines-13-00126"><label>286.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Datta</surname><given-names>M.</given-names></name>
<name><surname>Rajeev</surname><given-names>A.</given-names></name>
<name><surname>Chattopadhyay</surname><given-names>I.</given-names></name>
</person-group><article-title>Application of antimicrobial peptides as next-generation therapeutics in the biomedical world</article-title><source>Biotechnol. Genet. Eng. Rev.</source><year>2023</year><volume>40</volume><fpage>2458</fpage><lpage>2496</lpage><pub-id pub-id-type="doi">10.1080/02648725.2023.2199572</pub-id><pub-id pub-id-type="pmid">37036043</pub-id>
</element-citation></ref><ref id="B287-vaccines-13-00126"><label>287.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yao</surname><given-names>J.</given-names></name>
<name><surname>Chen</surname><given-names>Y.</given-names></name>
<name><surname>Zhang</surname><given-names>L.</given-names></name>
<name><surname>Cheng</surname><given-names>Y.</given-names></name>
<name><surname>Chen</surname><given-names>Z.</given-names></name>
<name><surname>Zhang</surname><given-names>Y.</given-names></name>
<name><surname>Zheng</surname><given-names>X.</given-names></name>
<name><surname>Lv</surname><given-names>Y.</given-names></name>
<name><surname>Wang</surname><given-names>S.</given-names></name>
<name><surname>Li</surname><given-names>Z.</given-names></name>
</person-group><article-title>pH-responsive CuS/DSF/EL/PVP nanoplatform alleviates inflammatory bowel disease in mice via regulating gut immunity and microbiota</article-title><source>Acta Biomater.</source><year>2024</year><volume>178</volume><fpage>265</fpage><lpage>286</lpage><pub-id pub-id-type="doi">10.1016/j.actbio.2024.02.034</pub-id><pub-id pub-id-type="pmid">38417643</pub-id>
</element-citation></ref><ref id="B288-vaccines-13-00126"><label>288.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Patra</surname><given-names>J.K.</given-names></name>
<name><surname>Das</surname><given-names>G.</given-names></name>
<name><surname>Fraceto</surname><given-names>L.F.</given-names></name>
<name><surname>Campos</surname><given-names>E.V.R.</given-names></name>
<name><surname>Rodriguez-Torres</surname><given-names>M.d.P.</given-names></name>
<name><surname>Acosta-Torres</surname><given-names>L.S.</given-names></name>
<name><surname>Diaz-Torres</surname><given-names>L.A.</given-names></name>
<name><surname>Grillo</surname><given-names>R.</given-names></name>
<name><surname>Swamy</surname><given-names>M.K.</given-names></name>
<name><surname>Sharma</surname><given-names>S.</given-names></name>
</person-group><article-title>Nano based drug delivery systems: Recent developments and future prospects</article-title><source>J. Nanobiotechnol.</source><year>2018</year><volume>16</volume><fpage>1</fpage><lpage>33</lpage><pub-id pub-id-type="doi">10.1186/s12951-018-0392-8</pub-id><pub-id pub-id-type="pmid">30231877</pub-id>
</element-citation></ref><ref id="B289-vaccines-13-00126"><label>289.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Reddy</surname><given-names>P.R.K.</given-names></name>
<name><surname>Yasaswini</surname><given-names>D.</given-names></name>
<name><surname>Reddy</surname><given-names>P.P.R.</given-names></name>
<name><surname>Kumar</surname><given-names>D.S.</given-names></name>
<name><surname>Elghandour</surname><given-names>M.M.</given-names></name>
<name><surname>Salem</surname><given-names>A.</given-names></name>
</person-group><article-title>Nanotechnology in Veterinary Sector: Current Applications, Limitations and Future Perspective</article-title><source>Handbook of Green and Sustainable Nanotechnology: Fundamentals, Developments and Applications</source><publisher-name>Springer</publisher-name><publisher-loc>Berlin/Heidelberg, Germany</publisher-loc><year>2023</year><fpage>1541</fpage><lpage>1567</lpage></element-citation></ref><ref id="B290-vaccines-13-00126"><label>290.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Celis-Giraldo</surname><given-names>C.T.</given-names></name>
<name><surname>L&#x000f3;pez-Ab&#x000e1;n</surname><given-names>J.</given-names></name>
<name><surname>Muro</surname><given-names>A.</given-names></name>
<name><surname>Patarroyo</surname><given-names>M.A.</given-names></name>
<name><surname>Manzano-Rom&#x000e1;n</surname><given-names>R.</given-names></name>
</person-group><article-title>Nanovaccines against animal pathogens: The latest findings</article-title><source>Vaccines</source><year>2021</year><volume>9</volume><elocation-id>988</elocation-id><pub-id pub-id-type="doi">10.3390/vaccines9090988</pub-id><pub-id pub-id-type="pmid">34579225</pub-id>
</element-citation></ref><ref id="B291-vaccines-13-00126"><label>291.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Renu</surname><given-names>S.</given-names></name>
<name><surname>Han</surname><given-names>Y.</given-names></name>
<name><surname>Dhakal</surname><given-names>S.</given-names></name>
<name><surname>Lakshmanappa</surname><given-names>Y.S.</given-names></name>
<name><surname>Ghimire</surname><given-names>S.</given-names></name>
<name><surname>Feliciano-Ruiz</surname><given-names>N.</given-names></name>
<name><surname>Senapati</surname><given-names>S.</given-names></name>
<name><surname>Narasimhan</surname><given-names>B.</given-names></name>
<name><surname>Selvaraj</surname><given-names>R.</given-names></name>
<name><surname>Renukaradhya</surname><given-names>G.J.</given-names></name>
</person-group><article-title>Chitosan-adjuvanted <italic toggle="yes">Salmonella</italic> subunit nanoparticle vaccine for poultry delivered through drinking water and feed</article-title><source>Carbohydr. Polym.</source><year>2020</year><volume>243</volume><fpage>116434</fpage><pub-id pub-id-type="doi">10.1016/j.carbpol.2020.116434</pub-id><pub-id pub-id-type="pmid">32532387</pub-id>
</element-citation></ref><ref id="B292-vaccines-13-00126"><label>292.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wang</surname><given-names>X.</given-names></name>
<name><surname>Dai</surname><given-names>Y.</given-names></name>
<name><surname>Zhao</surname><given-names>S.</given-names></name>
<name><surname>Tang</surname><given-names>J.</given-names></name>
<name><surname>Li</surname><given-names>H.</given-names></name>
<name><surname>Xing</surname><given-names>Y.</given-names></name>
<name><surname>Qu</surname><given-names>G.</given-names></name>
<name><surname>Li</surname><given-names>X.</given-names></name>
<name><surname>Dai</surname><given-names>J.</given-names></name>
<name><surname>Zhu</surname><given-names>Y.</given-names></name>
</person-group><article-title>PAMAM-Lys, a novel vaccine delivery vector, enhances the protective effects of the SjC23 DNA vaccine against <italic toggle="yes">Schistosoma japonicum</italic> infection</article-title><source>PLoS ONE</source><year>2014</year><volume>9</volume><elocation-id>e86578</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0086578</pub-id><pub-id pub-id-type="pmid">24497955</pub-id>
</element-citation></ref><ref id="B293-vaccines-13-00126"><label>293.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Coleman</surname><given-names>C.M.</given-names></name>
<name><surname>Liu</surname><given-names>Y.V.</given-names></name>
<name><surname>Mu</surname><given-names>H.</given-names></name>
<name><surname>Taylor</surname><given-names>J.K.</given-names></name>
<name><surname>Massare</surname><given-names>M.</given-names></name>
<name><surname>Flyer</surname><given-names>D.C.</given-names></name>
<name><surname>Glenn</surname><given-names>G.M.</given-names></name>
<name><surname>Smith</surname><given-names>G.E.</given-names></name>
<name><surname>Frieman</surname><given-names>M.B.</given-names></name>
</person-group><article-title>Purified coronavirus spike protein nanoparticles induce coronavirus neutralizing antibodies in mice</article-title><source>Vaccine</source><year>2014</year><volume>32</volume><fpage>3169</fpage><lpage>3174</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2014.04.016</pub-id><pub-id pub-id-type="pmid">24736006</pub-id>
</element-citation></ref><ref id="B294-vaccines-13-00126"><label>294.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Al-Halifa</surname><given-names>S.</given-names></name>
<name><surname>Gauthier</surname><given-names>L.</given-names></name>
<name><surname>Arpin</surname><given-names>D.</given-names></name>
<name><surname>Bourgault</surname><given-names>S.</given-names></name>
<name><surname>Archambault</surname><given-names>D.</given-names></name>
</person-group><article-title>Nanoparticle-based vaccines against respiratory viruses</article-title><source>Front. Immunol.</source><year>2019</year><volume>10</volume><elocation-id>22</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2019.00022</pub-id><pub-id pub-id-type="pmid">30733717</pub-id>
</element-citation></ref><ref id="B295-vaccines-13-00126"><label>295.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhu</surname><given-names>D.</given-names></name>
<name><surname>Long</surname><given-names>Q.</given-names></name>
<name><surname>Xu</surname><given-names>Y.</given-names></name>
<name><surname>Xing</surname><given-names>J.</given-names></name>
</person-group><article-title>Evaluating nanoparticles in preclinical research using microfluidic systems</article-title><source>Micromachines</source><year>2019</year><volume>10</volume><elocation-id>414</elocation-id><pub-id pub-id-type="doi">10.3390/mi10060414</pub-id><pub-id pub-id-type="pmid">31234335</pub-id>
</element-citation></ref><ref id="B296-vaccines-13-00126"><label>296.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Desai</surname><given-names>N.</given-names></name>
<name><surname>Chavda</surname><given-names>V.</given-names></name>
<name><surname>Singh</surname><given-names>T.R.R.</given-names></name>
<name><surname>Thorat</surname><given-names>N.D.</given-names></name>
<name><surname>Vora</surname><given-names>L.K.</given-names></name>
</person-group><article-title>Cancer nanovaccines: Nanomaterials and clinical perspectives</article-title><source>Small</source><year>2024</year><volume>20</volume><fpage>2401631</fpage><pub-id pub-id-type="doi">10.1002/smll.202401631</pub-id><pub-id pub-id-type="pmid">38693099</pub-id>
</element-citation></ref><ref id="B297-vaccines-13-00126"><label>297.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhao</surname><given-names>G.</given-names></name>
<name><surname>Jiang</surname><given-names>Y.</given-names></name>
<name><surname>Ma</surname><given-names>P.</given-names></name>
<name><surname>Wang</surname><given-names>S.</given-names></name>
<name><surname>Nie</surname><given-names>G.</given-names></name>
<name><surname>Li</surname><given-names>N.</given-names></name>
</person-group><article-title>Membrane-based cancer nanovaccines: The time is now</article-title><source>QJM Int. J. Med.</source><year>2023</year><volume>116</volume><fpage>621</fpage><lpage>624</lpage><pub-id pub-id-type="doi">10.1093/qjmed/hcad089</pub-id></element-citation></ref><ref id="B298-vaccines-13-00126"><label>298.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Sharma</surname><given-names>H.</given-names></name>
<name><surname>Thakur</surname><given-names>S.</given-names></name>
</person-group><article-title>2 Membrane-Based Nano</article-title><source>Nanoparticles in Cancer Therapy: Innovations and Clinical Applications</source><publisher-name>CRC Press</publisher-name><publisher-loc>Boca Raton, FL, USA</publisher-loc><year>2024</year><fpage>19</fpage></element-citation></ref><ref id="B299-vaccines-13-00126"><label>299.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Liu</surname><given-names>Y.</given-names></name>
<name><surname>Cheng</surname><given-names>W.</given-names></name>
<name><surname>Xin</surname><given-names>H.</given-names></name>
<name><surname>Liu</surname><given-names>R.</given-names></name>
<name><surname>Wang</surname><given-names>Q.</given-names></name>
<name><surname>Cai</surname><given-names>W.</given-names></name>
<name><surname>Peng</surname><given-names>X.</given-names></name>
<name><surname>Yang</surname><given-names>F.</given-names></name>
<name><surname>Xin</surname><given-names>H.</given-names></name>
</person-group><article-title>Nanoparticles advanced from preclinical studies to clinical trials for lung cancer therapy</article-title><source>Cancer Nanotechnol.</source><year>2023</year><volume>14</volume><fpage>28</fpage><pub-id pub-id-type="doi">10.1186/s12645-023-00174-x</pub-id><pub-id pub-id-type="pmid">37009262</pub-id>
</element-citation></ref><ref id="B300-vaccines-13-00126"><label>300.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Al-Thani</surname><given-names>A.N.</given-names></name>
<name><surname>Jan</surname><given-names>A.G.</given-names></name>
<name><surname>Abbas</surname><given-names>M.</given-names></name>
<name><surname>Geetha</surname><given-names>M.</given-names></name>
<name><surname>Sadasivuni</surname><given-names>K.K.</given-names></name>
</person-group><article-title>Nanoparticles in cancer theragnostic and drug delivery: A comprehensive review</article-title><source>Life Sci.</source><year>2024</year><volume>352</volume><fpage>122899</fpage><pub-id pub-id-type="doi">10.1016/j.lfs.2024.122899</pub-id><pub-id pub-id-type="pmid">38992574</pub-id>
</element-citation></ref><ref id="B301-vaccines-13-00126"><label>301.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sun</surname><given-names>L.</given-names></name>
<name><surname>Liu</surname><given-names>H.</given-names></name>
<name><surname>Ye</surname><given-names>Y.</given-names></name>
<name><surname>Lei</surname><given-names>Y.</given-names></name>
<name><surname>Islam</surname><given-names>R.</given-names></name>
<name><surname>Tan</surname><given-names>S.</given-names></name>
<name><surname>Tong</surname><given-names>R.</given-names></name>
<name><surname>Miao</surname><given-names>Y.-B.</given-names></name>
<name><surname>Cai</surname><given-names>L.</given-names></name>
</person-group><article-title>Smart nanoparticles for cancer therapy</article-title><source>Signal Transduct. Target. Ther.</source><year>2023</year><volume>8</volume><fpage>418</fpage><pub-id pub-id-type="doi">10.1038/s41392-023-01642-x</pub-id><pub-id pub-id-type="pmid">37919282</pub-id>
</element-citation></ref><ref id="B302-vaccines-13-00126"><label>302.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Selvaraj</surname><given-names>J.</given-names></name>
<name><surname>Rajendran</surname><given-names>V.</given-names></name>
<name><surname>Ramalingam</surname><given-names>B.</given-names></name>
</person-group><article-title>Nanovaccine: A Modern Approach to Vaccinology</article-title><source>Nanotechnol. Med.</source><year>2021</year><volume>4</volume><fpage>57</fpage><lpage>74</lpage></element-citation></ref><ref id="B303-vaccines-13-00126"><label>303.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sun</surname><given-names>M.</given-names></name>
<name><surname>Pratama</surname><given-names>A.C.</given-names></name>
<name><surname>Qiu</surname><given-names>H.</given-names></name>
<name><surname>Liu</surname><given-names>Z.</given-names></name>
<name><surname>He</surname><given-names>F.</given-names></name>
</person-group><article-title>Toward innovative veterinary nanoparticle vaccines</article-title><source>Anim. Dis.</source><year>2024</year><volume>4</volume><fpage>14</fpage><pub-id pub-id-type="doi">10.1186/s44149-024-00119-w</pub-id></element-citation></ref><ref id="B304-vaccines-13-00126"><label>304.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Geng</surname><given-names>Q.</given-names></name>
<name><surname>Tai</surname><given-names>W.</given-names></name>
<name><surname>Baxter</surname><given-names>V.K.</given-names></name>
<name><surname>Shi</surname><given-names>J.</given-names></name>
<name><surname>Wan</surname><given-names>Y.</given-names></name>
<name><surname>Zhang</surname><given-names>X.</given-names></name>
<name><surname>Montgomery</surname><given-names>S.A.</given-names></name>
<name><surname>Taft-Benz</surname><given-names>S.A.</given-names></name>
<name><surname>Anderson</surname><given-names>E.J.</given-names></name>
<name><surname>Knight</surname><given-names>A.C.</given-names></name>
</person-group><article-title>Novel virus-like nanoparticle vaccine effectively protects animal model from SARS-CoV-2 infection</article-title><source>PLoS Pathog.</source><year>2021</year><volume>17</volume><elocation-id>e1009897</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1009897</pub-id><pub-id pub-id-type="pmid">34492082</pub-id>
</element-citation></ref><ref id="B305-vaccines-13-00126"><label>305.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Duvall</surname><given-names>M.N.</given-names></name>
<name><surname>Knight</surname><given-names>K.</given-names></name>
</person-group><source>FDA Regulation of Nanotechnology</source><publisher-name>Beveridge and Diamond, PG</publisher-name><publisher-loc>Washington, DC, USA</publisher-loc><year>2012</year></element-citation></ref><ref id="B306-vaccines-13-00126"><label>306.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cs&#x000f3;ka</surname><given-names>I.</given-names></name>
<name><surname>Ismail</surname><given-names>R.</given-names></name>
<name><surname>J&#x000f3;j&#x000e1;rt-Laczkovich</surname><given-names>O.</given-names></name>
<name><surname>Pallagi</surname><given-names>E.</given-names></name>
</person-group><article-title>Regulatory considerations, challenges and risk-based approach in nanomedicine development</article-title><source>Curr. Med. Chem.</source><year>2021</year><volume>28</volume><fpage>7461</fpage><lpage>7476</lpage><pub-id pub-id-type="doi">10.2174/0929867328666210406115529</pub-id><pub-id pub-id-type="pmid">33823761</pub-id>
</element-citation></ref><ref id="B307-vaccines-13-00126"><label>307.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Paliwal</surname><given-names>R.</given-names></name>
<name><surname>Kumar</surname><given-names>P.</given-names></name>
<name><surname>Chaurasiya</surname><given-names>A.</given-names></name>
<name><surname>Kenwat</surname><given-names>R.</given-names></name>
<name><surname>Katke</surname><given-names>S.</given-names></name>
<name><surname>Paliwal</surname><given-names>S.R.</given-names></name>
</person-group><article-title>Development of nanomedicines and nano-similars: Recent advances in regulatory landscape</article-title><source>Curr. Pharm. Des.</source><year>2022</year><volume>28</volume><fpage>165</fpage><lpage>177</lpage><pub-id pub-id-type="doi">10.2174/1381612827666211115170001</pub-id><pub-id pub-id-type="pmid">34781869</pub-id>
</element-citation></ref><ref id="B308-vaccines-13-00126"><label>308.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Souto</surname><given-names>E.B.</given-names></name>
<name><surname>Blanco-Llamero</surname><given-names>C.</given-names></name>
<name><surname>Krambeck</surname><given-names>K.</given-names></name>
<name><surname>Kiran</surname><given-names>N.S.</given-names></name>
<name><surname>Yashaswini</surname><given-names>C.</given-names></name>
<name><surname>Postwala</surname><given-names>H.</given-names></name>
<name><surname>Severino</surname><given-names>P.</given-names></name>
<name><surname>Priefer</surname><given-names>R.</given-names></name>
<name><surname>Prajapati</surname><given-names>B.G.</given-names></name>
<name><surname>Maheshwari</surname><given-names>R.</given-names></name>
</person-group><article-title>Regulatory Insights into Nanomedicine and Gene Vaccine Innovation: Safety Assessment, Challenges, and Regulatory Perspectives</article-title><source>Acta Biomater.</source><year>2024</year><volume>180</volume><fpage>1</fpage><lpage>17</lpage><pub-id pub-id-type="doi">10.1016/j.actbio.2024.04.010</pub-id><pub-id pub-id-type="pmid">38604468</pub-id>
</element-citation></ref><ref id="B309-vaccines-13-00126"><label>309.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Gogoi</surname><given-names>N.R.</given-names></name>
<name><surname>Bezbaruah</surname><given-names>R.</given-names></name>
<name><surname>Patel</surname><given-names>V.</given-names></name>
<name><surname>Satasia</surname><given-names>R.</given-names></name>
<name><surname>Bhattacharjee</surname><given-names>B.</given-names></name>
<name><surname>Mazumder</surname><given-names>B.</given-names></name>
</person-group><article-title>Regulatory Pathways for Nanocarrier Vaccine</article-title><source>Nanocarrier Vaccines: Biopharmaceutics-Based Fast Track Development</source><publisher-name>Wiley Online Library</publisher-name><publisher-loc>Hoboken, NJ, USA</publisher-loc><year>2024</year><fpage>465</fpage><lpage>485</lpage></element-citation></ref><ref id="B310-vaccines-13-00126"><label>310.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Florindo</surname><given-names>H.</given-names></name>
<name><surname>Lopes</surname><given-names>J.</given-names></name>
<name><surname>Silva</surname><given-names>L.</given-names></name>
<name><surname>Corvo</surname><given-names>M.</given-names></name>
<name><surname>Martins</surname><given-names>M.</given-names></name>
<name><surname>Gaspar</surname><given-names>R.</given-names></name>
</person-group><article-title>Regulatory development of nanotechnology-based vaccines</article-title><source>Micro and Nanotechnology in Vaccine Development</source><publisher-name>Elsevier</publisher-name><publisher-loc>Amsterdam, The Netherlands</publisher-loc><year>2017</year><fpage>393</fpage><lpage>410</lpage></element-citation></ref><ref id="B311-vaccines-13-00126"><label>311.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Araste</surname><given-names>F.</given-names></name>
<name><surname>Bakker</surname><given-names>A.D.</given-names></name>
<name><surname>Zandieh-Doulabi</surname><given-names>B.</given-names></name>
</person-group><article-title>Potential and risks of nanotechnology applications in COVID-19-related strategies for pandemic control</article-title><source>J. Nanoparticle Res.</source><year>2023</year><volume>25</volume><fpage>229</fpage><pub-id pub-id-type="doi">10.1007/s11051-023-05867-3</pub-id></element-citation></ref><ref id="B312-vaccines-13-00126"><label>312.</label><element-citation publication-type="book"><person-group person-group-type="author">
<collab>World Health Organization</collab>
</person-group><source>State of the World&#x02019;s Vaccines and Immunization</source><publisher-name>World Health Organization</publisher-name><publisher-loc>Geneva, Switzerland</publisher-loc><year>2009</year></element-citation></ref><ref id="B313-vaccines-13-00126"><label>313.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Fernandes</surname><given-names>C.</given-names></name>
<name><surname>Jathar</surname><given-names>M.</given-names></name>
<name><surname>Sawant</surname><given-names>B.K.S.</given-names></name>
<name><surname>Warde</surname><given-names>T.</given-names></name>
</person-group><article-title>Scale-up of nanoparticle manufacturing process</article-title><source>Pharmaceutical Process Engineering and Scale-Up Principles</source><publisher-name>Springer</publisher-name><publisher-loc>Berlin/Heidelberg, Germany</publisher-loc><year>2023</year><fpage>173</fpage><lpage>203</lpage></element-citation></ref><ref id="B314-vaccines-13-00126"><label>314.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Liu</surname><given-names>X.</given-names></name>
<name><surname>Meng</surname><given-names>H.</given-names></name>
</person-group><article-title>Consideration for the scale-up manufacture of nanotherapeutics&#x02014;A critical step for technology transfer</article-title><source>View</source><year>2021</year><volume>2</volume><fpage>20200190</fpage><pub-id pub-id-type="doi">10.1002/VIW.20200190</pub-id></element-citation></ref><ref id="B315-vaccines-13-00126"><label>315.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Borrajo</surname><given-names>M.L.</given-names></name>
<name><surname>Lou</surname><given-names>G.</given-names></name>
<name><surname>Anthiya</surname><given-names>S.</given-names></name>
<name><surname>Lapuhs</surname><given-names>P.</given-names></name>
<name><surname>&#x000c1;lvarez</surname><given-names>D.M.</given-names></name>
<name><surname>Tob&#x000ed;o</surname><given-names>A.</given-names></name>
<name><surname>Loza</surname><given-names>M.I.</given-names></name>
<name><surname>Vidal</surname><given-names>A.</given-names></name>
<name><surname>Alonso</surname><given-names>M.J.</given-names></name>
</person-group><article-title>Nanoemulsions and nanocapsules as carriers for the development of intranasal mRNA vaccines</article-title><source>Drug Delivery and Translational Research</source><publisher-name>Springer</publisher-name><publisher-loc>Berlin/Heidelberg, Germany</publisher-loc><year>2024</year><fpage>1</fpage><lpage>16</lpage></element-citation></ref><ref id="B316-vaccines-13-00126"><label>316.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hu</surname><given-names>C.</given-names></name>
<name><surname>Bai</surname><given-names>Y.</given-names></name>
<name><surname>Liu</surname><given-names>J.</given-names></name>
<name><surname>Wang</surname><given-names>Y.</given-names></name>
<name><surname>He</surname><given-names>Q.</given-names></name>
<name><surname>Zhang</surname><given-names>X.</given-names></name>
<name><surname>Cheng</surname><given-names>F.</given-names></name>
<name><surname>Xu</surname><given-names>M.</given-names></name>
<name><surname>Mao</surname><given-names>Q.</given-names></name>
<name><surname>Liang</surname><given-names>Z.</given-names></name>
</person-group><article-title>Research progress on the quality control of mRNA vaccines</article-title><source>Expert Rev. Vaccines</source><year>2024</year><volume>23</volume><fpage>570</fpage><lpage>583</lpage><pub-id pub-id-type="doi">10.1080/14760584.2024.2354251</pub-id><pub-id pub-id-type="pmid">38733272</pub-id>
</element-citation></ref><ref id="B317-vaccines-13-00126"><label>317.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Whitley</surname><given-names>J.</given-names></name>
<name><surname>Zwolinski</surname><given-names>C.</given-names></name>
<name><surname>Denis</surname><given-names>C.</given-names></name>
<name><surname>Maughan</surname><given-names>M.</given-names></name>
<name><surname>Hayles</surname><given-names>L.</given-names></name>
<name><surname>Clarke</surname><given-names>D.</given-names></name>
<name><surname>Snare</surname><given-names>M.</given-names></name>
<name><surname>Liao</surname><given-names>H.</given-names></name>
<name><surname>Chiou</surname><given-names>S.</given-names></name>
<name><surname>Marmura</surname><given-names>T.</given-names></name>
</person-group><article-title>Development of mRNA manufacturing for vaccines and therapeutics: mRNA platform requirements and development of a scalable production process to support early phase clinical trials</article-title><source>Transl. Res.</source><year>2022</year><volume>242</volume><fpage>38</fpage><lpage>55</lpage><pub-id pub-id-type="doi">10.1016/j.trsl.2021.11.009</pub-id><pub-id pub-id-type="pmid">34871810</pub-id>
</element-citation></ref><ref id="B318-vaccines-13-00126"><label>318.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rosa</surname><given-names>S.S.</given-names></name>
<name><surname>Prazeres</surname><given-names>D.M.</given-names></name>
<name><surname>Azevedo</surname><given-names>A.M.</given-names></name>
<name><surname>Marques</surname><given-names>M.P.</given-names></name>
</person-group><article-title>mRNA vaccines manufacturing: Challenges and bottlenecks</article-title><source>Vaccine</source><year>2021</year><volume>39</volume><fpage>2190</fpage><lpage>2200</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2021.03.038</pub-id><pub-id pub-id-type="pmid">33771389</pub-id>
</element-citation></ref><ref id="B319-vaccines-13-00126"><label>319.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Guerrini</surname><given-names>G.</given-names></name>
<name><surname>Magr&#x000ec;</surname><given-names>D.</given-names></name>
<name><surname>Gioria</surname><given-names>S.</given-names></name>
<name><surname>Medaglini</surname><given-names>D.</given-names></name>
<name><surname>Calzolai</surname><given-names>L.</given-names></name>
</person-group><article-title>Characterization of nanoparticles-based vaccines for COVID-19</article-title><source>Nat. Nanotechnol.</source><year>2022</year><volume>17</volume><fpage>570</fpage><lpage>576</lpage><pub-id pub-id-type="doi">10.1038/s41565-022-01129-w</pub-id><pub-id pub-id-type="pmid">35710950</pub-id>
</element-citation></ref><ref id="B320-vaccines-13-00126"><label>320.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lee</surname><given-names>J.H.</given-names></name>
<name><surname>Yeo</surname><given-names>Y.</given-names></name>
</person-group><article-title>Controlled drug release from pharmaceutical nanocarriers</article-title><source>Chem. Eng. Sci.</source><year>2015</year><volume>125</volume><fpage>75</fpage><lpage>84</lpage><pub-id pub-id-type="doi">10.1016/j.ces.2014.08.046</pub-id><pub-id pub-id-type="pmid">25684779</pub-id>
</element-citation></ref><ref id="B321-vaccines-13-00126"><label>321.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Svenson</surname><given-names>S.</given-names></name>
<name><surname>Tomalia</surname><given-names>D.A.</given-names></name>
</person-group><article-title>Dendrimers in biomedical applications&#x02014;Reflections on the field</article-title><source>Adv. Drug Deliv. Rev.</source><year>2012</year><volume>64</volume><fpage>102</fpage><lpage>115</lpage><pub-id pub-id-type="doi">10.1016/j.addr.2012.09.030</pub-id></element-citation></ref><ref id="B322-vaccines-13-00126"><label>322.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jain</surname><given-names>K.</given-names></name>
<name><surname>Kesharwani</surname><given-names>P.</given-names></name>
<name><surname>Gupta</surname><given-names>U.</given-names></name>
<name><surname>Jain</surname><given-names>N.</given-names></name>
</person-group><article-title>Dendrimer toxicity: Let&#x02019;s meet the challenge</article-title><source>Int. J. Pharm.</source><year>2010</year><volume>394</volume><fpage>122</fpage><lpage>142</lpage><pub-id pub-id-type="doi">10.1016/j.ijpharm.2010.04.027</pub-id><pub-id pub-id-type="pmid">20433913</pub-id>
</element-citation></ref><ref id="B323-vaccines-13-00126"><label>323.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>George</surname><given-names>E.</given-names></name>
<name><surname>Goswami</surname><given-names>A.</given-names></name>
<name><surname>Lodhiya</surname><given-names>T.</given-names></name>
<name><surname>Padwal</surname><given-names>P.</given-names></name>
<name><surname>Iyer</surname><given-names>S.</given-names></name>
<name><surname>Gauttam</surname><given-names>I.</given-names></name>
<name><surname>Sethi</surname><given-names>L.</given-names></name>
<name><surname>Jeyasankar</surname><given-names>S.</given-names></name>
<name><surname>Sharma</surname><given-names>P.R.</given-names></name>
<name><surname>Dravid</surname><given-names>A.A.</given-names></name>
</person-group><article-title>Immunomodulatory effect of mycobacterial outer membrane vesicles coated nanoparticles</article-title><source>Biomater. Adv.</source><year>2022</year><volume>139</volume><elocation-id>213003</elocation-id><pub-id pub-id-type="doi">10.1016/j.bioadv.2022.213003</pub-id><pub-id pub-id-type="pmid">35882150</pub-id>
</element-citation></ref><ref id="B324-vaccines-13-00126"><label>324.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wang</surname><given-names>S.</given-names></name>
<name><surname>Gao</surname><given-names>J.</given-names></name>
<name><surname>Wang</surname><given-names>Z.</given-names></name>
</person-group><article-title>Outer membrane vesicles for vaccination and targeted drug delivery</article-title><source>Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol.</source><year>2019</year><volume>11</volume><elocation-id>e1523</elocation-id><pub-id pub-id-type="doi">10.1002/wnan.1523</pub-id><pub-id pub-id-type="pmid">29701017</pub-id>
</element-citation></ref><ref id="B325-vaccines-13-00126"><label>325.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zheng</surname><given-names>Y.</given-names></name>
<name><surname>Zhao</surname><given-names>Y.</given-names></name>
<name><surname>Bai</surname><given-names>M.</given-names></name>
<name><surname>Gu</surname><given-names>H.</given-names></name>
<name><surname>Li</surname><given-names>X.</given-names></name>
</person-group><article-title>Metal&#x02013;organic frameworks as a therapeutic strategy for lung diseases</article-title><source>J. Mater. Chem. B</source><year>2022</year><volume>10</volume><fpage>5666</fpage><lpage>5695</lpage><pub-id pub-id-type="doi">10.1039/D2TB00690A</pub-id><pub-id pub-id-type="pmid">35848605</pub-id>
</element-citation></ref><ref id="B326-vaccines-13-00126"><label>326.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tousian</surname><given-names>B.</given-names></name>
<name><surname>Khosravi</surname><given-names>A.R.</given-names></name>
<name><surname>Ghasemi</surname><given-names>M.H.</given-names></name>
<name><surname>Kadkhodaie</surname><given-names>M.</given-names></name>
</person-group><article-title>Biomimetic Functionalized Metal Organic Frameworks as Multifunctional Agents: Paving the Way for Cancer Vaccine Advances</article-title><source>Mater. Today Bio</source><year>2024</year><volume>27</volume><elocation-id>101134</elocation-id><pub-id pub-id-type="doi">10.1016/j.mtbio.2024.101134</pub-id><pub-id pub-id-type="pmid">39027676</pub-id>
</element-citation></ref><ref id="B327-vaccines-13-00126"><label>327.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Manimaran</surname><given-names>V.</given-names></name>
<name><surname>Nivetha</surname><given-names>R.</given-names></name>
<name><surname>Tamilanban</surname><given-names>T.</given-names></name>
<name><surname>Narayanan</surname><given-names>J.</given-names></name>
<name><surname>Vetriselvan</surname><given-names>S.</given-names></name>
<name><surname>Fuloria</surname><given-names>N.K.</given-names></name>
<name><surname>Chinni</surname><given-names>S.V.</given-names></name>
<name><surname>Sekar</surname><given-names>M.</given-names></name>
<name><surname>Fuloria</surname><given-names>S.</given-names></name>
<name><surname>Wong</surname><given-names>L.S.</given-names></name>
</person-group><article-title>Nanogels as novel drug nanocarriers for CNS drug delivery</article-title><source>Front. Mol. Biosci.</source><year>2023</year><volume>10</volume><elocation-id>1232109</elocation-id><pub-id pub-id-type="doi">10.3389/fmolb.2023.1232109</pub-id><pub-id pub-id-type="pmid">37621994</pub-id>
</element-citation></ref><ref id="B328-vaccines-13-00126"><label>328.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nakahashi-Ouchida</surname><given-names>R.</given-names></name>
<name><surname>Yuki</surname><given-names>Y.</given-names></name>
<name><surname>Kiyono</surname><given-names>H.</given-names></name>
</person-group><article-title>Development of a nanogel-based nasal vaccine as a novel antigen delivery system</article-title><source>Expert Rev. Vaccines</source><year>2017</year><volume>16</volume><fpage>1231</fpage><lpage>1240</lpage><pub-id pub-id-type="doi">10.1080/14760584.2017.1395702</pub-id><pub-id pub-id-type="pmid">29053938</pub-id>
</element-citation></ref><ref id="B329-vaccines-13-00126"><label>329.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kabanov</surname><given-names>A.V.</given-names></name>
<name><surname>Vinogradov</surname><given-names>S.V.</given-names></name>
</person-group><article-title>Nanogels as pharmaceutical carriers: Finite networks of infinite capabilities</article-title><source>Angew. Chem. Int. Ed.</source><year>2009</year><volume>48</volume><fpage>5418</fpage><lpage>5429</lpage><pub-id pub-id-type="doi">10.1002/anie.200900441</pub-id><pub-id pub-id-type="pmid">19562807</pub-id>
</element-citation></ref><ref id="B330-vaccines-13-00126"><label>330.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Shinde</surname><given-names>V.</given-names></name>
<name><surname>Fries</surname><given-names>L.</given-names></name>
<name><surname>Wu</surname><given-names>Y.</given-names></name>
<name><surname>Agrawal</surname><given-names>S.</given-names></name>
<name><surname>Cho</surname><given-names>I.</given-names></name>
<name><surname>Thomas</surname><given-names>D.N.</given-names></name>
<name><surname>Spindler</surname><given-names>M.</given-names></name>
<name><surname>Lindner</surname><given-names>E.</given-names></name>
<name><surname>Hahn</surname><given-names>T.</given-names></name>
<name><surname>Plested</surname><given-names>J.</given-names></name>
</person-group><article-title>Improved titers against influenza drift variants with a nanoparticle vaccine</article-title><source>N. Engl. J. Med.</source><year>2018</year><volume>378</volume><fpage>2346</fpage><lpage>2348</lpage><pub-id pub-id-type="doi">10.1056/NEJMc1803554</pub-id><pub-id pub-id-type="pmid">29897849</pub-id>
</element-citation></ref><ref id="B331-vaccines-13-00126"><label>331.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Brazzoli</surname><given-names>M.</given-names></name>
<name><surname>Piccioli</surname><given-names>D.</given-names></name>
<name><surname>Marchetti</surname><given-names>F.</given-names></name>
</person-group><article-title>Challenges in development of vaccines directed toward antimicrobial resistant bacterial species</article-title><source>Hum. Vaccines Immunother.</source><year>2023</year><volume>19</volume><fpage>2228669</fpage><pub-id pub-id-type="doi">10.1080/21645515.2023.2228669</pub-id><pub-id pub-id-type="pmid">37449650</pub-id>
</element-citation></ref><ref id="B332-vaccines-13-00126"><label>332.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Weber</surname><given-names>J.S.</given-names></name>
<name><surname>Carlino</surname><given-names>M.S.</given-names></name>
<name><surname>Khattak</surname><given-names>A.</given-names></name>
<name><surname>Meniawy</surname><given-names>T.</given-names></name>
<name><surname>Ansstas</surname><given-names>G.</given-names></name>
<name><surname>Taylor</surname><given-names>M.H.</given-names></name>
<name><surname>Kim</surname><given-names>K.B.</given-names></name>
<name><surname>McKean</surname><given-names>M.</given-names></name>
<name><surname>Long</surname><given-names>G.V.</given-names></name>
<name><surname>Sullivan</surname><given-names>R.J.</given-names></name>
</person-group><article-title>Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): A randomised, phase 2b study</article-title><source>Lancet</source><year>2024</year><volume>403</volume><fpage>632</fpage><lpage>644</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(23)02268-7</pub-id><pub-id pub-id-type="pmid">38246194</pub-id>
</element-citation></ref><ref id="B333-vaccines-13-00126"><label>333.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Saied</surname><given-names>A.A.</given-names></name>
</person-group><article-title>mRNA vaccines and clinical research in Africa-From hope to reality</article-title><source>Int. J. Surg.</source><year>2022</year><volume>105</volume><fpage>106833</fpage><pub-id pub-id-type="doi">10.1016/j.ijsu.2022.106833</pub-id><pub-id pub-id-type="pmid">35963578</pub-id>
</element-citation></ref><ref id="B334-vaccines-13-00126"><label>334.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sekiya</surname><given-names>T.</given-names></name>
<name><surname>Ohno</surname><given-names>M.</given-names></name>
<name><surname>Nomura</surname><given-names>N.</given-names></name>
<name><surname>Handabile</surname><given-names>C.</given-names></name>
<name><surname>Shingai</surname><given-names>M.</given-names></name>
<name><surname>Jackson</surname><given-names>D.C.</given-names></name>
<name><surname>Brown</surname><given-names>L.E.</given-names></name>
<name><surname>Kida</surname><given-names>H.</given-names></name>
</person-group><article-title>Selecting and using the appropriate influenza vaccine for each individual</article-title><source>Viruses</source><year>2021</year><volume>13</volume><elocation-id>971</elocation-id><pub-id pub-id-type="doi">10.3390/v13060971</pub-id><pub-id pub-id-type="pmid">34073843</pub-id>
</element-citation></ref><ref id="B335-vaccines-13-00126"><label>335.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chu</surname><given-names>Y.</given-names></name>
<name><surname>Liu</surname><given-names>Q.</given-names></name>
<name><surname>Wei</surname><given-names>J.</given-names></name>
<name><surname>Liu</surname><given-names>B.</given-names></name>
</person-group><article-title>Personalized cancer neoantigen vaccines come of age</article-title><source>Theranostics</source><year>2018</year><volume>8</volume><fpage>4238</fpage><pub-id pub-id-type="doi">10.7150/thno.24387</pub-id><pub-id pub-id-type="pmid">30128050</pub-id>
</element-citation></ref><ref id="B336-vaccines-13-00126"><label>336.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhao</surname><given-names>W.</given-names></name>
<name><surname>Wu</surname><given-names>W.</given-names></name>
<name><surname>Xu</surname><given-names>X.</given-names></name>
</person-group><article-title>Oral vaccination with liposome-encapsulated recombinant fusion peptide of urease B epitope and cholera toxin B subunit affords prophylactic and therapeutic effects against <italic toggle="yes">H. pylori</italic> infection in BALB/c mice</article-title><source>Vaccine</source><year>2007</year><volume>25</volume><fpage>7664</fpage><lpage>7673</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2007.08.034</pub-id><pub-id pub-id-type="pmid">17913305</pub-id>
</element-citation></ref><ref id="B337-vaccines-13-00126"><label>337.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kim</surname><given-names>B.</given-names></name>
<name><surname>Bowersock</surname><given-names>T.</given-names></name>
<name><surname>Griebel</surname><given-names>P.</given-names></name>
<name><surname>Kidane</surname><given-names>A.</given-names></name>
<name><surname>Babiuk</surname><given-names>L.</given-names></name>
<name><surname>Sanchez</surname><given-names>M.</given-names></name>
<name><surname>Attah-Poku</surname><given-names>S.</given-names></name>
<name><surname>Kaushik</surname><given-names>R.</given-names></name>
<name><surname>Mutwiri</surname><given-names>G.</given-names></name>
</person-group><article-title>Mucosal immune responses following oral immunization with rotavirus antigens encapsulated in alginate microspheres</article-title><source>J. Control. Release</source><year>2002</year><volume>85</volume><fpage>191</fpage><lpage>202</lpage><pub-id pub-id-type="doi">10.1016/S0168-3659(02)00280-8</pub-id><pub-id pub-id-type="pmid">12480324</pub-id>
</element-citation></ref><ref id="B338-vaccines-13-00126"><label>338.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Riccardi</surname><given-names>D.</given-names></name>
<name><surname>Baldino</surname><given-names>L.</given-names></name>
<name><surname>Reverchon</surname><given-names>E.</given-names></name>
</person-group><article-title>Liposomes, transfersomes and niosomes: Production methods and their applications in the vaccinal field</article-title><source>J. Transl. Med.</source><year>2024</year><volume>22</volume><fpage>339</fpage><pub-id pub-id-type="doi">10.1186/s12967-024-05160-4</pub-id><pub-id pub-id-type="pmid">38594760</pub-id>
</element-citation></ref><ref id="B339-vaccines-13-00126"><label>339.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Saggese</surname><given-names>A.</given-names></name>
<name><surname>Baccigalupi</surname><given-names>L.</given-names></name>
<name><surname>Donadio</surname><given-names>G.</given-names></name>
<name><surname>Ricca</surname><given-names>E.</given-names></name>
<name><surname>Isticato</surname><given-names>R.</given-names></name>
</person-group><article-title>The bacterial spore as a mucosal vaccine delivery system</article-title><source>Int. J. Mol. Sci.</source><year>2023</year><volume>24</volume><elocation-id>10880</elocation-id><pub-id pub-id-type="doi">10.3390/ijms241310880</pub-id><pub-id pub-id-type="pmid">37446054</pub-id>
</element-citation></ref><ref id="B340-vaccines-13-00126"><label>340.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Abouelela</surname><given-names>M.E.</given-names></name>
<name><surname>Helmy</surname><given-names>Y.A.</given-names></name>
</person-group><article-title>Next-Generation Probiotics as Novel Therapeutics for Improving Human Health: Current Trends and Future Perspectives</article-title><source>Microorganisms</source><year>2024</year><volume>12</volume><elocation-id>430</elocation-id><pub-id pub-id-type="doi">10.3390/microorganisms12030430</pub-id><pub-id pub-id-type="pmid">38543481</pub-id>
</element-citation></ref><ref id="B341-vaccines-13-00126"><label>341.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chin</surname><given-names>J.S.</given-names></name>
<name><surname>Chooi</surname><given-names>W.H.</given-names></name>
<name><surname>Wang</surname><given-names>H.</given-names></name>
<name><surname>Ong</surname><given-names>W.</given-names></name>
<name><surname>Leong</surname><given-names>K.W.</given-names></name>
<name><surname>Chew</surname><given-names>S.Y.</given-names></name>
</person-group><article-title>Scaffold-mediated non-viral delivery platform for CRISPR/Cas9-based genome editing</article-title><source>Acta Biomater.</source><year>2019</year><volume>90</volume><fpage>60</fpage><lpage>70</lpage><pub-id pub-id-type="doi">10.1016/j.actbio.2019.04.020</pub-id><pub-id pub-id-type="pmid">30978509</pub-id>
</element-citation></ref><ref id="B342-vaccines-13-00126"><label>342.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hii</surname><given-names>A.R.K.</given-names></name>
<name><surname>Qi</surname><given-names>X.</given-names></name>
<name><surname>Wu</surname><given-names>Z.</given-names></name>
</person-group><article-title>Advanced strategies for CRISPR/Cas9 delivery and applications in gene editing, therapy, and cancer detection using nanoparticles and nanocarriers</article-title><source>J. Mater. Chem. B</source><year>2024</year><volume>12</volume><fpage>1467</fpage><lpage>1489</lpage><pub-id pub-id-type="doi">10.1039/D3TB01850D</pub-id><pub-id pub-id-type="pmid">38288550</pub-id>
</element-citation></ref><ref id="B343-vaccines-13-00126"><label>343.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Li</surname><given-names>J.</given-names></name>
<name><surname>Li</surname><given-names>J.</given-names></name>
<name><surname>Peng</surname><given-names>Y.</given-names></name>
<name><surname>Du</surname><given-names>Y.</given-names></name>
<name><surname>Yang</surname><given-names>Z.</given-names></name>
<name><surname>Qi</surname><given-names>X.</given-names></name>
</person-group><article-title>Dendritic cell derived exosomes loaded neoantigens for personalized cancer immunotherapies</article-title><source>J. Control. Release</source><year>2023</year><volume>353</volume><fpage>423</fpage><lpage>433</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2022.11.053</pub-id><pub-id pub-id-type="pmid">36470333</pub-id>
</element-citation></ref><ref id="B344-vaccines-13-00126"><label>344.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ott</surname><given-names>P.A.</given-names></name>
<name><surname>Hu</surname><given-names>Z.</given-names></name>
<name><surname>Keskin</surname><given-names>D.B.</given-names></name>
<name><surname>Shukla</surname><given-names>S.A.</given-names></name>
<name><surname>Sun</surname><given-names>J.</given-names></name>
<name><surname>Bozym</surname><given-names>D.J.</given-names></name>
<name><surname>Zhang</surname><given-names>W.</given-names></name>
<name><surname>Luoma</surname><given-names>A.</given-names></name>
<name><surname>Giobbie-Hurder</surname><given-names>A.</given-names></name>
<name><surname>Peter</surname><given-names>L.</given-names></name>
</person-group><article-title>An immunogenic personal neoantigen vaccine for patients with melanoma</article-title><source>Nature</source><year>2017</year><volume>547</volume><fpage>217</fpage><lpage>221</lpage><pub-id pub-id-type="doi">10.1038/nature22991</pub-id><pub-id pub-id-type="pmid">28678778</pub-id>
</element-citation></ref><ref id="B345-vaccines-13-00126"><label>345.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yao</surname><given-names>R.</given-names></name>
<name><surname>Xie</surname><given-names>C.</given-names></name>
<name><surname>Xia</surname><given-names>X.</given-names></name>
</person-group><article-title>Recent progress in mRNA cancer vaccines</article-title><source>Hum. Vaccines Immunother.</source><year>2024</year><volume>20</volume><fpage>2307187</fpage><pub-id pub-id-type="doi">10.1080/21645515.2024.2307187</pub-id><pub-id pub-id-type="pmid">38282471</pub-id>
</element-citation></ref><ref id="B346-vaccines-13-00126"><label>346.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mi</surname><given-names>Y.</given-names></name>
<name><surname>Smith</surname><given-names>C.C.</given-names></name>
<name><surname>Serody</surname><given-names>J.S.</given-names></name>
<name><surname>Vincent</surname><given-names>B.G.</given-names></name>
<name><surname>Wang</surname><given-names>A.Z.</given-names></name>
<name><surname>Hyun</surname><given-names>H.</given-names></name>
</person-group><article-title>Neoantigen nanovaccine improves personalized cancer immunotherapy</article-title><source>Cancer Res.</source><year>2020</year><volume>80</volume><fpage>2866</fpage><pub-id pub-id-type="doi">10.1158/1538-7445.AM2020-2866</pub-id></element-citation></ref><ref id="B347-vaccines-13-00126"><label>347.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Feng</surname><given-names>R.</given-names></name>
<name><surname>Yu</surname><given-names>F.</given-names></name>
<name><surname>Xu</surname><given-names>J.</given-names></name>
<name><surname>Hu</surname><given-names>X.</given-names></name>
</person-group><article-title>Knowledge gaps in immune response and immunotherapy involving nanomaterials: Databases and artificial intelligence for material design</article-title><source>Biomaterials</source><year>2021</year><volume>266</volume><elocation-id>120469</elocation-id><pub-id pub-id-type="doi">10.1016/j.biomaterials.2020.120469</pub-id><pub-id pub-id-type="pmid">33120200</pub-id>
</element-citation></ref><ref id="B348-vaccines-13-00126"><label>348.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Zohuri</surname><given-names>B.</given-names></name>
<name><surname>Behgounia</surname><given-names>F.</given-names></name>
</person-group><article-title>Application of artificial intelligence driving nano-based drug delivery system</article-title><source>A Handbook of Artificial Intelligence in Drug Delivery</source><publisher-name>Elsevier</publisher-name><publisher-loc>Amsterdam, The Netherlands</publisher-loc><year>2023</year><fpage>145</fpage><lpage>212</lpage></element-citation></ref><ref id="B349-vaccines-13-00126"><label>349.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hasanzadeh</surname><given-names>A.</given-names></name>
<name><surname>Hamblin</surname><given-names>M.R.</given-names></name>
<name><surname>Kiani</surname><given-names>J.</given-names></name>
<name><surname>Noori</surname><given-names>H.</given-names></name>
<name><surname>Hardie</surname><given-names>J.M.</given-names></name>
<name><surname>Karimi</surname><given-names>M.</given-names></name>
<name><surname>Shafiee</surname><given-names>H.</given-names></name>
</person-group><article-title>Could artificial intelligence revolutionize the development of nanovectors for gene therapy and mRNA vaccines?</article-title><source>Nano Today</source><year>2022</year><volume>47</volume><fpage>101665</fpage><pub-id pub-id-type="doi">10.1016/j.nantod.2022.101665</pub-id><pub-id pub-id-type="pmid">37034382</pub-id>
</element-citation></ref><ref id="B350-vaccines-13-00126"><label>350.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hamilton</surname><given-names>S.</given-names></name>
<name><surname>Kingston</surname><given-names>B.R.</given-names></name>
</person-group><article-title>Applying artificial intelligence and computational modeling to nanomedicine</article-title><source>Curr. Opin. Biotechnol.</source><year>2024</year><volume>85</volume><elocation-id>103043</elocation-id><pub-id pub-id-type="doi">10.1016/j.copbio.2023.103043</pub-id><pub-id pub-id-type="pmid">38091874</pub-id>
</element-citation></ref><ref id="B351-vaccines-13-00126"><label>351.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Shi</surname><given-names>Y.</given-names></name>
<name><surname>Chen</surname><given-names>L.</given-names></name>
<name><surname>Zhu</surname><given-names>M.</given-names></name>
<name><surname>Zhao</surname><given-names>Y.</given-names></name>
</person-group><article-title>The Future of Nanomedicine</article-title><source>Nanomedicine</source><publisher-name>Springer</publisher-name><publisher-loc>Berlin/Heidelberg, Germany</publisher-loc><year>2022</year><fpage>1</fpage><lpage>28</lpage></element-citation></ref></ref-list></back><floats-group><fig position="float" id="vaccines-13-00126-f001"><label>Figure 1</label><caption><p>A brief history of conventional vaccine development.</p></caption><graphic xlink:href="vaccines-13-00126-g001" position="float"/></fig><fig position="float" id="vaccines-13-00126-f002"><label>Figure 2</label><caption><p>Timeline of nanoparticle-based vaccine development.</p></caption><graphic xlink:href="vaccines-13-00126-g002" position="float"/></fig><fig position="float" id="vaccines-13-00126-f003"><label>Figure 3</label><caption><p>Types of NPs. (<bold>a</bold>) Polymeric nanoparticle, (<bold>b</bold>) liposome, (<bold>c</bold>) solid lipid NP, (<bold>d</bold>) polymeric micelle, (<bold>e</bold>) lipid NP, (<bold>f</bold>) multilamellar lipid vesicles, (<bold>g</bold>) lipid nanoemulsion, (<bold>h</bold>) lipoprotein, (<bold>i</bold>) exosomes, (<bold>j</bold>) virosomes, (<bold>k</bold>) gold NP, (<bold>l</bold>) protein-based NP, (<bold>m</bold>) polymersomes, (<bold>n</bold>) polymeric nanosphere, (<bold>o</bold>) chitosan NP, (<bold>p</bold>) carbon nanotubes, (<bold>q</bold>) quantum dots, (<bold>r</bold>) mesorphous silica NP, (<bold>s</bold>) virus-like particle (VLP), and (<bold>t</bold>) dendrimer.</p></caption><graphic xlink:href="vaccines-13-00126-g003" position="float"/></fig><table-wrap position="float" id="vaccines-13-00126-t001"><object-id pub-id-type="pii">vaccines-13-00126-t001_Table 1</object-id><label>Table 1</label><caption><p>Comparison between conventional and nanoparticle-based vaccines.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Criterion</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Conventional Vaccines</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Nanoparticle-Based Vaccines</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Types</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Live attenuated, inactivated, subunit and toxoid vaccines</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Protein NPs, lipid NPs, polymer-based NPs, inorganic NPs, and virus-like particles</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Advantages</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Proven track record, strong and long-lasting immunity</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Can carry multiple antigens, enhanced stability, targeted delivery, potentially stronger response</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mechanism</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Uses attenuated/killed pathogens or pathogen components to stimulate immune response</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Delivers antigens in a targeted manner for better recognition and immune response</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Immune response</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Immunogenicity can vary and often requires adjuvants to elicit a robust response</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Designed for a more specific, potent immune response with built-in adjuvants</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Antigen delivery</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Direct administration, often less targeted</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Targeted delivery of specific cells or tissues</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Antigen stability</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Require strict temperature control and maintenance</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Nanocarriers extend the shelf life of antigens and protect them from degradation</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Production Complexity</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Long-established manufacturing processes</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Advanced bioengineering techniques, more complex production</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Stability</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Generally unstable, requires cold chain storage</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Often more stable, some formulations may require less stringent storage conditions</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Customization</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Limited adaptability to rapidly mutated pathogens</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Highly customizable for emerging pathogens</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Dosage</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Multiple administrations may be required for optimal immunogenicity, depending on the vaccine and target population</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Targeted delivery has minimized the administration of multiple doses</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Safety</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Almost safe with few risks of reversion to virulent form regarding live attenuated vaccines</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Potential toxicity of some NPs</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Examples</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Polio, hepatitis B, IB, NDV, tetanus, fowl pox</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Novavax (protein NPs) and COVID-19 mRNA vaccines (using lipid NPs)</td></tr></tbody></table></table-wrap><table-wrap position="float" id="vaccines-13-00126-t002"><object-id pub-id-type="pii">vaccines-13-00126-t002_Table 2</object-id><label>Table 2</label><caption><p>List of nanoparticle-based vaccines used for treating infectious and non-infectious diseases.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Nanoparticle Type</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Targeted Infectious Pathogen/Disease</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Pathogen Classification</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Reference</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Lipid-based NPs</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SARS-CoV-2, herpes simplex virus, leishmania and <italic toggle="yes">Schistosoma</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Virus/parasite</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B66-vaccines-13-00126" ref-type="bibr">66</xref>,<xref rid="B67-vaccines-13-00126" ref-type="bibr">67</xref>,<xref rid="B68-vaccines-13-00126" ref-type="bibr">68</xref>,<xref rid="B69-vaccines-13-00126" ref-type="bibr">69</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Gold NPs (AuNPs)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SARS-CoV-2, Hepatitis C Virus, Foot and Mouth Disease (FMD), <italic toggle="yes">Clostridia tetani</italic>, <italic toggle="yes">Burkholderia mallei</italic>, <italic toggle="yes">Salmonella</italic> Typhi and <italic toggle="yes">Vibrio vulnificus</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Virus/bacteria</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B70-vaccines-13-00126" ref-type="bibr">70</xref>,<xref rid="B71-vaccines-13-00126" ref-type="bibr">71</xref>,<xref rid="B72-vaccines-13-00126" ref-type="bibr">72</xref>,<xref rid="B73-vaccines-13-00126" ref-type="bibr">73</xref>,<xref rid="B74-vaccines-13-00126" ref-type="bibr">74</xref>,<xref rid="B75-vaccines-13-00126" ref-type="bibr">75</xref>,<xref rid="B76-vaccines-13-00126" ref-type="bibr">76</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mesoporous Silica NPs</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Tumor cells</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Tumor cells</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B77-vaccines-13-00126" ref-type="bibr">77</xref>,<xref rid="B78-vaccines-13-00126" ref-type="bibr">78</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Virus-like particles</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hepatitis B virus, malaria, <italic toggle="yes">Theileria parva</italic>, <italic toggle="yes">Respiratory Syncytial virus</italic> (RSV), influenza, circoviruses and SARS-CoV-2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">virus/parasite</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B79-vaccines-13-00126" ref-type="bibr">79</xref>,<xref rid="B80-vaccines-13-00126" ref-type="bibr">80</xref>,<xref rid="B81-vaccines-13-00126" ref-type="bibr">81</xref>,<xref rid="B82-vaccines-13-00126" ref-type="bibr">82</xref>,<xref rid="B83-vaccines-13-00126" ref-type="bibr">83</xref>,<xref rid="B84-vaccines-13-00126" ref-type="bibr">84</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Protein-based NPs</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SARS-CoV-2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Virus</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B85-vaccines-13-00126" ref-type="bibr">85</xref>,<xref rid="B86-vaccines-13-00126" ref-type="bibr">86</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Self-adjuvanting polyguanidine nanovaccines</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Tumor cells</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Tumor cells</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B87-vaccines-13-00126" ref-type="bibr">87</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Liposomes</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Influenza virus, hepatitis A, Human immunosuppressive Virus (HIV), <italic toggle="yes">Pseudomonas aeruginosa</italic>, and methicillin-resistant <italic toggle="yes">Staphylococcus aureus</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Virus/bacteria</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B76-vaccines-13-00126" ref-type="bibr">76</xref>,<xref rid="B88-vaccines-13-00126" ref-type="bibr">88</xref>,<xref rid="B89-vaccines-13-00126" ref-type="bibr">89</xref>,<xref rid="B90-vaccines-13-00126" ref-type="bibr">90</xref>,<xref rid="B91-vaccines-13-00126" ref-type="bibr">91</xref>,<xref rid="B92-vaccines-13-00126" ref-type="bibr">92</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Silicon scalable lipid NPs</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SARS-CoV-2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Virus</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B93-vaccines-13-00126" ref-type="bibr">93</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Dendrimer-RNA NPs</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">H1N1 influenza, Ebola, and <italic toggle="yes">Toxoplasma gondii</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Virus /parasite</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B94-vaccines-13-00126" ref-type="bibr">94</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Multiplexed dendrimer with lipid-based NPs</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Tumor cells</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Tumor cells</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B95-vaccines-13-00126" ref-type="bibr">95</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Fluoropolymer-based nanovaccines</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Tumor cells</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Tumor cells</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B96-vaccines-13-00126" ref-type="bibr">96</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Extracellular vesicle-coated multi-antigenic nanovaccines</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Multidrug resistant <italic toggle="yes">S. aureus</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Bacteria</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B97-vaccines-13-00126" ref-type="bibr">97</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">OMV-based nanovaccines</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">Escherichia coli</italic> serotype O<sub>2</sub></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Bacteria</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B98-vaccines-13-00126" ref-type="bibr">98</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Carbon nanotubes and poly-anhydrous NPs</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">Anaplasma marginale</italic> and <italic toggle="yes">Mycobacterium paratuberculosis</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Protozoa/bacteria</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B99-vaccines-13-00126" ref-type="bibr">99</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Chitosan</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">Salmonella</italic> Enteritidis, <italic toggle="yes">Streptococcus</italic>, avian pathogenic <italic toggle="yes">E</italic>. <italic toggle="yes">coli</italic>, NDV, tuberculosis, <italic toggle="yes">Flavobacterium columnare</italic>, <italic toggle="yes">S. aureus</italic>, <italic toggle="yes">E. coli K1</italic> and <italic toggle="yes">Toxoplasma</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Bacteria/virus/parasite</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B100-vaccines-13-00126" ref-type="bibr">100</xref>,<xref rid="B101-vaccines-13-00126" ref-type="bibr">101</xref>,<xref rid="B102-vaccines-13-00126" ref-type="bibr">102</xref>,<xref rid="B103-vaccines-13-00126" ref-type="bibr">103</xref>,<xref rid="B104-vaccines-13-00126" ref-type="bibr">104</xref>,<xref rid="B105-vaccines-13-00126" ref-type="bibr">105</xref>,<xref rid="B106-vaccines-13-00126" ref-type="bibr">106</xref>,<xref rid="B107-vaccines-13-00126" ref-type="bibr">107</xref>,<xref rid="B108-vaccines-13-00126" ref-type="bibr">108</xref>,<xref rid="B109-vaccines-13-00126" ref-type="bibr">109</xref>,<xref rid="B110-vaccines-13-00126" ref-type="bibr">110</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Polyanhydride NPs</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">Bacillus anthracis</italic> and <italic toggle="yes">Yersinia pestis</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Bacteria</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B111-vaccines-13-00126" ref-type="bibr">111</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Nanoplasmids</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">Trypanosoma cruzi</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Parasite</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B112-vaccines-13-00126" ref-type="bibr">112</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Antigen-absorbing silica vesicles</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Tick-borne diseases</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Tick-borne diseases</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B113-vaccines-13-00126" ref-type="bibr">113</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Zinc oxide NPs</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">E. coli</italic>, <italic toggle="yes">Salmonella</italic> spp. and H1N1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Bacteria/Virus</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B114-vaccines-13-00126" ref-type="bibr">114</xref>,<xref rid="B115-vaccines-13-00126" ref-type="bibr">115</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Selenium NPs</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">S. aureus</italic> and <italic toggle="yes">E. coli</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Bacteria</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B116-vaccines-13-00126" ref-type="bibr">116</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Poly (lactic acid-coglycolic acid) polymeric NPs</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">C. trachomatis</italic>, <italic toggle="yes">C. pneumoniae</italic>, <italic toggle="yes">Helicobacter pylori</italic>, <italic toggle="yes">Listeria monocytogenes</italic>, <italic toggle="yes">Salmonella</italic> Typhimurium and <italic toggle="yes">Brucella melitensis</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Bacteria</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B117-vaccines-13-00126" ref-type="bibr">117</xref>,<xref rid="B118-vaccines-13-00126" ref-type="bibr">118</xref>,<xref rid="B119-vaccines-13-00126" ref-type="bibr">119</xref>,<xref rid="B120-vaccines-13-00126" ref-type="bibr">120</xref>,<xref rid="B121-vaccines-13-00126" ref-type="bibr">121</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Chitosan and glutamic acid polymeric NPs</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">H. pylori</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Bacteria</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B122-vaccines-13-00126" ref-type="bibr">122</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Silver NPs (AgNPs)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">H3N2, feline calicivirus, infectious bursal disease virus (IBDV), respiratory syncytial virus (RSV), Rift Valley Fever virus (RVF), HIV, adenovirus, poliovirus, norovirus, <italic toggle="yes">Acinetobacter baumannii</italic>, feline coronavirus, <italic toggle="yes">E. coli</italic>, <italic toggle="yes">S. aureus</italic> and <italic toggle="yes">P. aeruginosa</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Virus/bacteria</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B123-vaccines-13-00126" ref-type="bibr">123</xref>,<xref rid="B124-vaccines-13-00126" ref-type="bibr">124</xref>,<xref rid="B125-vaccines-13-00126" ref-type="bibr">125</xref>,<xref rid="B126-vaccines-13-00126" ref-type="bibr">126</xref>,<xref rid="B127-vaccines-13-00126" ref-type="bibr">127</xref>,<xref rid="B128-vaccines-13-00126" ref-type="bibr">128</xref>,<xref rid="B129-vaccines-13-00126" ref-type="bibr">129</xref>,<xref rid="B130-vaccines-13-00126" ref-type="bibr">130</xref>,<xref rid="B131-vaccines-13-00126" ref-type="bibr">131</xref>,<xref rid="B132-vaccines-13-00126" ref-type="bibr">132</xref>,<xref rid="B133-vaccines-13-00126" ref-type="bibr">133</xref>,<xref rid="B134-vaccines-13-00126" ref-type="bibr">134</xref>,<xref rid="B135-vaccines-13-00126" ref-type="bibr">135</xref>,<xref rid="B136-vaccines-13-00126" ref-type="bibr">136</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Dendrimers</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">Schistosoma</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Parasite</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B137-vaccines-13-00126" ref-type="bibr">137</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Self-assembling polypeptide NPs</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Toxoplasmosis</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Parasite</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B138-vaccines-13-00126" ref-type="bibr">138</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Porous silicon NPs</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">P. aeruginosa</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Bacteria</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B139-vaccines-13-00126" ref-type="bibr">139</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Calcium-alginate NPs</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Methicillin-resistant <italic toggle="yes">S. aureus</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Bacteria</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B140-vaccines-13-00126" ref-type="bibr">140</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ferritin NPs</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">Neisseria gonorrhoeae</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Bacteria</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B141-vaccines-13-00126" ref-type="bibr">141</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Nanosuspensions</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">Cryptosporidium parvum</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Parasite</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B142-vaccines-13-00126" ref-type="bibr">142</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Selenium nanoparticle functionalized with oseltamivir</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Enterovirus</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Virus</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B143-vaccines-13-00126" ref-type="bibr">143</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">LNP- siVP35-3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">EBOV</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Virus</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B144-vaccines-13-00126" ref-type="bibr">144</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Multivalent peptide&#x02013;polymer NPs</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Influenza</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Virus</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B145-vaccines-13-00126" ref-type="bibr">145</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Nano-vesicles</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">A. marginale</italic> and <italic toggle="yes">shiga toxin by E. coli</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Parasite/bacteria</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B146-vaccines-13-00126" ref-type="bibr">146</xref>,<xref rid="B147-vaccines-13-00126" ref-type="bibr">147</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">TMC NPs</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Influenza</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Virus</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B148-vaccines-13-00126" ref-type="bibr">148</xref>]</td></tr></tbody></table></table-wrap><table-wrap position="float" id="vaccines-13-00126-t003"><object-id pub-id-type="pii">vaccines-13-00126-t003_Table 3</object-id><label>Table 3</label><caption><p>Examples of lipid-based NP vaccines widely used in preclinical and clinical studies.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Trade Name</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Composition</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Indication</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Ref.</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Vaxfectin<sup>&#x000ae;</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Liposomal vaccine</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Herpes simplex virus type 2 and influenza virus</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B91-vaccines-13-00126" ref-type="bibr">91</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Epaxal<sup>&#x000ae;</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Liposomal vaccine</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hepatitis A infection</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B92-vaccines-13-00126" ref-type="bibr">92</xref>,<xref rid="B159-vaccines-13-00126" ref-type="bibr">159</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Doxil<sup>&#x000ae;</sup> and Abraxane<sup>&#x000ae;</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Liposomal doxorubicin and albumin-bound paclitaxel</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Approved by the FDA and are used in treating Various cancers</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B160-vaccines-13-00126" ref-type="bibr">160</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Shingrix<sup>&#x000ae;</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Recombinant VZV glycoprotein E on liposomes carrier</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Approved by FDA against herpes virus</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B161-vaccines-13-00126" ref-type="bibr">161</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Onivyde<sup>&#x000ae;</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Liposomal irinotecan</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pancreatic cancer</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B162-vaccines-13-00126" ref-type="bibr">162</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">W_ova1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Liposome-formulated mRNAs</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ovarian cancer</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B163-vaccines-13-00126" ref-type="bibr">163</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DPX-0907</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Liposomes containing a polynucleotide adjuvant</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ovarian, breast, and prostate cancer</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B164-vaccines-13-00126" ref-type="bibr">164</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Lipovaxin-MM</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Tumor antigen-containing multicomponent liposomes with the DC-targeting molecule DMS-5000</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Metastatic melanoma</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B165-vaccines-13-00126" ref-type="bibr">165</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Vyxeos<sup>&#x000ae;</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Liposomal cytarabine and daunorubicin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Acute myeloid leukemia</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B166-vaccines-13-00126" ref-type="bibr">166</xref>,<xref rid="B167-vaccines-13-00126" ref-type="bibr">167</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">VaxiSome&#x02122;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Liposomal adjuvant</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Influenza</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B168-vaccines-13-00126" ref-type="bibr">168</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MPER-656</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HIV-1 gp41 membrane-proximal external region (MPER) on liposome carrier</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HIV</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B169-vaccines-13-00126" ref-type="bibr">169</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">LNP CL-0059/CL-0137</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">mRNA LNP</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">RSV</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B170-vaccines-13-00126" ref-type="bibr">170</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BNT165b1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">mRNA LNP</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Malaria</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B171-vaccines-13-00126" ref-type="bibr">171</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MRT5413</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">LNP-formulated, modified mRNA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Influenza</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B172-vaccines-13-00126" ref-type="bibr">172</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ARCT-021, MRT5500, Pfizer-BioNTech and Moderna COVID-19, ChulaCov19, mRNA-1273, CVnCoV, LNP-nCoV-saRNA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">mRNA LNP</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">COVID-19</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B68-vaccines-13-00126" ref-type="bibr">68</xref>,<xref rid="B173-vaccines-13-00126" ref-type="bibr">173</xref>,<xref rid="B174-vaccines-13-00126" ref-type="bibr">174</xref>,<xref rid="B175-vaccines-13-00126" ref-type="bibr">175</xref>,<xref rid="B176-vaccines-13-00126" ref-type="bibr">176</xref>,<xref rid="B177-vaccines-13-00126" ref-type="bibr">177</xref>,<xref rid="B178-vaccines-13-00126" ref-type="bibr">178</xref>,<xref rid="B179-vaccines-13-00126" ref-type="bibr">179</xref>,<xref rid="B180-vaccines-13-00126" ref-type="bibr">180</xref>]</td></tr></tbody></table></table-wrap></floats-group></article>